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Abstract 
 
EGFR activating mutations are present in 10-40% of non-small cell lung cancer.  
Such mutations render tumour cells sensitive to EGFR tyrosine kinase inhibitors 
(EGFR TKIs), with responses of up to 80% in populations selected for the presence 
of an activating mutation.  Unfortunately, almost all patients develop resistance 
after about a year.  Clinically described mechanisms of resistance include the 
presence of a secondary mutation (T790M) in EGFR which prevents EGFR TKIs 
binding to the EGF receptor, and amplification MET which permits survival 
signalling via the ERBB3 receptor.  However in 30% of cases, the mechanism of 
acquired resistance to EGFR TKIs is still unknown.  My aim was to carry out a 
genome-wide siRNA screen to identify novel mechanisms of resistance to EGFR 
TKIs.  I identified two genes that have not been implicated in EGFR TKI resistance 
previously, NF1 and DEPTOR, which are negative regulators of RAS and mTOR 
respectively.  Depletion of NF1 or DEPTOR leads to increased resistance to EGFR 
TKIs via upregulation of MAPK signalling by direct and indirect mechanisms.   
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Chapter 1. Introduction 
1.1 Cancer 
Cancer is a term that covers over two hundred different diseases defined by the 
uncontrolled proliferation of cells. Cancer cells undergo cell division without the 
proper regulation present in normal cells, leading to the formation of tumours. 
Cancer cells have acquired properties that normal cells do not have as a result of 
mutations in their DNA.  These mutations can arise as a result of a variety of 
causes, for example, exposure to various substances e.g. tobacco, radiation, or 
some viruses.  The transformation of a normal cell to a cancer cell is multi-step 
process (Foulds, 1954).  Early in vitro experiments showed that cells require at 
least two genetic aberrations before they are fully transformed (Hahn et al., 1999; 
Land et al., 1983), and research into cancer susceptibility syndromes seemed to 
support this hypothesis.  Knudson proposed the ‘two hit’ model on the basis of 
dominant inheritance of cancer in retinoblastoma patients, where statistical analysis 
suggested patients that inherited one mutation in RB1 (retinoblamstoma) required 
one more mutational event to develop cancer (Knudson, 1971).  Two mutations 
appear to be the minimum for tumourigenesis, and more mutations are thought to 
be necessary in non-inheritable cancers (Berger et al., 2011).   
 
Weinberg and Hanahan suggested a list of properties cancer cells must have 
acquired to successfully develop into malignant disease in their seminal paper, 
‘Hallmarks of Cancer’ which they re-evaluated in 2011(Hanahan and Weinberg, 
2011)(Fig.1.1).  
Chapter 1. Introduction 
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Figure 1.1. Hallmarks of Cancer. 
Properties cancer cells must acquire in order to develop into malignant disease. 
 
These properties include self-sufficiency from growth signals, insensitivity to anti-
growth signals, and the ability to evade apoptosis.  Mutations that confer these 
abilities to tumour cells and drive carcinogenesis can be broadly divided into two 
groups, those that affect tumour suppressors and those that affect oncogenes.  
Tumour suppressors are proteins whose action provides a block to tumour 
formation. Mutations in the genes encoding these proteins cause their loss of 
function, and remove their blockade to cancer formation. The most well-known 
tumour suppressor is p53. p53 acts as a tumour suppressor in a variety of ways, for 
example inducing cell cycle arrest in response to DNA damage to allow cells to 
repair it, and inducing apoptosis if the damage is irreparable (Vousden and Lu, 
2002).  On the other hand oncogenes promote cancer formation.  These tend to be 
genes that in normal cells promote growth and survival, but in cancer have 
undergone mutations that activate them to abnormally high levels.  Examples of 
oncogenes that will be discussed in greater detail are KRAS and EGFR.  
1.2 Non-small Cell Lung Cancer 
Lung cancer is the biggest cause of cancer deaths claiming over one million lives a 
year worldwide.  The most prevalent form of lung cancer is non-small cell lung 
cancer (NSCLC), comprising 80% of all lung cancer cases. NSCLC can be 
histologically subdivided into squamous-cell carcinoma, large-cell carcinoma, and 
adenocarcinoma, with adenocarcinoma accounting for 50% of cases (Pao and 
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Girard, 2011). In recent years several genes have been identified which are 
frequently mutated in NSCLC, leading to the development of rationale driven 
targeted therapies. The most common genetic alterations are mutations in KRAS, 
EGFR, and the occurrence of EML4-ALK gene fusions, all of which appear to be 
mutually exclusive (Kim et al., 2011). KRAS mutations are mostly associated with 
smokers, whereas EML4-ALK gene fusions and EGFR mutations are more 
common in never-smokers.  Also EGFR mutations are more common in women 
and patients of Asian origin.  Several other potential driver mutations have been 
identified in NSCLC at lower frequencies, including HER2, BRAF, AKT1, MAP2K1 
and PI3KCA and translocations in RET and ROS (Fig.1.2.) (Pao and Hutchinson, 
2012) (Heist and Engelman, 2012), providing attractive new therapeutic 
opportunities. However, the major problem with all targeted therapies is the ability 
of cancer cells to mutate and adapt to adverse conditions, leading to development 
of drug resistance and disease progression.  Such examples of drug resistance 
have been identified in EGFR-mutant and EML-ALK expressing NSCLC targeted 
with EGFR and ALK inhibitors respectively (Choi et al., 2010; Pao et al., 2005a). 
The remainder of this body of work will focus on the use of EGFR tyrosine kinase 
inhibitors in EGFR-mutant NSCLC and arising mechanisms of resistance.  
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Figure 1.1.2. Common mutations in NSCLC. 
Pie chart showing identified driver mutations in NSCLC representing the 
percentage of cases in which they have been identified.  TP53 and LKB1 are 
not shown as they significantly overlap with mutations indicated. The data 
represented is from Pao and Hutchinson, 2012 and Heist and Engelman 2012. 
1.3 EGFR signalling 
The role of EGFR in cancer was first indicated by the discovery that EGFR is the 
cellular homolog of the avian erythrocytosis virus (AEV) oncogene (Downward et 
al., 1984).  AEV is a c-term truncated version of EGFR, with additional mutations in 
the intracellular domain rendering it constitutively activated. This finding suggested 
that EGFR is a proto-oncogene, present in normal cells that when aberrantly 
activated functions as an oncogene to drive tumourigenesis (Downward et al., 
1984).  Subsequently, constitutively active EGFR signalling has been found in a 
range of human neoplasms including glioma, colorectal carcinoma and non-small 
cell lung cancer (Salomon et al., 1995).  The human epidermal growth factor 
receptor family (ERBB/Her) consists of four related receptors EGFR (HER1, 
ERBB1), HER2 (ERBB2) (King et al., 1985; Schechter et al., 1985), HER3 
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(ERBB3) (Kraus et al., 1989; Plowman et al., 1990) and HER4 (ERBB4) (Plowman 
et al., 1993). When EGFR ligands bind to the extracellular domain of the receptors 
they induce either heterodimerisation or homodimerisation of receptors and 
activation of intracellular tyrosine kinase activity.  The exact method of activation 
varies substantially between family members. EGFR and ERBB4 kinase activity are 
both activated by ligand binding.  On the other hand ERBB2 is not known to bind 
any ligand with high affinity and is thought to function mainly as a binding partner 
for other ERBB family members (Klapper et al., 1999). Instead, ERBB2 is the 
preferred dimerization partner of all ErbB family receptors (Graus-Porta et al., 
1997) and ERBB heterodimers containing ERBB2 are strong inducers of 
downstream signalling (Graus-Porta et al., 1995). Conversely, ERBB3 can only 
activate signalling when heterodimerised with other ERBB receptors as it lacks 
intracellular kinase activity (Kim et al., 1998).   
 
In the case of EGFR, ligand binding induces a conformational change in the 
receptor allowing the formation of receptor dimers. EGFR has six ligands: EGF, 
amphiregulin, TGF-α, heparin-binding growth factor, epiregulin and betacellulin 
(Salomon et al., 1995).  Autophosphorylation of the intracellular tyrosine kinase 
domain creates phosphotyrosine residues that act as SH2 binding sites for adaptor 
proteins, such as GRB2 (Lowenstein et al., 1992) and SHC (Pelicci et al., 1992), 
and other SH2-domain containing signalling proteins, such as PLC gamma, SRC 
and STATs (Marmor et al., 2004). Recruitment of adaptor proteins is vital for 
activation of RAS-MAPK and PI3K-AKT signalling pathways that will be discussed 
in more detail in later sections. Briefly, RAS is activated via GRB2/SOS, and PI3K 
via GRB2/GAB1 to potentiate downstream signalling. Fig.1.3. shows recruitment of 
various signalling molecules to EGFR and the downstream pathways they activate.  
 
EGFR signalling is terminated by ubiquitination and recruitment to clathrin coated 
pits at the membrane.  Activated receptors are then internalised via endocytosis to 
early endosomes, and subsequently either recycled to the plasma membrane or 
sorted to the lysosome for degradation (Madshus and Stang, 2009). It is thought 
that EGFR is still able to signal in the cytoplasm from endosomes, and that may be 
important in sustained MAPK and AKT activation.  However, recent research in 
dynamin-depleted cells, where EGFR endocytosis is inhibited, showed similar 
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stimulation of MAPK, indicating that the majority of signal activation occurs at the 
plasma membrane (Sousa et al., 2012). 
 
 
Figure 1.1.3. Key EGFR-activated signalling pathways 
Outline of major signalling pathways activated by EGFR. Activation of EGFR by 
ligands leads to autophosphorylation of the receptor and recruitment of adaptor 
molecules such as GRB2, and signalling molecules such as PLC gamma, SRC 
and STATs. GRB2/SOS binds to and activates RAS resulting in activation of 
downstream MAPK, whilst recruitment of GAB1 to GRB2 activates PI3K 
signalling. 
1.4 EGFR signalling in NSCLC 
EGFR signalling is hyper-activated in a large subset of NSCLC, via mutation, gene 
amplification, and overexpression of EGFR and its ligands, leading to the 
dependence of these tumours on EGFR signalling for survival. EGFR mutations 
have been reported in 10-40% of NSCLC, the majority of which are deletions of 
between 2 and 15 nucleotides in exon 19 or point mutation of L858R in exon 21 
Chapter 1. Introduction 
  21 
(Lynch et al., 2004; Paez et al., 2004). Both of these common mutations affect the 
kinase domain of the receptor, leading to ligand-independent EGFR signalling. The 
other known EGFR activating mutations also occur within exons 18-21 in the 
kinase domain (Gazdar, 2009).  Missense mutations of glycine 719 to serine, 
alanine or cysteine, and V765A and T783A, account for 4% and 1% of activating 
EGFR mutations respectively (Sharma et al., 2007), and additional in-frame 
duplications and insertions exist in exon 20 (Sharma et al., 2007).  Presence of 
these activating EGFR mutations was demonstrated to confer sensitivity to EGFR 
inhibitory drugs, and drove the use of EGFR tyrosine kinase inhibitors (EGFR-TKIs), 
such as erlotinib and gefitinib, in selected populations in NSCLC (Lynch et al., 
2004; Paez et al., 2004). 
 
Initially EGFR tyrosine kinase inhibitors were used in unselected populations of 
non-small cell lung cancer patients refractory to chemotherapy, under the rationale 
that EGFR is expressed or overexpressed in NSCLC (Fujino et al., 1996).  In phase 
II clinical trials, using gefinitib as a monotherapy, between 12.3 and 18.7% of 
patients exhibited a partial clinical response (Fukuoka et al., 2003; Kris et al., 2003).  
A clinical response is defined by Response Evaluation Criteria In Solid Tumors 
(RECIST) as a 30% reduction in tumour size.(Therasse et al., 2000). At the phase 
III clinical trial stage erlotinib treatment prolonged survival by a median of 2 months, 
which was deemed clinically meaningful (Shepherd et al., 2005).  Upon selection 
for activating EGFR mutations, the proportion of patients benefiting from treatment 
increases dramatically.  Approximately 70% of patients with activating EGFR 
mutations exhibit a clinical response to EGFR tyrosine kinase inhibitors, as found in 
several clinical trials (Maemondo et al., 2010; Mitsudomi et al., 2010; Mok et al., 
2009).  In these cases EGFR-TKI treatment increases progression free survival by 
between 3 and 5 months, compared to standard chemotherapy. These trials were 
carried out in Asian populations, however similar results have recently been 
reported in a European phase III clinical trial comparing erlotinib treatment with 
standard chemotherapy.  In this instance 64% of patients responded to the EGFR-
TKI, and erlotinib treatment lead to superior progression free survival (9.7 months 
versus 5.2 months)(Rosell et al., 2012).  
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EGFR amplification has also been identified in approximately 9% of NSCLC, where 
high gene copy number correlates to poor prognosis (Hirsch et al., 2003). There is 
some evidence that patients with no EGFR mutation but EGFR gene amplification 
can benefit from EGFR TKI therapy (Cappuzzo et al., 2005; Helfrich et al., 2006).  
Overexpression of EGFR is present in 40-80% of NSCLC patients and is generally 
associated with poor prognosis, however it is less strongly associated with 
response to EGFR-TKIs than EGFR copy number, or the presence of activating 
mutations (Hirsch et al., 2009).  It has also been suggested that high expression of 
other ERBB family members (ERBB2 and ERBB3) and EGFR ligands 
(amphiregulin and epiregulin) can confer sensitivity to EGFR-TKIs, however this is 
less well established (Fujimoto et al., 2005). Ultimately the vast majority of patients 
with EGFR activating mutations are responsive to EGFR-TKIs, as well as a minor 
population of wildtype EGFR patients, who may have upregulated EGFR signalling 
via other mechanisms. Unfortunately, after a year or so of treatment with TKIs 
almost all patients who initially show a clinical response develop resistance and 
exhibit tumour progression. 
1.5 RAS signalling 
1.5.1 RAS family proteins 
As mentioned previously, one of the major effectors of EGFR signalling is RAS.  
The RAS superfamily consists of over 150 different proteins, which can be 
subdivided into 5 major groups, RAS, RHO, RAB, RAN and ARF (Wennerberg et 
al., 2005). The RAS subfamily in humans contains 39 proteins encoded by 36 
genes.  Of the RAS subfamily the most studied members are H-RAS, K-RAS and 
N-RAS due to their extensive roles in cancer, as they are mutated in around 20% of 
human tumours (Downward, 2009).  The cellular homologues of viral H-RAS and 
K-RAS were first identified in the rat genome in 1981 (DeFeo et al., 1981).  
Subsequently mutant alleles of K-RAS and H-RAS were identified in a variety of 
human cancer cell lines (Der et al., 1982) and human tumours (Santos et al., 1984). 
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1.5.2 RAS function 
RAS is essential for growth and survival signals in response to extracellular stimuli. 
RAS is a GTPase, which means it hydrolyses GTP to GDP, and through this 
activity functions as a molecular switch.  When RAS is bound to GTP it is in an 
active signalling state and can activate downstream effectors. Hydrolysis of GTP 
then converts RAS back to its inactive form, switching off RAS signalling (Fig.1.4).  
The function of RAS as a GTPase was discovered by three groups by comparing 
normal and oncogenic alleles of RAS, which differed by a single amino acid (at 
position 12, 13 and 61) (Gibbs et al., 1984; McGrath et al., 1984) (Sweet et al., 
1984).  It was determined that these mutations decrease the ability of RAS to 
hydrolyse GTP, therefore lock it in a constitutively active state. 
 
The ratio of RAS-GTP to RAS-GDP is regulated by RAS GEFs (Guanine nucleotide 
Exchange Factors) and GAPs (GTPase Activating Proteins).  GTP hydrolysis by 
RAS proteins alone occurs at a level too low to be physiologically important, 
instead GTPase activity is stimulated by the interaction with GEFs.  RAS GEFs, 
such as SOS bind to RAS and cause conformational changes resulting in a 10,000-
fold increase in the rate of release of GDP from RAS, which is replaced by the 
more abundant GTP, activating RAS (Karnoub and Weinberg, 2008).  RAS GAPs, 
such as p120 (Trahey and McCormick, 1987) and NF1 (Martin et al., 1990) 
inactivate RAS by catalysing the hydrolysis rate of GTP to GDP by approximately 
100,000 fold returning RAS to an inactive state (Gideon et al., 1992). 
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Figure 1.1.4. Ras activation. 
RAS is active when bound to GTP, GEFs activate RAS by increasing the rate at 
which GDP is released from RAS and replaced with GTP.  GAPs inactivate 
RAS by catalysing the hydrolysis of GTP to GDP and Pi (inorganic phosphate, 
orthophosphate).  
 
1.5.3 RAS activation in response to EGFR stimulation 
In 1993 it was discovered that RAS is activated in response to EGFR signalling 
(Buday and Downward, 1993). Downstream of EGFR activation, adaptor molecules 
GRB2 and SOS are recruited in a pre-complexed form to SH2 binding sites of the 
intracellular kinase domain of EGFR (Rozakis-Adcock et al., 1993).  This brings 
SOS into close proximity with RAS, for which it acts as a GEF, thereby activating 
RAS (Bonfini et al., 1992).  RAS-GTP can then activate a number of effectors, 
including RAF, PI3K, RALGDS, Tiam, RASSF1 and PLCε (Rajalingam et al., 2007).  
The RAF/MEK/ERK and PI3K signalling pathways are the RAS effector pathways 
most prominently involved in cancer, particularly in drug resistance, therefore these 
will be discussed in more detail. 
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1.6 RAF/MEK/ERK 
Upon activation RAS directly binds to the N-terminus of RAF (Moodie et al., 1993; 
Vojtek et al., 1993; Warne et al., 1993). There are 3 isoforms of RAF in humans, 
RAF-1 (C-RAF), B-RAF, and A-RAF, which are structurally conserved in 
invertebrates and mammals (Wellbrock et al., 2004). All isoforms are activated by 
RAS, however the mechanism of activation differs.  RAF-1 and A-RAF require RAS 
binding and phosphorylation by SRC for activation, whereas B-RAF only requires 
RAS for activation (Marais et al., 1997). Key sites for RAF-1 activation are S338 
and Y341.  Tyrosine phosphorylation at Y341 is mediated by SRC, however the 
kinase responsible for S338 phosphorylation is less clear.  Three other 
phosphorylation sites and several other proteins such as 14-3-3, p21-activated 
kinase (PAK), and calcium/calmodulin-dependent kinase II (CaMKII) have been 
implicated in RAF-1 activation (Salzano et al., 2012; Wellbrock et al., 2004).  
 
Binding of RAF to RAS results in the recruitment of RAF to the plasma membrane 
(Marais et al., 1995) where it can then phosphorylate and activate extracellular 
signal regulated kinase (ERK) kinase (MEK) (Dent et al., 1992). The two isoforms 
of MEK (MEK1 and MEK2) are activated by RAF phosphorylating them at two 
serine residues within their activation domain (S217 and S221 in MEK1) (Zheng 
and Guan, 1994).  The activation of MEK is enhanced by scaffold proteins such as 
kinase suppressor of RAS (KSR), which recruits MEK to the membrane and 
presents it to RAF (Brown and Sacks, 2009).  KSR was first identified in C-elegans 
as a positive regulator of MAPK signalling (Kornfeld et al., 1995), then later found 
to bind Raf-1, MEK1/2 and ERK1/2 suggesting it’s role as a scaffold (Morrison, 
2001). Activated MEK then phosphorylates ERK1/2, linking RAS and ERK1/2 
signalling.  RAS was originally discovered to positively regulate ERK1/2 signalling 
in 1992 (Leevers and Marshall, 1992), before knowledge of the RAS-RAF-MEK-
ERK1/2 signalling cascade had been fully established.   
 
ERK1/2 proteins when activated can either form homodimers and activate a 
number of cytosolic proteins or translocate to the nucleus in monomeric form to 
phosphorylate transcription factors, such as the ETS family of transcription factors 
including ELK1 (Casar et al., 2008). Phosphorylation of ELK1 increases its DNA 
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binding and transactivation ability.  ELK1 in cooperation with serum response factor 
(SRF) binds to serum response elements (SRE) in promoters to activate 
transcription of genes such as c-FOS to promote proliferation (Yordy and Muise-
Helmericks, 2000). ERK1 and 2 activate the transcription of a number of genes 
important in cell survival and cell cycle progression, for example MYC (Chuang and 
Ng, 1994) and Cyclin D1 (Weber et al., 1997). Cytosolic targets of ERK1/2 include 
the BH3-only pro-apopotic protein BIMEL (Ley et al., 2003).  ERK1/2 phosphorylate 
BIMEL, which targets BIMEL for degradation by the proteasome and inhibits 
apoptosis. ERK1/2 also phosphorylates FOXO3a, promoting its translocation from 
the nucleus to the cytoplasm, and targeting it for further ubiquitination by MDM2 
and proteasomal degradation (Yang et al., 2008).  
1.6.1 RAF/MEK/ERK activation in cancer 
The RAF/MEK/ERK pathway is frequently dysregulated in cancer, not just at the 
level of activation by oncogenic RAS or upstream receptors.  ERK1/2 is 
dysregulated in approximately 30% of all cancers, demonstrating its pivotal role in 
cancer cell signalling. BRAF is frequently mutated in melanoma, thyroid cancer, 
colorectal cancer and ovarian cancers leading to hyperactivation of ERK1/2 in 
these tumours (Wellbrock et al., 2004). MEK1 and MEK2 mutations are not 
commonly observed in human cancers, however a mutated form of MEK1 was 
recently identified in NSCLC (Pao and Girard, 2011). Other mechanisms of ERK1/2 
activation include repression of negative regulators of the MAPK pathway such as 
SPROUTY2 (Frank et al., 2009) and NF1 (Mendes-Pereira et al., 2011). As 
previously mentioned NF1 is a RAS GAP, therefore it negatively regulates RAS 
activity (Basu et al., 1992).  Mutations in NF1 are the genetic basis for 
neurofibromatosis type 1, a hereditary disease characterised by increased 
formation of benign and malignant tumours of neural crest origin.   NF1 functions 
as a tumour suppressor and NF1 genetic inactivation has been reported in a 
number of tumour types including sporadically occurring gliomas, ovarian cancer, 
adult acute myelogenous leukaemia and lung adenocarcinomas (The Cancer 
Genome Atlas Research Network, 2008; The Cancer Genome Atlas Research 
Network, 2011; Ding et al., 2008; Parkin et al., 2010).  Ding et al. reported that 
13/188 lung tumours had NF1 mutations indicating that mutations in NF1 may have 
a role in NSCLC. 
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1.7 PI3K signalling 
The other major RAS effector pathway most commonly aberrantly activated in 
cancer is the PI3K/AKT pathway (Castellano and Downward, 2011).  PI3K converts 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), which in turn recruits AKT to the plasma membrane via its 
pleckstrin homology domain where it is activated. PI3K is a heterodimeric protein 
consisting of a regulatory and catalytic subunit. The PI3K family is subdivided into 
class I, II and III members, of which class I can be further separated into A and B 
members. Classification separates family members by the regulatory and catalytic 
subunits they contain (Vanhaesebroeck et al., 2010).  The most common isoform 
implicated in cancer is a class IA PI3K (and will be the isoform referred to hereon 
in) and consists of a p110α catalytic subunit bound to a p85 regulatory subunit 
(Zhao and Vogt, 2008).  RAS can bind directly to p110α, where it is thought to 
induce conformational changes to enhance activity (Pacold et al., 2000).  PI3K can 
also be activated by EGFR signalling independently of RAS, via GRB2.  As 
previously stated GRB2 can bind SH2 sites on EGFR, and can then recruit GAB1, 
a scaffold protein which binds to p85 (Pawson, 2004). The p85 subunit of PI3K is 
recruited directly to pYXXM motifs within the intracellular domain of RTKs such as 
ErbB3, created upon ligand activation, but p85 is not thought to bind to EGFR 
directly (Olayioye et al., 2000). The production of PIP3 by PI3K also leads to the 
recruitment of PDK1 (3-phosphoinositide dependent protein kinase-1) to the 
plasma membrane, where in close proximity it can phosphorylate AKT at Thr308 
(Currie et al., 1999). AKT is then fully activated by further phosphorylation at 
Ser473 by mTORC2 (Hresko and Mueckler, 2005; Sarbassov et al., 2005).  
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Figure 1.1.5. PI3K-AKT signalling. 
PI3K activation downstream of EGFR.  Activated PI3K produces PIP3 which 
recruits AKT and PDK to the plasma membrane.  PDK then phosphorylates 
AKT, which is then fully activated by phosphorylation by mTORC2.  AKT 
substrates include forkhead transcription factors, GSK3 and BAD, which it 
inhibits to prevent apoptosis. AKT activates cyclin D1 and mTORC1 to promote 
proliferation, and protein synthesis. 
 
1.7.1 PI3K/AKT signalling in cancer    
PI3K/AKT signalling is dysregulated in a variety of tumour types at multiple points 
in the pathway, from amplification and activation of receptors at the cell membrane 
downwards. The most common mechanisms of aberrant activation occur though 
activating mutations in PIK3CA, the gene encoding the catalytic PI3K subunit 
p110α, and loss of PTEN (phosphatase and tensin homolog), a negative regulator 
of PI3K/AKT signalling (Yuan and Cantley, 2008). 
 
PIK3CA is mutated in approximately 30% of human cancers, including those of the 
breast, colon, endometrium and prostate (Zhao and Vogt, 2008).  80% of mutations 
are one of three ‘hotspot’ mutations that lead to increased lipid kinase activity (Vogt 
et al., 2007).  PTEN is a dual protein and lipid phosphatase whose lipid 
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phosphatase activity counteracts the function of PI3K. PTEN desphosphorylates 
PIP3 , and therefore attenuates recruitment and activation of AKT at the plasma 
membrane (Cantley and Neel, 1999).   Loss of PTEN leads to an accumulation of 
PIP3 and unrestrained activation of downstream signalling.  PTEN germline 
mutations result in PTEN hamartoma tumour syndrome (PHTS) that is 
characterised by benign growths and high susceptibility to developing cancers of 
the breast, endometrium and thyroid (Hollander et al., 2011).  PTEN is also 
mutated or deleted in a range of sporadically occurring tumours, for example loss 
of heterozygosity at 10q23 (which includes PTEN) is present in approximately 40% 
of sporadic breast tumours (Singh et al., 1998).  Additionally levels of PTEN can be 
downregulated by promoter methylation, microRNAs, and loss of the PTEN 
pseudogene, and activity can be affected by posttranslational modifications such as 
ubiquitination and acetylation (Carracedo et al., 2011).  Also, PI3K signalling can 
be aberrantly activated by mutations in the p85 regulatory subunit of PI3K.  
Inactivating mutations in PIK3R1 and PIK3R2 are relatively rare in common 
cancers, but are mutated at a high frequency in endometrial cancer (Cheung et al., 
2011b).  
 
Downstream of PI3K, amplifications of AKT isoforms have been found in pancreatic, 
ovarian and head and neck cancers (Engelman et al., 2006).  An activating somatic 
mutation has also been discovered in AKT1 in breast, colorectal, ovarian and 
endometrial cancers (Carpten et al., 2007; Shoji et al., 2009).  This mutation 
(E17K) in the pleckstrin homology domain constitutively tethers AKT to the plasma 
membrane, activating signalling.  
1.7.2 mTOR signalling 
One of the major pathways downstream of AKT activation is the mTOR 
(mechanistic target of rapamycin) signalling pathway.  mTOR signalling is a highly 
complex pathway subject to much crosstalk and feedback inhibition.  mTOR is a 
serine/threonine kinase of the phosphatidylinositol kinase related protein family 
(Menon and Manning, 2008).  mTOR kinase exists in two distinct macromolecular 
complexes in humans (mTORC1 and mTORC2)(Fig 1.1.6). Both complexes 
contain mTOR, mLST8 (mammalian Lethal with SEC13 protein 8), DEPTOR (DEP 
domain-containing mTOR interacting protein), and scaffold proteins TTI1 (TEL2 
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interacting protein 1) and TEL2 (telomere maintance 2) (Kaizuka et al., 2010).  
mTORC1 also contains RAPTOR (Regulatory associated protein of mTOR), and 
PRAS40 (40 kDa Pro-rich Akt substrate). mTORC2 includes RICTOR (Rapamycin 
insensitive companion of mTOR), mSIN1 (mammalian Stress-activated protein 
kinase-interacting protein 1) and PROTOR (protein observed with RICTOR) 
(Laplante and Sabatini, 2012). Due to the presence of these different non-core 
components mTORC1 and 2 are functionally distinct, and subject to differences in 
regulation. For example mTORC1 is sensitive to inhibition with rapamycin whereas 
mTORC2 is substantially less sensitive, as rapamycin forms a complex with 
FKBP12 which binds to and inhibits mTORC1 only (Sarbassov et al., 2004). 
 
 
Figure 1.1.6. Components of mTORC1 and 2. 
mTOR complex 1 and 2 differ by non-core components, as shown here 
(adapted from Laplante and Sabatini, 2012).  
 
mTORC1 and 2 are activated by different upstream pathways.  As is a recurrent 
theme in mTOR signalling much more is known about the activation of mTORC1 
than mTORC2.  mTORC1 incorporates signals from multiple intracellular and 
extracellular inputs including amino acids, energy status, growth factors, stress and 
oxygen levels (Zoncu et al., 2011).  The majority of these inputs converge at the 
level of TSC1/2  (tuberous sclerosis 1/2) heterodimer, which acts as a GTPase 
activating protein for Rheb (Ras homolog enriched in brain).  Rheb in its active 
GTP-bound form binds to and activates mTORC1, therefore TSC1/2 negatively 
regulates mTORC1 activity by speeding up the conversion of Rheb-GTP to Rheb-
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GDP (Inoki et al., 2003a).  Several pathways act on TSC1/2 as demonstrated in Fig 
1.1.7.  TSC1/2 activity is inhibited by AKT, ERK and RSK phosphorylation, and 
further enhanced by phosphorylation by AMPK (Inoki et al., 2002) (Ma et al., 2005) 
(Roux et al., 2004) (Inoki et al., 2003b). Additionally mTORC1 activity is regulated 
independently of TSC1/2 by AKT via inhibition of PRAS40 (an mTORC1 inhibitor). 
Upon activation of insulin signalling PRAS40 is phosphorylated by AKT, after which 
it ceases to bind mTOR, and is instead sequestered by 14-3-3 proteins, allowing 
activation of mTORC1 signalling (Vander Haar et al., 2007).  Also, AMPK can 
directly phosphorylate RAPTOR causing allosteric inhibition of mTORC1 in a low 
energy state (Inoki et al., 2003b).  Amino acids are essential for the activation of 
mTORC1 by all inputs, for translocation from the cytoplasm to the lysosomal 
surface via interaction with Rag GTPases.  This is thought to bring mTORC1 into 
proximity with Rheb, which is localised in endomembranes (Sancak et al., 2010).  
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Figure 1.1.7. Overview of mTOR signalling. 
mTORC1 is activated in response to growth factor signalling through RAS-
MAPK, PI3K-AKT, as well as amino acids which facilitate translocation to the 
lysosomal surface.  mTORC1 is inhibited by hypoxia and stress signalling 
through AMPK. Key substrates of mTORC1 are S6K and 4EBP1 resulting in 
increased translation. mTORC2 is activated through growth factors via PI3K, to 
stimulate AGC kinases AKT, SGK1 and PKCα, to promote cell survival and 
cytoskeletal reorganisation. 
 
On the other hand, the mechanism of mTORC2 activation is not well defined.  It is 
not activated by Rheb, and appears to be stimulated by growth factors via PI3K, 
although the exact mechanism is still unclear.  More recently a role for ribosomes in 
mTORC2 activation has been postulated as mTORC2-ribosome association is 
stimulated by PI3K signalling, and seemingly required for mTORC2 activation 
(Zinzalla et al., 2011).  
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mTORC1 is involved in the activation of a variety of cellular processes, the most 
well studied being protein synthesis. Key mTORC1 effectors in this process are 
S6K and 4-EBP1 (Ma and Blenis, 2009). mTORC1 phosphorylates and activates 
S6K, which has important functions in regulating translation initiation factors and 
ribosomal biogenesis.  For example, S6K1 phosphorylates eIF4B that promotes 
recruitment of eIF4B to the pre-initiation complex, where it enhances eIF4A 
function (Holz et al., 2005). eIF4A is required to unwind structured mRNAs to allow 
ribosome binding and translation. Additionally S6K1 enhances eIF4A function by 
inhibiting the negative regulator of eIF4A, PDCD4 (Dorrello et al., 2006). mTORC1 
phosphorylates 4-EBP1 to relieve its repression of eIF4E, also important in 
translation. 4-EBP1 phosphorylation promotes disassociation from eIF4E, which 
can then bind eIF4G and is recruited to the 5’ end of an mRNA, to promote cap-
dependent translation (Ma and Blenis, 2009).  
 
Downstream of mTORC2 activation, relatively few targets have been well 
described.  Confirmed downstream substrates of mTORC2 are the AGC kinases 
AKT, SGK1 and PKC alpha. After many years of searching mTORC2 was identified 
as the second AKT kinase, phosphorylating AKT on Ser473 which is required for 
full activation (Hresko and Mueckler, 2005) (Sarbassov et al., 2005). mTORC2 
activates SGK1 which in conjunction with AKT, negatively regulates FOXO1/3a to 
prevent apoptosis (Garcia-Martinez and Alessi, 2008). FOXO induces the 
expression of pro-apoptotic factors such as Fas-L and the BH3-only protein BIMEL 
(Fu and Tindall, 2008).  AKT and SGK1 can also phosphorylate BAD, which leads 
to its sequestration by 14-3-3 proteins in the cytoplasm, and blocks its pro-
apoptotic function (Datta et al., 1997).  mTORC2 regulates the cell cytoskeleton 
through activation of PKC alpha, rho, rac and paxillin (Jacinto et al., 2004; 
Sarbassov et al., 2004).   
 
mTOR activity is negatively regulated by interaction with a number of other proteins. 
TSC1/2 and PRAS40 only affect the activity of mTORC1, whilst DEPTOR equally 
inhibits both complexes (Peterson et al., 2009). DEPTOR binds to both mTOR 
complexes as the endogenous protein can be immunoprecipitated with antibodies 
against mTOR, RICTOR and RAPTOR from HeLa cell lysates.  DEPTOR inhibits 
mTOR signalling, however the mechanism by which this occurs is not well defined.  
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DEPTOR loss leads to increased activation of mTORC substrates S6K, AKT and 
SGK in full serum conditions (Peterson et al., 2009).  
 
1.7.3 mTOR signalling in cancer 
mTORC signalling is aberrantly activated in a wide range of tumours, as the 
previously described PI3K/AKT and MAPK pathways which are frequently activated 
in cancer both feed into this pathway.  Aside from this, mTORC signalling is also 
upregulated by mutations in LKB1 and TSC1 and TSC2.  LKB1 is an important 
upstream activator of AMPK, which inhibits mTORC1 in nutrient deprived 
conditions. LKB1 loss therefore leads to loss of AMPK activation and subsequent 
downregulation of TSC2 activity. LKB1 has been described as one of the most 
frequently mutated genes in lung adenocarcinoma (Ding et al., 2008). Either by 
mutation or homozygous deletion LKB1 is thought to be inactivated in 
approximately 40% of NSCLC (Gill et al., 2011).  Mutations in TSC1/2 result in 
Tuberous Sclerosis Complex, a tumour susceptibility syndrome characterised by 
benign tumours in multiple organs as a consequence of constitutively active 
mTORC1 signalling. Occasionally, such tumours progress to malignant tumours, 
most commonly in the kidney or pancreas (Inoki and Guan, 2009). Additionally 
mTORC2 is hyperactivated in glioma compared to normal brain through 
overexpression of RICTOR (Masri et al., 2007). 
 
1.8 Mechanisms of resistance to EGFR TKIs in EGFR-mutant 
NSCLC 
1.8.1 Primary resistance to EGFR TKIs 
In populations of patients in which the presence of activating EGFR-mutations has 
not been selected for, treatment with EGFR TKIs provides little advantage to the 
patient.  In unselected trials response rate ranges from 10–55%, whereas in 
patients selected for EGFR activating mutations response rates are substantially 
higher at 70-75% (Pircher et al., 2010).   In addition to lack of response in wild type 
EGFR patients, it has been suggested KRAS mutations cause primary resistance 
to EGFR TKIs in NSCLC, analogous to the situation in colorectal cancer (Dempke 
and Heinemann, 2010). KRAS mutations are associated with poor outcome in 
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response to EGFR TKIs (Bonanno et al., 2010). However, it also appears that 
EGFR and KRAS mutations are mutually exclusive in NSCLC, therefore patients 
with mutated KRAS would most likely express wildtype EGFR, and consequently 
be unlikely to respond to EGFR-TKIs (Pao et al., 2005b). EML4-ALK chromosomal 
rearrangements have also been linked to lack of response to EGFR-TKIs, however 
yet again EML4-ALK expressing tumours generally have wildtype EGFR (Shaw et 
al., 2009).  
 
It also appears that some EGFR mutations although they cause constitutive 
activation of EGFR signalling, and are able to transform NIH-3T3 cells, do not 
render cells sensitive to EGFR tyrosine kinase inhibitors (Greulich et al., 2005).   
Lung adenocarcinoma patients with insertion mutations in exon 20 of EGFR are not 
sensitive to erlotinib or gefitinib, although they are sensitive to irreversible EGFR 
inhibitors. 
1.8.2 The T790M mutation  
As aforementioned, the occurrence of resistance to EGFR TKI is a major problem 
in their efficacy to treat lung cancer.  Several mechanisms of acquired resistance 
have been suggested, however few have been validated in a clinical setting.  The 
most common causes of resistance occurring in patients are a secondary mutation 
in the EGFR kinase domain (T790M) and the amplification of MET, encoding the 
receptor for HGF (Engelman et al., 2007; Pao et al., 2005a). 
 
A secondary T790M mutation in the EGFR kinase domain is the most frequently 
found mechanism of acquired resistance, occurring in approximately 60% of 
resistant cases (Pao et al., 2005a).  This ‘gate-keeper’ mutation reduces the ability 
of EGFR TKIs to bind in the ATP cleft, analogous to the T315I mutation conferring 
resistance to the BCR-ABL inhibitor imatinib (Gorre et al., 2001).  It is also thought 
that T790M mutation mediates resistance by increasing the affinity of EGFR for 
ATP (Yun et al., 2008).  EGFR TKIs must compete with ATP, the natural substrate 
of EGFR to bind in the ATP binding pocket.  EGFR activating mutations sensitise 
EGFR to inhibition by TKIs as they reduce its affinity for ATP, allowing TKIs 
opportunity to bind.  The T790M mutation restores the affinity of mutant EGFR to 
wildtype levels, thereby reducing the effect of TKIs (Yun et al., 2008).  
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There is some evidence that T790M when occurring in cis with activating EGFR 
mutations, enhances EGFR signalling and increases oncogenic capacity of cells 
(Godin-Heymann et al., 2008). However counter-intuitively, patients with acquired 
resistance to EGFR TKIs and the T790M mutation have been shown to have longer 
progression-free survival and tend to develop metastases later than patients 
without the mutation when maintained on EGFR TKI treatment (Oxnard et al., 
2011b). This indicates T790M mutation may not enhance the tumourigenic capacity 
of cells beyond conferring resistance to EGFR TKIs.  It has been argued that the 
T790M mutation may actually slow growth of tumour cells, therefore it does not 
provide any growth advantage in the absence of the selection pressure provided by 
EGFR TKIs (Chmielecki et al., 2011).  Chmielecki et al. derived PC9 and HCC827 
cells resistant to erlotinib or an irreversible EGFR inhibitor, which they found to 
contain the T790M allele.  The growth rate of T790M-containing cells was 
significantly slower than that of the TKI-sensitive non-T790M cells, and the T790M 
mutation was lost from the cell population over time in the absence of an EGFR TKI 
(Chmielecki et al., 2011).  This indicates that in the absence of drug selection the 
T790M provides no proliferative advantage to tumour cells, and could possibly 
explain how patients who have become resistant to erlotinib, may re-respond to 
treatment after a ‘drug holiday’ (Becker et al., 2011; Oxnard et al., 2011a).  
However it is important to note that H3225 cells generated in the same manner 
retained T790M in the absence of EGFR TKIs, and it did not affect the growth rate, 
indicating it is likely to be highly context dependent (Chmielecki et al., 2011). 
Therefore whether T790M in cis with activating EGFR mutations increases 
oncogenic capacity beyond EGFR-TKI resistance is still under debate. 
 
Another question surrounding T790M mediated resistance, is how it arises?  Is it a 
de novo mutation, or is it present at a low level in tumours and selected for during 
drug treatment? With the development of increasingly sensitive techniques it 
seems that T790M drug resistant clones are present at low frequencies in tumours 
pre-treatment, and that they are selected for during TKI treatment due to their 
survival advantage (Maheswaran et al., 2008) (Oh et al., 2011).   
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1.8.3 Other secondary EGFR mutations that confer resistance to EGFR 
TKIs 
T790M is the secondary EGFR mutation overwhelmingly associated with EGFR 
TKI resistance, however it is possible other EGFR mutations may also play a role.  
D761Y mutations have been found in rare cases in NSCLC patients that have 
EGFRL858R activating mutations but are refractory to EGFR TKI treatment (Balak et 
al., 2006; Tokumo et al., 2006).  In one patient who initially responded to gefitinib 
the EGFRD761Y mutation was found in a brain metastasis shortly after disease 
progression (Balak et al., 2006).  In a separate case study the D761Y mutation was 
found in the primary tumour and liver metastasis of a patient unresponsive to 
gefitinib (Tokumo et al., 2006).  293T cells transfected with an L858R D761Y 
mutant EGFR cDNA were modestly more resistant to gefitinib treatment than the 
L858R mutant alone, indicating the mutation increases resistance to EGFR TKIs.  
However the increase in resistance was small compared to that conferred by the 
T790M mutation (Balak et al., 2006).  
1.8.4 Amplification of MET  
Aside from the T790M mutation, amplification of the MET gene encoding the MET 
tyrosine kinase receptor is the most prevalent mechanism, found in 5-15% of 
resistant cases (Arcila et al., 2011; Sequist et al., 2011).  MET amplification 
provides an alternative route to maintain AKT signalling, necessary for survival, in 
erlotinib-treated cells. In MET amplified cells MET heterodimerises with ERBB3, 
leading to the recruitment of p85, and through this mechanism PI3K-AKT signalling 
is retained in the presence of EGFR TKIs (Engelman et al., 2007).   
 
As with the T790M mutation, recent studies suggest MET amplification is also 
present at low levels within a tumour cell population, and preferentially selected for 
during drug treatment.  Turke and colleagues detected MET amplification in 6% 
HCC827 cells examined (Turke et al., 2010).  Turke et al. also linked expression of 
MET receptor ligand HGF to the emergence of MET amplification in HCC827 cells.  
They found that co-treatment of HCC827 cells with gefitinib and HGF, lead to a 
significant increase in gefitinib resistance, and that cells remained resistant after 
HGF withdrawal due to a 3 to 4 fold amplification of MET.  This is presumably 
because cells expressing amplified levels of MET have a selective advantage in the 
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presence of high levels of HGF.  Interestingly, it appears that whilst accelerating 
selection of MET amplified clones, HGF also causes a transient increase in 
resistance by a distinct signalling mechanism.  HGF treatment renders NSCLC 
cells transiently resistant to EGFR TKIs by promoting the association of GAB1 and 
the p85 subunit of PI3K, thus activating AKT. However in contrast to MET amplified 
cells, this mechanism is independent of ERBB3 (Yano et al., 2008) (Fig.1.8). 
 
Figure 1.1.8. MET-mediated acquired resistance to EGFR-TKIs. 
Amplification of MET leads to increased PI3K-AKT activation via 
heterodimerisation with ERBB3.  MET amplification is hastened by exposure to 
HGF, however HGF also mediates transient resistance by increasing PI3K-AKT 
signalling via GAB1 independently of ERBB3. 
1.8.5 Histological transformation to SCLC  
Recently Sequist and colleagues published a study detailing the histological and 
genetic alterations of 37 patients with drug-resistant NSCLC with EGFR mutations 
(Sequist et al., 2011). In this study they identified the previously known T790M 
mutation and MET amplification as well as some novel mechanisms of resistance.  
The most surprising finding was the histological transition of 5 patients’ tumours 
from NSCLC to SCLC, and their subsequent sensitisation to standard SCLC 
treatments.  Another rebiopsy study also revealed this phenomenon, albeit at a 
lower frequency.  Arcila and colleagues found 2% of patients exhibited SCLC 
morphology in resistant tumours, where NSCLC had been observed before 
treatment, a substantially lower percentage than the 14% identified by Sequist et 
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al.(Arcila et al., 2011).  Detection of EGFR-TKI refractory SCLC after an initial 
diagnosis of EGFR-mutant adenocarcinoma is rare but had been reported prior to 
the new studies.  Zakowski describes one patient with adenocarcinoma who had a 
partial response to erlotinib treatment, but after disease progression was found to 
have SCLC, however this patient did not respond to etoposide, a common 
treatment for SCLC (Zakowski et al., 2006).  
 
1.8.6 Activation of PI3K/AKT signalling by somatic mutations in PIK3CA 
and PTEN 
Other mechanisms of resistance observed by Sequist and colleagues included an 
acquired PIK3CA mutation, with resistance presumably arising from increased 
PI3K signalling.  Other groups have observed PIK3CA mutations in approximately 
4% of NSCLC, which is correlated to poor outcome for patients treated with EGFR 
TKIs (Ludovini et al., 2011). In this study time to progression between wildtype and 
mutant PIKCA3 patients was 30.2 months compared to 9.9 months respectively. 
They identified one patient with an EGFR and a PIKC3A mutation, who 
experienced an extremely short (4 months) response to erlotinib suggesting 
PI3KCA mutations may attenuate response to TKI treatment.  PIK3CA mutations 
have been linked to poor response to other ERBB family (HER2) inhibitors 
trastuzumab and lapatinib in HER2-positive breast cancer indicating they may 
cause resistance to ERBB family targeted therapies (Wang et al., 2011).  
 
Loss of PTEN, again activating PI3K signalling has also been suggested as a 
mechanism for resistance to EGFR TKIs in NSCLC. Sos and colleagues identified 
homozygous loss of PTEN as the reason for erlotinib resistance in the EGFR-
mutant NSCLC cell line H1650 (Sos et al., 2009). As a result of PTEN loss H1650 
cells retained high levels of phosphorylated AKT despite inhibition of EGFR by 
erlotinib.  This effect could be reversed by reconstitution of PTEN expression in 
these cells. They also described that silencing of PTEN in PC9 cells lead to 
increased phosphorylation of ERK and EGFR in erlotinib-treated conditions 
compared to PTEN expressing cells, possibly through upregulation of EGFR ligand 
expression by ERK.  Additionally, PTEN instability has been described to cause 
resistance to gefitinib in a cetuximab resistant subline of EGFR-mutant NSCLC 
Chapter 1. Introduction 
  40 
HCC827 cells, whereas parental HCC827 cells are sensitive to EGFR TKIs (Kim et 
al., 2010a). PTEN loss is relatively common in NSCLC (approximately 35%), 
however a causative link to EGFR-TKI resistance in patients is yet to be clinically 
established (O'Byrne et al., 2011).  
 
1.8.7 Epithelial-Mesenchymal Transition 
Sequist and colleagues additionally found 2 cases of epithelial-to-mesenchymal 
transition (EMT) (Sequist et al., 2011). EMT is a phenotypic transformation of 
epithelial cells to a more mesenchymal phenotype. Presence of EMT is often 
demonstrated by loss of epithelial markers such as E-cadherin and cytokeratins, 
and gain of mesenchymal markers such as vimentin and N-cadherin (Thiery, 2002). 
EMT has been proposed as a mechanism of resistance to EGFR inhibitors in a 
number of studies in vitro (Buck et al., 2007; Thomson et al., 2005; Thomson et al., 
2008).  Thomson et al. suggest EMT confers resistance by causing a switch in 
kinase pathway activation. They find EGFR, ERBB2 and ERBB3 phosphorylation is 
attenuated in mesenchymal-like cells, and expression of EGFR family ligands is 
decreased (Thomson et al., 2005; Thomson et al., 2008). Conversely PDGFR, 
FGFR and TGFβ receptor expression increased in cells stimulated to undergo EMT 
by TGFβ overexpression (Thomson et al., 2008). However it is important to note 
these studies were carried out in wild-type EGFR cell lines, potentially limiting their 
relevance to the clinical situation.  
 
Sequist et al provides clinical evidence for EMT as a mechanism of acquired 
resistance in EGFR-mutant NSCLC (Sequist et al., 2011).  This discovery is 
supported by another study where Chung and colleagues found HCC827 cells 
generated to be resistant to irreversible EGFR inhibitor CL-387,785 showed the 
hallmarks of EMT such as loss of E-cadherin and increased vimentin expression 
(Chung et al., 2010). 
1.8.8 Alterations in IGFR signalling 
Other potential mechanisms of resistance discovered link to alterations in IGFR 
signalling. It has been described that loss of IGF binding proteins can cause 
resistance to EGFR TKIs by activating the IGF1 receptor (Guix et al., 2008).  In 
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gefitinib resistant A431 cells IGFR1 activation lead to constitutive association of 
IRS-1 with PI3K, and subsequent phosphorylation of AKT, even in the presence of 
EGFR TKIs.  IRS-1 and PI3K are not found to be associated in parental A431 cells, 
which are sensitive to EGFR inhibition, indicating this interaction is an adaptation 
acquired by resistant cells (Guix et al., 2008).  
 
IGFR1 signalling was also found to be essential for the emergence of drug tolerant 
PC9 NSCLC cells (Sharma et al., 2010).  Sharma and colleagues noticed that 
whenever they acutely treated PC9 cells with EGFR TKIs, there was always a 
small population of cells still surviving after 9 days treatment.  Upon further 
investigation they found these cells arise de novo from the population and are 
transiently resistant to drug treatment due to epigenetic mechanisms.  Drug tolerant 
cells express higher levels of KDM5A, a histone demethylase, and also increased 
levels of IGFBP3 that leads to elevated IGFR1 phosphorylation.  Co-treatment of 
PC9 cells with EGFR TKI and an IGF1R inhibitor prevents the emergence of drug 
tolerant cells.  Elevated IGF1R signalling and KMD5A expression appear to be 
linked and necessary for acquisition of transient drug tolerance (Sharma et al., 
2010). 
1.8.9 NF Kappa B signalling 
Another suggested mechanism of resistance to erlotinib in NSCLC is via activation 
of the NF Kappa B signalling pathway (Bivona et al., 2011).  NF Kappa B signalling 
has previously been implicated in lung tumourigenesis in a KRAS-driven p53 null 
background. Bivona and colleagues found that RNAi mediated silencing of FAS 
and other components of the NF Kappa B pathway such as RELA and c-FLIP 
enhances sensitivity of NSCLC cells to erlotinib treatment (Bivona et al., 2011).   
Additionally they found IkB expression correlated with survival in a cohort of 52 
EGFR-mutant lung cancer patients who had been treated with EGFR TKIs.  Low 
expression of IkB, indicating high NF Kappa B activation, correlated with poorer 
progression-free survival.  This effect seemed specific to EGFR TKI treatment, as 
IkB expression was not predictive of outcome in patients receiving chemotherapy 
and surgery.    
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1.8.10 CRKL amplification 
One of the most recently proposed mechanisms of resistance to EGFR-TKIs is the 
amplification of CRKL (Cheung et al., 2011a).  CRKL is an adaptor protein 
containing an SH2 domain and two SH3 domains, allowing binding to other 
important signalling proteins such as GAB1, SOS and p85 (Birge et al., 2009; 
Feller, 2001).  CRKL is amplified in a subset of primary lung adenocarcinomas and 
NSCLC cell lines (Kim et al., 2010b).  Cheung and colleagues found CRKL 
amplification in samples from a patient with acquired resistance to EGFR-TKIs, 
where there was no evidence of CRKL amplification prior to EGFR-TKI treatment. 
CRKL amplification is thought to mediate resistance by activation of MAPK 
signalling via increased recruitment of SOS to the plasma membrane, and 
enhanced PI3K-AKT signalling via p85 (Cheung et al., 2011a). 
1.8.11 Activation of AXL kinase 
A novel mechanism of resistance established this year is the activation of the 
receptor tyrosine kinase AXL (Zhang et al., 2012).  Zhang and colleagues found 
AXL expression and activation was increased in erlotinib resistant HCC827 cells 
and resistant tumour xenografts.  AXL upregulation seems to increase resistance at 
least in part by activating the PI3K-AKT and MAPK pathways. Additionally AXL 
ligand GAS6 expression was increased in erlotinib resistant cell lines and some 
erlotinib resistant tumours, indicating overexpression of AXL or increased activation 
by GAS6 can drive resistance (Zhang et al., 2012).  Also Zhang et al. found 
increased expression of vimentin in some erlotinib resistant tumours with AXL 
upregulation, which is suggestive of EMT, however a direct link between AXL 
expression and EMT is yet to be established. 
 
1.8.12 Alternative mechanisms of resistance 
Current clinically validated mechanisms of resistance; EGFRT790M mutation, MET 
amplification and SCLC transformation account for 70% of EGFR TKI resistant 
NSCLC cases (Fig.1.9) (Oxnard et al., 2011a; Sequist et al., 2011).  Taking in to 
account all mechanisms, cause of resistance is still unknown in 25-30% of cases. 
Therefore the aim of my project was to determine novel mechanisms of resistance 
to EGFR TKIs. 
Chapter 1. Introduction 
  43 
 
 
Figure 1.1.9. Mechanisms of acquired resistance to EGFR-TKIs in NSCLC. 
Frequency of acquired resistance to EGFR-TKIs. PIK3CA mutations and EMT 
are included in unknown, as they have been found in small subsets of patients 
and currently the prevalence is unclear.  Adapted from Sequist et al., 2011.   
 
1.8.13 Outline of subsequent chapters 
The first results chapter of this thesis describes a genome-wide siRNA screen we 
carried out in order to identify novel genes involved in the response to EGFR-TKIs 
in EGFR-mutant NSCLC. The aim of the screen was to identify new therapeutic 
targets that could be targeted to improve the efficacy of erlotinib, or alternatively 
identify potential biomarkers of resistance.  The remaining results chapters 
describe two genes that we identified in the screen (DEPTOR and NF1 
respectively).   Depletion of these genes by RNAi increases resistance of EGFR-
mutant NSCLC to erlotinib treatment. Mechanisms of resistance caused by loss of 
these genes are described, as well as potential combination therapies for patients 
in which function of these genes is lost.  
 
Chapter 2. Materials and Methods  
  44 
Chapter 2. Materials & Methods 
2.1 Materials 
2.1.1 Drugs 
All drugs were solubilised in DMSO or H20 according to manufacturer’s instructions 
and stored at -20°C. 
 
AKT inhibitors 
MK2206 (Acitve Biochem) 
 
mTOR allosteric inhibitors 
Temsirolimus (LC Laboratories) 
 
mTOR kinase inhibitors 
AZD8055 (ChemieTek) 
 
EGFR inhibitors 
Erlotinib (Enzo Life Sciences) 
Gefitinib (Enzo Life Sciences) 
 
MEK inhibitors 
AZD6244 (Axon MedChem) 
 
Taxane and platinum-based therapeutric drugs 
Docetaxel (Sigma) 
Cisplatin (Sigma) 
 
 
2.1.2 Antibodies 
Antibodies were used at the dilutions indicated in PBS supplemented with 0.1% 
Tween-20 and 3% BSA. Antibodies were stored at -20°C or 4°C according to 
manufacturer’s instructions.   
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α-Tubulin 
Mouse monoclonal (Sigma), 1:1000 dilution 
Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
p44/42 MAPK (ERK1/2) 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
Phospho-AKT (Ser473) 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
AKT 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
Phospho-EGF Receptor (Tyr1068) 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
EGF Receptor  
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
EGF Receptor coupled to agarose beads 
Goat IgG (Santa Cruz), 50 µl per immunoprecipitation 
HER2 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
HER3  
Rabbit monoclonal (Cell Signalling), 1:1000 dilution 
IGF-IR β 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
MET 
Mouse monoclonal (Cell Signalling), 1:1000 dilution 
NF1 
Rabbit polyclonal (Bethyl Laboratories), 1:1000 dilution  
Phospho-S6 Ribosomal Protein (Ser235/236) 
Rabbit polyclonal (Cell Signalling) 1:1000 dilution 
S6 Ribosomal Protein 
Rabbit monoclonal (Cell Signalling), 1:1000 dilution 
Phospho-4-EBP1 (Thr37/46) 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
4-EBP1 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
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DEPTOR 
Rabbit polyclonal (Novus Biologicals), 1:500 dilution 
Phospho-NDRG1 (Thr346) 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
NDRG1 
Rabbit polyclonal (Cell Signalling), 1:1000 dilution 
 
2.1.3 Buffers and solutions 
NuPAGE LDS Sample buffer and MES running buffer were purchased from 
Invitrogen. PBS, trypsin and versene were provided by CRUK Cell Services. Dried 
milk was from Marvel.  All chemicals were from Sigma. 
 
Commonly used buffers and solutions were: 
 
Cell lysis buffer 
20 mM Tris-HCl (pH 7.4) 
137 mM NaCl 
2 mM EDTA 
10% glycerol 
1% Triton X-100 
 
Tris buffered saline (TBS) 
137 mM NaCl 
25 mM Tris-HCl (pH 7.4) 
 
Triton X-100 lysis buffer 
20 nM Tris-HCl (pH 7.4) 
137 mM NaCl 
2 mM EDTA 
10% Glycerol 
1% Triton X-100 
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Transfer buffer 
25 mM Tris Base 
250 mM glycine 
20% methanol 
 
Washing buffer (TBST) 
TBS 
0.1% Tween-20 
 
Blocking solution 
TBS 
0.1% Tween-20 
5% dried milk (Marvel) 
 
2.1.4 siRNA oligonucleotides 
The human genome wide siGENOME SMARTpool library was purchased from 
Dharmacon.  Each SMARTpool contained 4 oligonucleotides of different 
sequences to target the gene of interest. Shown below is the sequence information 
of each of the 4 oligos of the 26 top hits from the genome-wide screen, which 
validated in the deconvolution analysis. 
 
Top Hits 
Target Gene Locus ID RefSeq  19mer sense sequence 
ABBC8 6833  NM_000352 GGUCAACGCCAGCGAAUCA 
ABBC8 6833  NM_000352 GGUCUACUAUCACAACAUC 
ABBC8 6833  NM_000352 GGUACAAGAUGGUCAUUGA 
ABBC8 6833  NM_000352 CAACAUUGCUUCCCUCUUC 
BRD2  6046  NM_005104 UUAGAGAGCUUGAGCGCUA 
BRD2  6046  NM_005104 GAUGAAGGCUCUGUGGAAA 
BRD2  6046  NM_005104 GAAAAGAUAUUCCUACAGA 
BRD2  6046  NM_005104 AGAAAGGGCUCAUCGCUUA 
C10ORF76 79591  NM_024541 UAUCACAUAUGGCGACACA 
C10ORF76 79591  NM_024541 CAGAAGAAGUGUCGGGUAC 
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C10ORF76 79591  NM_024541 UCAAAGAGCUGGUUCGAUC 
C10ORF76 79591  NM_024541 GGUCAGCCUUGAUAAAUUU 
C21ORF2 755  NM_004928 GAAGACAUAUGGCAAGUUU 
C21ORF2 755  NM_004928 CGAAACAGCUGGAUUCAGA 
C21ORF2 755  NM_004928 UCAACAGACUCACUAAAUA 
C21ORF2 755  NM_004928 GGAAGAAGCUUGUACGUGA 
CD72  971  NM_001782 GUUCACAGGUGUCGCGAUC 
CD72  971  NM_001782 GACAAAGCCUCCUUCGCUA 
CD72  971  NM_001782 ACACCAGGGUCUCGGAAUU 
CD72  971  NM_001782 CAACGCGGGUCUCAGGUUU 
CDX4  1046  NM_005193 AAUAAUGCCCACAGGGACA 
CDX4  1046  NM_005193 GCGCAACAAUGGCCACAGU  
CDX4  1046  NM_005193 CGACGCAGCCUUUGAAUGG 
CDX4  1046  NM_005193 GGAUCUACCUGAAGUUAAG 
COX4I1 1327  NM_001861 CCAAGUGGGACUACGAAAA 
COX4I1 1327  NM_001861 CGAGUUGUAUCGCAUUAAG 
COX4I1 1327  NM_001861 GCAGAAGCACUAUGUGUAC 
COX4I1 1327  NM_001861 UGUACGAGCUCAUGAAAGU 
DEPDC6 64798  NM_022783 GGACGAUUGUCAUGGAAGU 
DEPDC6 64798  NM_022783 GAUCGUGUCUGCAGUGAGG 
DEPDC6 64798  NM_022783 ACAGAGAGACGGCAAUUAA 
DEPDC6 64798  NM_022783 GGACAGAGGCUAUAUGAAA 
ECGF1 1890  NM_001953 GUAUCGUGGGUCAGAGUGA 
ECGF1 1890  NM_001953 GGACGGAAUCCUAUAUGCA 
ECGF1 1890  NM_001953 GCUGCAAGGUGCCAAUGAU 
ECGF1 1890  NM_001953 CAGCCUCCAUUCUCAGUAA 
IRAK4  51135  NM_016123 AAAGUUAGCUGAAUAUGGA 
IRAK4  51135  NM_016123 GAACAGCUCACAAGUAUAU 
IRAK4  51135  NM_016123 GUACAUACCUGGCUGGAUU 
IRAK4  51135  NM_016123 GCACGAGUAUCUUUGUUUA 
LOC388633 388633 NM_001010978 GUUCACAGGUGUCGCGAUC 
LOC388633 388633 NM_001010978 GACAAAGCCUCCUUCGCUA 
LOC388633 388633 NM_001010978 ACACCAGGGUCUCGGAAUU 
LOC388633 388633 NM_001010978 CAACGCGGGUCUCAGGUUU 
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LPXN  9404  NM_004811 GGUACAAGUUCCAUCCUGA 
LPXN  9404  NM_004811 GCGCAGCUCGUGUAUACUA 
LPXN  9404  NM_004811 CUUCGGAGAUCCUUUCUAU 
LPXN  9404  NM_004811 AGAGUUAGAUGCCUUAUUG 
MEF2A 4205  NM_005587 CAACAGCUCUAACAAACUG 
MEF2A 4205  NM_005587 GAAUGGAUUUGUAAACUCA 
MEF2A 4205  NM_005587 CAAACCACAUUACAUAGAA 
MEF2A 4205  NM_005587 GAGAAAGUUUGGAUUAAUG 
MGC26818 127281 NM_152371 GAUGAUGUUUUCCUACUUU 
MGC26818 127281 NM_152371 CUGUUAAGCUUCAUCAGUA 
MGC26818 127281 NM_152371 GAACUGAGGAGACUCUUUG 
MGC26818 127281 NM_152371 GGACAGGGAAGUCUUAUUU 
NF1  4763  NM_000267 GGAAUAAGAUGGUAGAAUA 
NF1  4763  NM_000267 GAUAGAAGCUACAGUAAUA 
NF1  4763  NM_000267 CAACAAAGCUAAUCCUUAA 
NF1  4763  NM_000267 CACCGAGUCUUACAUUUAA 
PDXK  8566  NM_003681 GAGGAAGCCUUGCGGGUGA 
PDXK  8566  NM_003681 ACUACGUGCUCACAGGUUA 
PDXK  8566  NM_003681 UGACCGAAACUUGAUAUUU 
PDXK  8566  NM_003681 GACCGAAACUUGAUAUUUU 
PHF8  23133  NM_015107 GGACAUCUUUCGCGGUUUG 
PHF8  23133  NM_015107 GGAGGGAACUUCUUACACA 
PHF8  23133  NM_015107 CAGCAGACCUCUUCAGAUU 
PHF8  23133  NM_015107 GAACCAAGAUAGCAAAGAA 
PHKA1 5255  NM_002637 GGUCUGAUCAUACAAGUUA 
PHKA1 5255  NM_002637 GAACAGACCUCUCCUACCU 
PHKA1 5255  NM_002637 UCACUCAGCUGAUAGAUGA 
PHKA1 5255  NM_002637 GCAAACAACCUGCGACUUA 
POLE4 56655  NM_019896 ACGUGACGCUAGCGGGACA 
POLE4 56655  NM_019896 AGAGGAGAGACUUGGAUAA 
POLE4 56655  NM_019896 GAGUGAAGGCCUUGGUGAA 
POLE4 56655  NM_019896 GGAAGGUACUUUAGAUUGA 
PQLC1 80148  NM_025078 UCAAGAUGGUGCUCAUGUG 
PQLC1 80148  NM_025078 GGAGCAGCUUCUCGGACUA 
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PQLC1 80148  NM_025078 GCAGAGCGCCAUCAUGAUC 
PQLC1 80148  NM_025078 UCACCUACCUGUCCAUUGA 
SDC2   6383  NM_002998 GGUCAGAUGCACUCGGAAC 
SDC2   6383  NM_002998 AGGUCCUGGUGUACAAUAA 
SDC2   6383  NM_002998 CUACUGACUUUCCCGGUAA 
SDC2   6383  NM_002998 GGAAUGAGAAGCUAAAGAA 
SGPP2 130367 NM_152386 ACUGGAAUAUUGACCCUUA 
SGPP2 130367 NM_152386  CAUCUGCGCUACAACCUUU 
SGPP2 130367 NM_152386 AGAAGUACGUCGUGAAGAA 
SGPP2 130367 NM_152386 UGAAGUGCCUUACAAGUUU 
SLC4A8 9498  NM_004858 GGACACUCAUUCAGAGGUA 
SLC4A8 9498  NM_004858 CAAAUGCUGUGUCUUAUAG 
SLC4A8 9498  NM_004858 UCACUAAGCACUCGUGUUA 
SLC4A8 9498  NM_004858 GAACCAAGAUGAAUAGCAA 
WDFY1 57590  NM_020830 UCGAGGCGCUUUCAGGUAA 
WDFY1 57590  NM_020830 GCAAAGGAUUCGGAAACUU 
WDFY1 57590  NM_020830 UAGACAAACUGAAUGGAUU 
WDFY1 57590  NM_020830 GAACGCACUAUUACAGUUA 
ZC3HDC6 376940 NM_198581 CAAACAGCGUGGUCAAGUA 
ZC3HDC6 376940 NM_198581 CAAGAAAGGCCACUACGAA 
ZC3HDC6 376940 NM_198581 GGAAUUCUGUCUUCACAAG 
ZC3HDC6 376940 NM_198581 CAAAGCAGCUGUACUUCUC 
ZNF291 49855  NM_020843 GAACAUCGAUCGCAACAUC 
ZNF291 49855  NM_020843 UGAGAGAGGAUGAUUCUUA 
ZNF291 49855  NM_020843 CAGCAAGUCUGAAGUUGAA 
ZNF291 49855  NM_020843 CCAUGAACAUCGAUCGCAA 
 
Controls 
Target Gene Locus ID RefSeq  19mer sense sequence 
PLK1   5430   NM_005030  CAACCAAAGUCGAAUAUGA 
PLK1   5430   NM_005030 CAAGAAGAAUGAAUACAGU 
PLK1   5430   NM_005030 GAAGAUGUCCAUGGAAAUA 
PLK1   5430   NM_005030  CAACACGCCUCAUCCUCUA 
UBB   7314   NM_018955  GCCGUACUCUUUCUGACUA 
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UBB   7314   NM_018955  GUAUGCAGAUCUUCGUGAA 
UBB   7314   NM_018955  GACCAUCACUCUGGAGGUG 
UBB   7314   NM_018955  UCGAAAAUGUGAAGGCCAA 
BIRC5  332  NM_001168 CAACGGAUUUGGUCGUAUU 
BIRC5  332  NM_001168 CAACGGAUUUGGUCGUAUU 
BIRC5  332  NM_001168  CAACGGAUUUGGUCGUAUU 
BIRC5  332  NM_001168 GUCAACGGAUUUGGUCGUA 
 
Also used as controls were: 
siGENOME RISC-Free Control siRNA 
siGENOME Non-Targeting siRNA Pool #2 
ON-TARGET Non-Targeting pool 
(All purchased from Dharmacon) 
 
2.1.5 ShRNA constructs 
Open Biosystems 
The following shRNA constucts were purchased from Open Biosystems as target 
sets of varying numbers of constructs. Listed below are the mature sense 
sequences of each hairpin used.  These constructs were based on the pGIPZ 
lentiviral vector backbone. 
 
NF1 (Target set for NM_000267) 
shNF1 #1 V2LHS_ 189526  CAGATACACCTGTCAGCAA 
shNF1#2 V2LHS_76027  CTGGCAGTTTCAAACGTAA 
 
Non-silencing GIPZ lentiviral shRNAmir negative control viral particles (RHS4348) 
were used to generate shSC control cells. 
 
Addgene 
The following constructs were purchased from Addgene.  Shown below are the 
sequences of the hairpins expressed from these constructs. 
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Addgene plasmid 1864 - Scrambled shRNA (Sarbassov et al., 2005). 
 
5’- CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 
 
Addgene plasmid 21335 - DEPTOR shRNA 1 (Peterson et al., 2009). 
 
5'-
CCGGGCCATGACAATCGGAAATCTACTCGAGTAGATTTCCGATTGTCATGGCT
TTTTG 
 
Addgene plasmid 21336 - DEPTOR shRNA 2 (Peterson et al., 2009) 
 
5'-
CCGGGCAAGGAAGACATTCACGATTCTCGAGAATCGTGAATGTCTTCCTTGCT
TTTTG 
 
2.2 Methods 
2.2.1 Mammalian cell culture 
 
2.2.1.1 Cell lines and culture conditions 
HCC827, H1650, H3255, HCC2935 and HCC4006 cells were obtained from ATCC 
(American Type Culture Collection).  PC9 cells and Phoenix-ampho cells were 
provided by Cancer Research UK Cell Services. HEK293T cells were obtained 
from Thermo Scientific Open Biosystems. With the exception of the packaging cell 
lines, all cells were cultured as monolayers in RPMI (Roswell Park Memorial 
Institute) media supplemented with 10% foetal bovine serum (FBS), and antibiotics 
penicillin (0.006g/l) and streptomycin (0.1g/l).  Cells were kept in incubators at 37°C 
and 5% CO2 atmosphere and were split at 1:10 every 2-3 days when they had 
become confluent. HEK293T and Phoenix-ampho cell lines were cultured in DMEM 
(Dulbecco’s Modified Eagle Medium) with the aforementioned supplements, and 
kept in incubators at 37°C and 5% CO2 atmosphere. To split the cells, the media 
was removed, the cells were washed once in PBS and then a 1:3 tryspin/versene 
mixture was added to detach cells.  Once cells had detached the trypsin was 
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neutralised with fresh media.  Cells were counted using a cell counter (Countess, 
Invitrogen), and replated.  
 
For storage cells were trypsinised and centrifuged at for 4 mins at 1200 rpm, and 
resuspended in freezing media (RPMI media containing 10% FBS and 10% 
DMSO).  Cell were aliquoted into 1.5 ml cryogenic vials and frozen in isopropanol 
freezing tanks at -80°C for 24 hours before being transferred to liquid nitrogen for 
long term storage.  
 
PC9-ER (erlotinib resistant) cells were generated previously by growing PC9 cells 
in media containing 1µM erlotinib. Surviving clones were picked and cultured in the 
presence of 1µM erlotinib for 3 months, and thereafter without erlotinib. 
 
2.2.2 Screening  
 
2.2.2.1 Genome-wide screen 
The genome-wide screen was conducted in both erlotinib-treated and untreated 
conditions in two independent experiments.  In each screen every siRNA was 
transfected in triplicate for treated and untreated conditions. The Dharmacon 
siGENOME SMARTpool siRNA library containing 21121 siRNA pools was 
aliquoted into sets of 201 384-well plates by the High Throughput Screening 
Facility and stored at -20°C. On the first day of each screen, we transfected one 
batch of 201 plates in the morning and one in the afternoon, for the control and 
drug treated plates respectively. Firstly, the library was thawed for 20 mins and the 
plates were centrifuged at 1500 rpm for 1 min.  Then 2.5 µl/ well of the control 
siRNAs were added per well to the first four columns of each plate which had been 
left empty for this purpose. Risc Free and ON TARGET-non-targeting were used as 
negative controls to normalise for the stress of transfection without gene silencing.  
BIRC5, PLK1 and UBB were included as killing controls, which cause a significant 
amount of cell death.   
 
Next, 3 µl diluted Dharmafect 2 (Dharmacon) (0.025 µl/µl) was added per well 
using the WellMate dispenser to give a final amount of 0.075 µl Dharmafect 2 per 
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well.  Plates were then incubated at room temperature for 15 mins, before the 
WellMate was again used to dispense 80 µl per well PC9 cell suspension (6.25 × 
103 cell/ml) resulting in a final cell number of 500 cells per well.  After 48 hours, 
media was removed from the cells using a plate washer and 80 µl of fresh RPMI 
was added either with or without 30 nM erlotinib using the WellMate.  As a control 
for the drug treatment 2 columns of the control siRNAs were left untreated in the 
erlotinib-treated plates. After an additional 72 hours media was removed with a 
plate washer and 90 µl ice-cold 80% EthOH was added with the WellMate. Plates 
were then stored at -20°C and subsequently stained in batches.  For the staining 
each plate was washed 3 times with PBS using a plate washer, then 20 µl/well 
DAPI (diluted in PBS 1:10,000) was added using WellMate.  Plates were incubated 
at room temperature in the dark for 1 hour before plates were washed once with 
PBS. Plates were sealed and stored at 4°C in PBS for scanning.  Plates were 
scanned using an Acumen Explorer microplate cytometer (TTP LabTech) to 
quantify the number of cells in each well. 
 
The subsequent deconvolution screen was also carried out using the same method 
as described here, however the plate layouts were adapted so that untreated and 
erlotinib-treated wells for each siRNA were in the same plate.  Additonally, 
siGENOME non-targeting siRNA pool #2 was included as a negative control. 
 
2.2.2.2 Data analysis of genome-wide screen 
The raw value recorded for each sample was cell number.  Each screening plate 
was normalised using a robust Z score calculation: 
 𝑥!"! = 𝑥!" −  𝑚𝑒𝑑𝑖𝑎𝑛!𝑀𝐴𝐷!  
 
The median value of all samples on plate i is represented by mediani and is 
subtracted from the raw value of well k represented by 𝑥!". Each well is then 
divided by the median absolute deviation (MAD) of all sample wells on that plate (𝑀𝐴𝐷!) to provide the normalised Z score shown as 𝑥!"! . In order to account for 
positional and edge effects a smoothed Z score was also calculated.  This was 
based on the median and MAD calculated when comparing the distribution of Z 
Chapter 2. Materials and Methods  
  55 
scores of a well position across all plates within the screen. Here 𝑚𝑒𝑑𝑖𝑎𝑛!" is the 
median Z score of a single well position (k) in all plates in the screen.  𝑀𝐴𝐷!" is the 
MAD calculated from all samples at position (k) across all plates of the screen. 
 
 𝑆𝑚𝑜𝑜𝑡ℎ𝑒𝑑  𝑍 𝑠𝑐𝑜𝑟𝑒 = 𝑥!"! −   𝑚𝑒𝑑𝑖𝑎𝑛!"𝑀𝐴𝐷!"  
 
In order to identify differences between drug and control screens, the smoothed Z 
score from the drug screen was plotted against the smoothed Z score from the 
control screen for each replicate (nine comparisons in total). The residual 
difference for each data point was then calculated as the perpendicular distance 
between the data point and the line of best fit (as calculated by linear regression). 
Negative residual differences represent those genes where the viability score within 
the drug screen is lower than would be expected based on the control viability, 
whereas positive scores indicate genes with viability within the drug screen that is 
higher than expected based on the control viability. Data analysis was carried out 
by the High-throughput laboratory.  Z scores were calculated using the software 
package CellHTS2 (Boutros et al., 2006) and residual Z scores were calculated 
using R programming language and software. 
 
2.2.2.3 Data analysis of deconvolution screen 
In the deconvolution screen we measured the Sensitivity Index (SI) of each siRNA.  
The SI is an index used to determine whether an siRNA oligo antagonises or 
sensitises cells to drug treatment.  The SI for each siRNA was calculated by 
subtracting the observed combined effect of drug and siRNA from the expected 
total viability effect (Swanton et al., 2007).  
 𝑆𝐼 = 𝑅𝑐𝐶𝑐 ∗ 𝐶𝑑𝐶𝑐 − 𝑅𝑑𝐶𝑐  
 
Rc/Cc represents the viability effect of the siRNA without drug compared to the SC 
control (siGENOME non-targeting siRNA pool #2).  The effect of drug treatment on 
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SC control transfected cells is represented by Cd/Cc.  Therefore the expected 
combined effect of the siRNA and drug on viability is Rc/Cc*Cd/Cc.  From this the 
observed combined effect on viability (Rd/Cc) can be substracted.  Positive SI 
values indicate a sensitising effect of the siRNA, whereas negative SI values 
indicate an antagonistic effect of the siRNA to drug treatment. For our final hit 
selection we used the cut-off SI value of ≥ 0.10 for sensitising siRNAs and ≤ -0.15 
for desensitising siRNAs, which is the same as the criteria employed by Swanton et 
al (Swanton et al., 2007).  SI values shown are the median of 3 replicates. 
 
2.2.3 RNAi  follow up experiments  
2.2.3.1 siRNA transfections 
In 96 well experiments in the screen follow up siRNA transfections were carried out 
as follows.  Reverse transfections were performed using 0.1 µl Dharmafect 2 
transfection reagent per well and a final concentration of 37.5 nM siRNA.  For 
transfection of PC9 cells 1000 cells per well were seeded.  Firstly, siRNA was 
diluted to 375 nM in HBSS (Hanks’ Balanced Salt Solution), and Dharmafect 2 was 
diluted to 0.01µl/µl in Optimem media.  The siRNA and transfection reagent 
dilutions were incubated separately at room temperature for 5 mins, before equal 
volumes of both mixtures were combined and left for 15 mins to allow complexes to 
form.  20 µl of this mix was plated per well, before 80 µl of cell suspension (12,500 
cells/ml) in RPMI was added.  To assess gene silencing by Real Time-QPCR cells 
were lysed 48 hours after transfection.  In cell survival assays, cells were exposed 
to drug for 72 hours, which commenced 48 hours after transfection.  For protein 
analysis, transfections were scaled up to 6 well plate format.  Reverse transfections 
were performed using 1 µl Dharmafect 2 transfection reagent per well and a final 
concentration of 37.5 nM siRNA.  For transfection of 100,000 cells per well were 
seeded. siRNA was diluted to 375 nM in HBSS, and Dharmafect 2 was diluted to 
0.01µl/µl in Optimem media, which were incubated and combined as described 
previously.  200 µl of this mix was plated per well, before the addition of 800 µl cell 
suspension (125,000 cells/ml).  In experiments where drug treatments were 
performed drug treatments were commenced 48 hours after transfection.  In 
experiments involving co-transfection of two siRNAs, each sRNA was used at a 
final concentration of 25 nM. 
Chapter 2. Materials and Methods  
  57 
 
2.2.3.2 Generation of stable cell lines 
To generate shRNA expressing cells 293T cells were infected with the lentiviral 
shRNAmir construct in combination with the packaging plasmids pCMV-VSVg 
(Addgene plasmid #8454) and pCMV-Δ8.2 (Addgene plasmid #8455) using 
Lipofectamine 2000 (Invitrogen). Viral supernatants were collected after 48 and 72 
hours, concentrated by ultracentrifugation, and added to the culture medium of 
NSCLC cells in the presence of polybrene (8µg/ml). Cells with successful lentiviral 
integration were selected by puromycin (1.5µg/ml).  shRNAmir constructs which 
included an EGFP expression cassette (pGIPZ constructs) were subsequently 
sorted by FACS (Fluorescence Activated Cell Sorting) to obtain the top 25% EGFP 
expressing cells which enriched the population for high expression of the lentiviral 
shRNAmir construct.  
 
MEK-DD and myr-AKT expressing cells were generated by retroviral transfection of 
PC9-EcoR cells. PC9-EcoR cells expressing the murine ecotropic receptor had 
been generated previously.  Briefly, Phoenix cells were transfected with MEK-DD 
(Addgene #15268) and myr-AKT1 (Addgene #15294) retroviral constructs using 
Effectene transfection reagent (Qiagen) to produce viral supernatants. Viral 
supernatants were filtered then added to the media of PC9-EcoR cells in the 
presence of polybrene (8µg/ml). Cells with successful lentiviral integration were 
selected by puromycin (1.5µg/ml).  
 
For the studies re-expressing NF1-GRD, PC9 cells were transfected using 
Lipofectamine 2000. The full-length NF1 construct was kindly provided by Dr. D. 
Lowy (Johnson et al., 1994).  The NF1-GRD expression construct was generated 
by subcloning of this region into pcDNA3.1 expression vector. pcDNA3.1 was 
transfected into PC9 cells to generate empty vector (ev) control cells. Transfected 
cells were selected for the presence of the expression construct by G418 Sulphate 
(Geneticin) (1 µg/ml).  
 
2.2.3.3 Cell survival assays 
For siRNA experiments, cells were transfected as described above and drug 
treatment commenced 48 hours after transfection. In experiments where cells 
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stably expressing shRNA were used drug treatment was started 24 hours after 
plating (2000 cells/well) in 96 well plates.  Cell viability was measured after an 
additional 72hr using the CellTiter-Blue assay (Promega). This assay is based on 
the ability of living cells to convert a redox dye (resazurin) into a fluorescent end 
product (resorufin). 5 µl CellTiter-Blue reagent was added to each well, and plates 
were incubated at 37°C for 1.5 hours before fluorescence was read on a plate 
reader (EnVision, Perkin Elmer), excitation was achieved at 560 nm and 
fluorescence was read at 590 nm. Values were normalised to the untreated control 
wells.  Graphical representations of these data were produced using GraphPad 
Prism version 5, and were used to calculate the effect on IC50.  IC50 is the 
concentration of drug needed to give half the maximal biological response, 
therefore the higher the IC50 the more resistant cells are to a drug. Alternatively, 
SF50  (survival fraction 50) is used as a measure of cell viability in response to drug 
treatment. SF50 is the concentration of drug at which 50% of cells are surviving 
compared to the untreated control (Turner et al., 2010), which was also calculated 
using GraphPad Prism version 5. 
 
2.2.3.4 Colony formation assays 
Single cell suspensions were seeded into 24-well plates (200 cells/well) and 
cultured in the indicated concentration of erlotinib. The media was replaced every 
2-3 days to ensure the drug remained active. At the point that untreated cells 
reached confluency, cells were fixed with 10% TCA, washed and stained with 
Sulphorhodamine B as described by V Vichai and K Kirtikara (Vichai and Kirtikara, 
2006). The protein-bound dye is dissolved in 10 mM Tris base solution for OD 
determination at 530 nm using a microplate reader, and normalised to the 
untreated control wells.  
 
2.2.4 Quantitative Real Time PCR 
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen). For Real-Time 
RT-PCR assays analysing levels of NF1 and EGFR assays were performed with 
QuantiTect SYBR Green RT-PCR Kit (Qiagen), using 7500 Fast Real-Time-PCR 
system (Applied Biosystems) according to manufacturer’s instructions. 
Thermocycling conditions were: reverse transcription at 50°C for 30min, first 
Chapter 2. Materials and Methods  
  59 
denaturation at 95°C for 15 min followed by 40 cycles of denaturation at 94°C for 
15 s, annealing at 55°C for 30s and extension at 72°C for 30 s. Fluorescence data 
collection was performed during the extension phase of the cycle.  A dissociation 
curve was produced after each run to verify that only one product has been 
amplified.  All primers were QuantiTect Primers obtained from Qiagen, with the 
exception of NF1-GRD primers that were as described previously (Holzel et al., 
2010). Relative mRNA levels were analysed using the comparative CT method 
(Livak and Schmittgen, 2001) and normalised to the housekeeping gene GAPDH.  
 
For analysis of DEPTOR mRNA levels RNA was isolated using the RNeasy Mini Kit, 
and performed using the Taqman RNA-to-CT 1 Step Kit (Applied Biosystems) 
according to manufacturer’s instructions.  Thermocycling conditions were: reverse 
transcription at 48°C for 15 min, first denaturation at 95°C for 10 min followed by 40 
cycles of denaturation at 94°C for 15 s, annealing and extension at 60°C for 1 min. 
Fluorescence data collection was performed during the anneal/extension phase of 
the cycle. cDNA was amplified using Taqman Gene Expression Assays for 
DEPTOR and GAPDH. Relative mRNA levels were analysed using the 
comparative CT method (Livak and Schmittgen, 2001) and normalised to the 
housekeeping gene GAPDH as before.  
 
2.2.5 Protein analysis 
2.2.5.1 Lysis of cells 
Cells were washed with ice-cold PBS, then lysed on ice with Triton X-100 lysis 
buffer (20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 2 mM EDTA, 10% glycerol, I% 
Triton X-100) supplemented with 1% Protease Inhibitor Cocktail set III 
(Calbiochem) and 1% Phosphatase Inhibitor Cocktail set III (Calbiochem).  Lysates 
were vortexed and incubated on ice for 20 mins, then centrifuged at 14000 rpm at 
4°C for 20 mins.  After determining the protein concentration, the appropriate 
volume of 4x NuPAGE LDS sample buffer (Invitrogen) containing 250 mM DTT was 
added to supernatant, lysates were boiled for 5 mins at 95°C, and briefly 
centrifuged.  Alternatively cells were lysed directly in 1x NuPAGE LDS sample 
buffer with DTT, then sonicated before boiling and centrifugation. 
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2.2.5.2 Determination of protein concentration 
Protein concentration of cell lysates was determined using Bio-Rad Protein Assay 
based on the Bradford dye-binding assay (Bradford, 1976).  It is a colorimetric 
assay based on the colour change of Coomassie Brilliant Blue G-250 in response 
to binding to basic and aromatic amino acids. BSA standards from 0 to 10 mg/ml 
protein were made by dilution in lysis buffer.  1 µl of BSA standard or protein lysate 
was plated in duplicate in a 96 well plate with 200 µl protein assay solution and 
incubated for 5 mins.  The plate was read on a plate reader at 595 nm, and the 
BSA standard values used to construct a standard curve and determine the protein 
concentration of the cell lysates.  
 
2.2.5.3 SDS PAGE 
Cell lysates were resolved by SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) on NuPAGE 4-12% Bis-Tris gradient gels in 
MES buffer (Invitrogen).  A full-range pre-stained molecular weight marker (Full 
Range Rainbow Marker, GE Healthcare) was also run on each gel to check 
proteins detected were of the correct molecular weight. Gels were run at 120 V for 
2 hours. 
 
2.2.5.4 Western blotting 
After gel electrophoresis, proteins were transferred to Immobilon 
PVDF(polyvinylidene fluoridine) membranes (Millipore) in transfer buffer  
(25 mM Tris Base, 250 mM glycine, 20% methanol).  The transfer was carried out 
in a wet transfer chamber for 1.5 hrs at 100 V at 4°C.  
 
2.2.5.5 Detection of immobilised proteins 
Membranes were blocked in 5% milk in TBS for 1 hour whilst gently shaking.  
Primary antibodies were diluted in PBS containing 0.1% Tween-20 and 3% BSA, 
and incubated with the membranes overnight at 4°C.  Membranes were washed 3 
times with TBST for 10 mins, then incubated for 1 hour with the appropriate 
secondary antibody diluted 1 in 5000 in TBS containing 1% milk.  Membranes were 
again washed 3 times with TBST for 10 mins.  Proteins were visualised by 
enhanced chemoluminesence using Amersham ECL western blotting detection 
reagents (GE Healthcare).  Equal volumes of reagents 1 and 2 were mixed, applied 
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to the membrane and incubated for 1 minute.  Enhanced chemoluminescence 
visualises a peroxidase-catalysed reaction, therefore detects the peroxidase 
labelled secondary antibodies, which are bound via the specific primary antibodies 
to the target proteins on the membrane.  The membranes were exposed to X-ray 
film (FujiFilm) in a hypercassette to visualise the reaction. 
 
2.2.5.6 Ras activation assay 
Ras-GTP levels were detected using a Ras activation assay, following the 
manufacturer’s instructions (Pierce Biotechnology).  Cells were cultured in the 
presence or absence of 30 nM erlotinib for 1hr, then washed with ice-cold TBS and 
lysed with Lysis/Binding/Wash buffer (25mM Tris-HCl pH 7.2, 150mM NaCl, 
5mM MgCl2, 1% NP-40, 5% glycerol) supplemented with 1% Protease Inhibitor 
Cocktail set III and 1% Phosphatase Inhibitor Cocktail set III.  The lysates were 
then vortexed and centrifuged at 14000 rpm at 4°C for 15 mins.  At this point some 
supernatant (total cell lysate) was reserved from each sample to use as loading 
controls.  The remaining supernatant was added to spin cups containing 
glutathione-coupled beads and GST-tagged Raf1-RBD (80 µg), and incubated with 
gentle shaking for 1 hr. Ras-GTP is immunoprecipitated from cell lysates by the 
GST-tagged Raf1-RBD, which is in turn immobilised on the glutathione resin. After 
incubation beads are washed with Lysis/Binding/Wash buffer and collected by 
centrifugation (6000 g, at 4°C for 30 secs) 3 times. Active Ras is eluted with 50 µl 
of 2x SDS Sample Buffer (1.5mL, contains 125mM Tris-HCl pH 6.8, 2% glycerol, 
4% SDS (w/v), 0.05% bromophenol blue, 5% β-mercaptoethanol), and boiled for 5 
mins 95°C. Ras pull-down assays were resolved by SDS-PAGE alongside total cell 
lysates as loading controls. 
 
2.2.5.7 EGFR Immunoprecipitation 
Cells were cultured in the presence or absence of 30 nM erlotinib for 1hr, then 
washed with ice-cold PBS, and lysed on ice with RIPA buffer (1% Triton X-100, 10 
mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% aprotinin, 250 µM PMSF, 1 mM NaF, 100 
µM sodium orthovanadate).  Lysates were centrifuged at 14000 rpm at 4°C for 10 
mins, and the supernatant was carefully removed.  Protein concentration was 
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determined by Bradford and equalised in all samples.  At this point some total 
lysate was reserved from each sample to use as loading controls.  The remaining 
equalised lysates were incubated with shaking, with 50 µl of EGFR-goat IgG 
coupled to agarose beads (Santa Cruz) for 2 hrs at 4°C.  The beads were washed 
two times with Buffer A (0.2% Triton X-100, 10 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, 2 mM EDTA), by 30 secs vortexing, and centrifuged at 5000 rpm at 4°C for 
30 secs to collect the beads, then the supernatant was removed.  This was 
repeated with one wash with Buffer B (0.2% Triton X-100, 10 mM Tris-HCl (pH 8.0), 
500 mM NaCl, 2 mM EDTA).  The bound proteins were eluted in 30 µl of 2x LDS 
buffer containing DTT, lysates were boiled for 5 mins at 95°C, and briefly 
centrifuged. Lysates were resolved by SDS-PAGE as described previously. 
 
2.2.6 Statistical analysis 
Data are presented as mean values.  For RT-QPCR error bars represent standard 
deviation of triplicate samples.  For long term and short term cell survival assays, 
statistics were calculated using GraphPad Prism 5 software and error bars 
represent standard error of the mean.  All experiments were performed at least 
three times and a representative experiment is depicted. 
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Chapter 3. Identifying determinants of resistance to 
erlotinib treatment – a genome-wide screen 
3.1 Introduction 
In order to identify novel mechanisms of resistance to EGFR tyrosine kinase 
inhibitors we carried out a genome-wide siRNA screen in PC9 cells.  PC9 cells are 
a NSCLC cell line carrying an activating EGFR mutation (exon 19 deletion E746-
A750), which renders them exquisitely sensitive to EGFR TKI treatment 
(McDermott et al., 2007). We carried out a genome-wide screen in the presence 
and absence of erlotinib to determine which genes upon silencing have a 
sensitising or desensitising effect on the cells to drug treatment. We hoped our 
results might inform how to best treat erlotinib resistant patients, for example if loss 
of a gene sensitises cells to erlotinib it could potentially be a therapeutic target. On 
the other hand if loss of a gene makes cells more resistant it could be screened for 
in resistant patients, and the signalling pathway it influences could be targeted in 
combination with erlotinib if such drugs are available. 
 
3.2 RNAi technology  
RNA inference (RNAi) is an incredibly useful tool in biological research as it allows 
you to block the expression of a gene, and observe the effect that has on cells.  
This permits you to probe the functions of specific genes.  RNAi-mediated silencing 
takes advantage of a cell’s degradation of double-stranded RNA, which functions 
as a defence against RNA-based viruses.  RNAi was identified in C.elegans where 
injection of dsRNA caused silencing of endogenous genes with sequences 
complementary to the dsRNA (Fire et al., 1998). The genome-wide screen we 
conducted employed the use of synthetic small interfering RNAs (siRNAs). siRNA 
molecules are 20-25 nuclotide long double-stranded RNA fragments, with a 3’ 2nt 
overhang and a 5’ phosphate group. Natural siRNAs are produced by the 
processing of long dsRNAs by the RNAse enzyme DICER.  siRNAs were first 
identified in plants (Hamilton and Baulcombe, 1999) and it was shown 
subsequently that synthetic siRNAs could be used to silence gene expression in 
mammalian cells (Elbashir et al., 2001). One strand of the siRNA molecule 
becomes incorporated into the RISC (RNA-induced silencing complex) by 
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association with the Argonaut family of proteins.  The strand that is incorporated is 
determined by the thermostability of the 5’ end.  The strand whose 5’end is at the 
least stable end of the dsRNA is incorporated into RISC and is called the guide 
strand (Schwarz et al., 2003).  Once the siRNA duplex has been unwound by 
helicases, and the guide strand incorporated into RISC, the endonuclease 
component of RISC cleaves mRNA complementary to the siRNA sequence 
(Sontheimer, 2005).   
3.3 Genome-wide screen set up 
3.3.1 siRNA library 
We used the Dharmacon siRNA library which consists of 4 subsets: G Protein 
Coupled Receptor set (516 genes), Protein Kinase set (779 genes), Human 
Druggable set (6,022 genes) and the Human Genome set (13,858 genes), 
which together totals 21,175 genes.  Each gene is targeted by a SMARTpool 
consisting of 4 different siRNA oligos targeting different sequences in the mRNA 
transcript.  The rationale behind pooling of siRNAs is to keep the concentration of 
individual siRNAs low, to limit non-specific effects, whilst maintaining a high enough 
overall siRNA concentration for effective gene silencing. 
 
3.3.2 Choice of cell line 
PC9 cells were used for the screen as they are a well-studied NSCLC cell line, 
carrying a defined EGFR mutation (DelE746A750) that makes them extremely 
sensitive to erlotinib treatment (McDermott et al., 2007). Other advantages of this 
cell line are that it is fast growing, so we were easily able to culture enough cells 
necessary for genome-wide experiments, and PC9 cells are relatively easy to 
transfect. Additionally they have an epithelial phenotype, forming classical 
cobblestone colonies.  This makes them easy to scan on automated plate-readers, 
unlike some other cell types, which form clusters making individual cells difficult to 
distinguish. 
 
3.3.3 Screen read-out 
The desired read-out of the screen was cell survival.  A measurement of cell 
survival can be obtained either by counting cell number, or by using measuring 
metabolic activity.  We tested four different methods of determining survival to 
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ascertain which would give the most accurate, and reproducible reading.  Methods 
tested based on cell number were staining with crystal violet, and DAPI staining.  
Crystal violet is a protein-binding dye, with can be measured using colorimetry 
(absoption read at 568 nm), to quantify cell number.  DAPI is a fluorescent DNA-
binding dye, which we used to count cell nuclei.  Metabolic assays were CellTiter-
Blue and CellTiter-Glo, which quantify the reducing capacity and ATP-content of 
cells respectively.  Fig.3.1 shows the comparison of all four methods used to 
determine survival of PC9 cells over a dose response curve of erlotinib.  DAPI, 
crystal violet and CellTiter-Glo all gave similar results, suggesting any of these 
methods would be appropriate to use for the screen.  We decided not to use 
CellTiter-Glo, as it is used on live cells, and it would not be possible to scan all 
plates of the screen within the limited timescale in which an accurate reading could 
be obtained.  We could have divided the screen into separate batches however this 
would have introduced additional variation in transfection efficiency.  We decided to 
use DAPI staining as it measures absolute cell number, and leaves the cells intact 
allowing us to stain them subsequently with an antibody, if desired.   
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Figure 3.1. Test of methods to use as a read-out of cell survival. 
PC9 cells were treated with the indicated concentrations of erlotinib for 72 hours 
before cell survival was determined using four different methods, CellTiter-Blue, 
CellTiter-Glo, crystal violet and DAPI staining. 
 
3.3.4 Erlotinib treatment 
In the screen we wanted to compare cell survival in untreated and erlotinib-treated 
conditions.  The concentration of erlotinib used was 30 nM as this concentration 
results in 40% cell survival after 72 hours of erlotinib treatment (Fig 3.2).  This level 
of survival allowed us to look both for genes that ‘sensitised’ or ‘desensitised’ cells 
to erlotinib treatment.  
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Figure 3.2. PC9 cells are exquisitely sensitive to inhibition by erlotinib. 
PC9 cells were treated with the indicated control of erlotinib for 72 hours.  Cell 
survival was measured using the Cell Titer Blue Assay.  Cell survival is 
expressed as a percentage of untreated controls. 
 
We chose 72 hours of drug treatment, as this duration is commonly used in cell 
survival assays (Engelman et al., 2007) and was the maximum length of time we 
were able to treat cells whilst ensuring there was still sufficient gene silencing. We 
waited 48 hours after transfection to treat the cells with erlotinib to ensure effective 
silencing at the protein level.  The duration of effective silencing by siRNA is 
between 5-7 days, therefore treating the cells for 72 hours, allowed us to finish the 
assay within 5 days of transfection.  Also when we tested different durations of drug 
treatment, we found that 72 hours provided the greatest difference in cell survival 
between untreated controls and the maximum erlotinib dose used. Therefore we 
chose this time point as this would hopefully make siRNAs that have an effect on 
cell survival easier to distinguish from the majority of siRNAs with no effect (Fig 3.3)  
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Figure 3.3. Test for optimal duration of erlotinib treatment.  
PC9 cells were treated with the indicated concentrations of erlotinib for 24, 48 
or 72 hours.  The maximal response, as measured by CellTiter-Blue was 
observed at 72 hours.  
 
3.3.5 Transfection reagent and conditions 
Next, it was necessary to determine the most efficient and least toxic transfection 
reagent to transfect the siRNA library into PC9 cells.  The High-throughput lab had 
tested previously various concentrations of siRNA to find the lowest concentration 
of siRNA oligonucleotides to use that achieved maximum gene silencing.  
Additionally low concentrations of siRNA are desirable to prevent the occurrence of 
off-target effects (effects not dependent on silencing of the intended target gene), 
which are explained further in the discussion. We used a final total concentration of 
37.5 nM siRNA in all experiments as it was the concentration found to achieve the 
most efficient gene silencing.  Twenty-two transfection reagents were tested at 
different concentrations for their ability to transfect PC9 cells with siRNA targeting 
LMNA the gene encoding Lamin A/C (Table 3.1). At this time we intended to 
perform the screen in a 96-well plate format, therefore these conditions were tested 
in a 96-well plate format. 
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Table 3.1. Transfection reagents and conditions tested for use in PC9 cells. 
Twenty-two transfection reagents were tested at two concentrations to 
determine optimum transfection conditions for PC9 cells. 
 
Silencing efficiency was determined by measuring Lamin A/C protein levels by 
immunofluorescence using the Acumen Explorer microplate cytometer. We 
excluded the possibility of using any reagent or condition that caused a dramatic 
decrease in cell viability compared to control transfected cells, as this indicated a 
high level of toxicity.  As the intended screen read-out was cell survival, we wished 
to limit any additional cell death that was due to the stress of transfection and not 
specifically a consequence of gene silencing or drug treatment. The Dharmafect 
transfection reagents (C1, D1, E1 and F1) (Fig 3.4) caused the most efficient gene 
silencing, with the smallest reduction in cell viability compared to siRNA only/no 
transfection reagent control (H5 and H6)(Fig 3.4). We decided to use Dharmafect 2 
for the screen, however all Dharmafect reagents performed similarly and any of the 
four would have been suitable. 
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Figure 3.4. Transfection reagent test for gene-silencing and toxicity. 
PC9 cells were transfected using the conditions listed in Table 1. Cell number 
(DAPI) and Lamin A/C were quantified by immunofluorescence using the 
Acumen Explorer microplate cytometer. 
 
3.3.6 384-well plate format 
During optimisation of the screening conditions, we decided to move from a 96-well 
plate format to a 384-well plate format.  The primary reason for this alteration was 
to make the screen more cost-effective.  Genome-wide screens are extremely 
expensive experiments, one of the most costly aspects of which is the plastic ware. 
We carried out two genome-wide screens, in untreated and erlotinib-treated 
conditions, and by using 384-well plates the number of plates used was reduced to 
402 plates in total.  Consequently, reducing the well size reduces the amount of 
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siRNA, transfection reagent, cells and all other reagents needed thereby also 
reducing cost.  Additionally, changing the format greatly increased the speed at 
which we were able to conduct the screen.  This allowed us to transfect the entire 
control screen in triplicate in the morning, and the entire drug treated screen in 
triplicate in the afternoon of the same day.  This meant all cells used were 
expanded from the same batch and were of identical passage number, also 
reducing variation. 
 
However, changing well size required further optimisation of the cell number and 
volume of transfection reagent needed.  Additionally we tested RISC-free and 
PLK1 siRNA transfection in the presence and absence of erlotinib to ensure these 
controls behaved as expected in erlotinib-treated conditions.  We wanted to ensure 
there was not an interaction between the act of transfection and erlotinib treatment, 
i.e. that the stress of transfection, not specific gene-silencing sensitised cells to 
drug treatment. As anticipated, RISC-free transfected cells had substantially 
reduced cell survival in erlotinib-treated conditions compared to untreated wells 
(Fig. 3.5).  On the other hand PLK1 and TOP2A silencing resulted in low levels of 
cell survival in both untreated and erlotinib-treated conditions (Fig 3.5).  These 
results indicated both drug treatment and gene silencing were effective in our 
chosen conditions. 
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Figure 3.5. Transfection conditions for a 384-well plate format. 
PC9 were plated at the different starting cell numbers indicated, and transfected 
with either RISC-free (RF), DNA topoisomerase 2α (Top2A) or PLK1, using the 
three difference volumes of Dharmafect 2 (Dh2) shown.  48 hours after 
transfection, cells were either left untreated, or treated with 30 nM erlotinib for 
72 hours.  
 
3.3.7 Control siRNAs 
In the screen we used several control siRNAs in each plate, in order to confirm the 
transfection had been successful across all plates of the screen. The performance 
of controls in the screen will be described in more detail later in this chapter.  To 
control for the stress of transfection, RISC-free siRNA was used.  RISC-free siRNA 
oligonucleotides are modified so they are not processed by RISC, therefore any 
change in cell survival in RISC-free transfected cells reflects the stress of 
transfection, and not engagement of the siRNA machinery or gene silencing.  Also 
used as a negative control was OT-NT (On-Target Non-Targeting siRNA). OT-NT 
is designed to minimally target any known gene expressed in humans, therefore 
should only reflect effects on cell viability caused by transfection stress. OT-NT can 
be incorporated into RISC, however it is designed not to be complementary to 
known mRNAs so should not result in gene silencing.   
 
Additionally we used several killing controls to confirm efficiency of transfection and 
gene silencing.  Killing controls used were BIRC5, UBB, PLK1.  BIRC5 encodes for 
the protein survivin, which belongs to the Inhibitor of Apoptosis (IAP) family.  
Survivin inhibits apoptosis, and is thought to function by directly binding to active 
forms of caspase-3 and -7 to block their activity (Tamm et al., 1998). UBB encodes 
for ubiquitin, a 76-amino acid protein which can be conjugated to the ε-amino group 
of lysine residues.  This conjugation, termed ubiquitination is a post-translational 
modification found to be essential in many cellular processes, such as proteasomal 
degradation of proteins, receptor endocytosis, DNA damage repair and DNA 
replication (Wagner et al., 2011).  Therefore, due to the involvement of ubiquitin in 
many processes, silencing of UBB strongly induces apoptosis.  The final killing 
control used was siRNA targeting PLK1.  PLK1 is a mitotic kinase that plays key 
roles in multiple points during mitotic progression, the silencing of which causes 
apoptosis in multiple cancer cell lines (Liu and Erikson, 2003).  
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3.3.8 Screen Protocol 
On day 1 of the experiment PC9 cells were plated at 500 cells per well and reverse 
transfected with 37.5 nM siRNA using 0.075 µl Dharmafect 2 transfection reagent 
per well. 48 hours after transfection the media was replaced with fresh media either 
with or without 30 nM erlotinib.  72 hours after treatment cells were fixed, washed 
and stained with DAPI.  The read-out of the screen was cell number.  This was 
quantified by counting the nuclei of DAPI stained cells using the Acumen Explorer 
microplate cytometer. See Fig 3.6 for a schematic of the screen set up. A more 
detailed account of the screen method is given in Materials and Methods. 
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Figure 3.6. Screen set-up.  
Schematic of screen.  PC9 cells were transfected with the genome-wide siRNA 
to use in either the control or drug screen.  After 48 hours the media was 
replaced with either 30 nM erlotinib on one set of plates, or normal media on the 
other set   72 hours after drug treatment cells were fixed and stained with DAPI.  
The screen read-out was cell numer, as quantified on the Acumen Explorer 
microplate cytometer. 
 
3.4 Analysis of genome-wide screen data 
3.4.1 Normalisation 
The initial statistic we used to score our siRNAs was the Z score, which is the 
number of standard deviations by which the result differs from the mean of the 
DAY 0 - 2x genome-wide siRNA library
 reverse transfected in PC9 cells
DAY 2 -
Control screen:
untreated
Drug screen:
30 nM erlotinib
72 hours
DAY 5 -
Cells !xed and 
stained with DAPI.
Cell number 
quanti!ed by 
microplate cytometer.
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entire data set.  During the analysis of a large-scale experiment it is necessary to 
perform normalisation steps in order to make data points comparable across the 
whole data set. There are many factors that can introduce variability into a large-
scale experiment. Variability was reduced where possible by automating various 
steps, such as cell plating, dispensing of media and all liquid reagents, however 
some variability is unavoidable.  The largest source of variability in screening is 
plate-to-plate variation, meaning the same samples can give rise to different scores 
on different plates.  To correct for plate-to-plate variation each screening plate was 
normalised using a robust Z score calculation.  This method is based on the 
distribution of values rather than controls and is described in the materials and 
methods chapter.  Briefly, the median value of samples on each plate was 
subtracted from each well, and then each well was divided by the median absolute 
deviation (MAD) of all sample wells on that plate.  Figure 3.7 shows the raw cell 
number values across all the plates of the screen, followed by the data after plate 
normalisation has been performed. Plate normalisation creates a more uniform 
distribution of siRNAs that do not have a significant impact on cell viability.  Also 
represented in the plots are the negative controls OT-NT and RISC-free, and the 
killing controls PLK1 and UBB.   
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Figure 3.7. Effect of plate normalisation. 
Scatter plots showing raw values and values after plate normalisation. A. the 
raw cell number of all samples is plotted for each plate of the screen. B. 
Normalised Z score of all samples are plotted for each plate to demonstrate 
effect of plate normalisation.  Negative and killing siRNA controls are 
reperesented as colour-coded in the key.   
 
Within a single plate there is also variation between wells due to slight differences 
in temperature and evaporation. As evaporation is higher in the outer wells, cells in 
these positions tend to behave slightly differently from cells in central wells of the 
plate.  Typically such effects produce repetitive patterns therefore it is possible to 
distinguish them from real differences, which are a result of biological effects of 
treatment, and correct for them in the analysis. In order to account for positional 
and edge effects a smoothed Z score was also calculated, as described in the 
materials and methods. This was based on the median and MAD calculated when 
comparing the distribution of Z scores at each well position across all plates within 
the screen.  The median Z score of a well position in all plates in the screen is 
subtracted from the previously calculated Z score.  This is then divided by the MAD, 
which is calculated from all samples at this well position in all plates. Figure 3.8 
shows a scatterplot of the raw cell number for each well position divided by the 
plate median, followed by the data after smoothing, which normalises for positional 
effects.  This step has less of an impact than plate normalisation, however clearly 
makes it easier to distinguish between the bulk of sample siRNAs with no effect on 
viability and the killing controls. 
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Figure 3.8. Effect of position normalisation. 
A. Scatterplot showing raw cell number/plate median for each well position per 
plate. B. Scatterplot showing normalised distribution per well position to 
demonstrate the effect of position normalisation. 
 
3.4.2 Correlation of replicates and performance of siRNA controls 
Another way to ascertain the amount of variability within the screen is to examine 
the similarity of the replicates.  By plotting one replicate against another one can 
see there is a good correlation between the replicates in the screen, the example 
shown in Fig, 3.9 is the correlation between replicates 1 and 3.  In this scatterplot it 
is also possible to see the performance of the controls in the screen.  The killing 
controls PLK1 and UBB generally have a negative Z score indicating that the 
siRNA had the intended negative impact on cell survival. On the scatterplot they 
are clustered together at the left hand side of the plot and are distinguishable from 
the bulk of siRNAs, indicating they performed as effective killing controls.  The 
negative controls OT-NT and RISC-free on the other hand tended to have positive 
Z scores and cluster towards the right hand side of the plot.  Ideally these controls 
should have appeared more centrally in the distribution of the population (ie. Z 
score =0), as they are designed to demonstrate the stress of transfection without 
gene-silencing, therefore should not have an impact on cell viability.  However they 
appear skewed towards having a positive effect on cell survival.  One possibility for 
this is that as RISC-free does not engage the RNAi machinery, therefore in 
comparison to all other siRNAs that do, RISC-free transfected cells are under less 
stress and are more viable.  OT-NT is designed to engage the RISC-free 
machinery without causing gene silencing, but it is possible it does not do this as 
efficiently as siRNAs targeted against human transcripts.   
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Figure 3.9. Correlation of replicates. 
Scatterplot of normalised Z scores for replicates 1 and 3 of the control screen to 
demonstrate correlation of replicates.  Negative and killing controls are 
represented as colour-coded in the key. 
 
3.4.3 Residual Z score – difference between control and drug-treated 
conditions 
As previously stated the Z score is the number of standard deviations away from 
the mean of the population that a data point lies.  At this stage we had calculated 
the Z scores for each siRNA pool in the control screen and the drug screen.  The 
information we really wanted to know was which siRNAs had the most different 
effects on survival in the drug screen than would be expected from the control 
screen.  One would predict these siRNAs targeted genes that in some way 
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antagonised or enhanced the effect of erlotinib treatment. In order to identify 
differences between drug and control screens, the smoothed Z score from the drug 
screen was plotted against the smoothed Z score from the control screen for each 
replicate (nine comparisons in total) to obtain a residual Z score (Fig 3.10).  The 
residual difference for each data point was calculated as the perpendicular distance 
between the data point and the line of best fit (as calculated by linear regression). 
The regression line is indicated in red. Negative residual differences represent 
those genes where the viability score within the drug screen is lower than would be 
expected based on the control viability, whereas positive scores indicate genes 
with viability within the drug screen that is higher than expected based on the 
control viability. All nine residual Z scores are given in Appendix 1.  The median of 
the 9 residual Z scores was used to evaluate the performance of each siRNA pool 
in the screen (highlighted in yellow in Appendix 1).  
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Figure 3.10. Residual difference method. 
Scatterplot demonstrating the residual difference method.  Normalised Z scores 
of each control and drug replicate were plotted against each other, and a line of 
best fit calculated by linear regression (shown in red).  The residual Z score is 
calculated by measuring the perpendicular distance of each data point to the 
line of best fit, to give a positive or negative value.  
 
3.5 Repeat of genome-wide screen 
We repeated the genome-wide screen using the same conditions to test the 
reproducibility of the screen.  The screen was normalised and analysed in the 
same way as the first screen, and the residual Z scores are provided in Appendix 1. 
As is clear in Appendix 1, the Z score values differ substantially between the two 
screens, however by ranking siRNAs in order of residual Z score we were able to 
analyse the overlap between the first and second screen. Residual Z scores were 
ranked by difference to 0 (i.e. the most positive or most negative scores were 
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ranked highest) to select for siRNAs that had the most substantially different effects 
in the drug and control screens. siRNA pools were selected that appeared in the 
top 2.5% of hits from the first screen, which gave us 528 siRNA pools. This 
corresponded to a residual Z score of greater than or equal to 1.7 or less than or 
equal to -1.7.126 of these siRNA pools were in the top 5% of hits in the second 
screen when ranked by residual Z score in the same way (Appendix 2).  The 
percentages chosen were relatively arbitrary in that they gave us a reasonable 
number of siRNA pools to follow up in more detail. These 126 siRNA pools were 
taken forward to a deconvolution screen. 
 
3.6 Deconvolution screen 
In order to determine the effects on erlotinib sensitivity were the result of gene 
silencing, rather than off-target effects we carried out a deconvolution screen 
(Echeverri et al., 2006).  In the genome-wide screen, each gene was targeted by a 
SMARTpool, consisting of 4 individual siRNA oligos targeting different regions of 
the nucleotide sequence.  In the deconvolution screen each oligo is assessed 
individually for the effect it has on erlotinib sensitivity.  The deconvolution screen 
was also carried out in 384-well plate format, using the same method as used for 
the genome-wide screen.  As siRNAs in the deconvolution screen had already 
been selected for having an effect on cell survival it was no longer possible to 
normalise the data based on background plate medians. Instead, we calculated a 
Sensitivity Index (SI) for each siRNA oligo, which is a measure of the synergistic or 
antagonistic effect of an siRNA on drug treatment (SI = si control/sc control * sc 
drug/sc control – si drug/ sc control) (Swanton et al., 2007).  This equation allows 
the calculation of the individual effect of the drug (sc drug/sc control) and the siRNA 
(siRNA control/sc control), and then lets you calculate whether the expected 
combined effect of the siRNA and drug on cell viability is different to the observed 
combined effect (siRNA drug/sc control).  Positive SI values indicate a sensitising 
effect of the siRNA, whereas negative SI values indicate an antagonistic effect of 
the siRNA to drug treatment. The control siRNA we used to normalise the data was 
non-targeting scrambled control pool #2.  We did not use RISC-free siRNA, as we 
did in the genome-wide screens as RISC-free controls appeared skewed towards 
enhancing cell survival instead of having no effect (Fig 3.10). SI scores of each 
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siRNA are shown in Appendix 3.  For our final hit selection we used the cut-off SI 
value of ≥ 0.10 for sensitising siRNAs and ≤ -0.15 for desensitising siRNAs, which 
is the same as the criteria employed by Swanton et al (Swanton et al., 2007).  26 
siRNA pools confirmed a reproducible phenotype with at least two out of four of 
their individual deconvoluted siRNAs meeting the above criteria (Table 3.2).   
 
 
Table 3.2. Genes that upon RNAi-mediated silencing affected cell survival in 
response to erlotinib treatment 
List of genes for which 2 out of 4 oligos met our hit criteria (SI value of ≥ 0.10 for 
sensitising siRNAs and ≤ -0.15 for desensitising siRNAs).  The value given for 
each oligo is the Sensitivity Index (SI) explained in the text.  The strength of the 
effect is indicated by the colour coding in the key. No colour indicates the siRNA 
had no effect on drug response. 
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3.7 Discussion 
In the final hit selection were 26 genes that had a reproducible effect on cell 
viability in the presence of erlotinib (Table 3.2). Silencing of only two of the genes, 
ABCC8 (ATP-binding cassette sub-family C member 8) and SLC4A8 (solute carrier 
4 sodium bicarbonate cotransporter member 8) resulted in increased sensitivity to 
erlotinib treatment.  It appears that our screen set-up preferentially aided the 
identification of genes that increase resistance to erlotinib treatment upon silencing.  
This may be because PC9 cells are already exquisitely sensitive to erlotinib 
treatment therefore it is difficult to make them more sensitive to erlotinib.  It seems 
that most siRNAs that decreased cell viability in the presence of erlotinib treatment 
also had an effect in the control screen, therefore the effect is not specific to 
erlotinib-induced cell death.  The genes targeted by these siRNAs could still yield 
interesting results, as silencing of these genes decreases the viability of a NSCLC 
cell line, however further work would be needed to confirm the specificity of the 
effects on cell viability.  If silencing of these genes also affects the viability of non-
cancerous cells in the same way, then targeting of these gene products would be 
likely to cause high levels of toxicity in patients.  We were more interested in genes 
that specifically affected response to erlotinib, therefore did not include more 
general killing siRNA pools in our follow-up.  
 
In our screen we used the siGENOME SMARTpool library as it contained 4 
different oligos to target each gene.  Using multiple siRNAs is necessary as siRNAs  
targeting the same gene can have variable effects of phenotype.  This was 
highlighted in a study by Collinet et al. (Collinet et al., 2010) where they used two 
different siRNA libraries and one endoribonuclease-prepared siRNA to target each 
transcript of a set of genes involved in endocytosis.  They found that siRNAs from 
the same and different siRNA libraries can have inconsistent phenotypic effects.  
There are many reasons for such differences, one of which is that not all siRNAs 
can silence their target gene with the same efficiency, possibility due to differences 
in thermostability or sequence complementarity between the siRNA oligo and target 
transcript. Also, for some genes it seems to be there is a threshold of gene 
silencing required to have a biological effect, i.e. that a phenotype is only seen 
when the level of gene silencing is 90% or greater.  Therefore although all siRNA 
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pools may silence gene expression to some degree, only a couple may reach the 
level of silencing required to produce a phenotype.   
 
As mentioned previously, siRNA can have off-target effects, which are not caused 
by specific silencing of the intended target gene.  Off-target effects are caused by 
silencing of genes other than the intended target due to similarities in nucleotide 
sequence. Complete complementarity between the siRNA and target nucleotide 
sequence is not necessary, and it is thought that 14 or even fewer base pairings 
are necessary for RISC-mediated cleavage of mRNA (Jackson et al., 2003).  
Additionally, siRNAs can cause off-target effects at the level of protein expression 
without affecting mRNA levels, as they can mimic the function of endogenous 
microRNAs (miRNAs).  miRNAs are small RNA molecules which inhibit gene 
expression at a post-transciptional level, by binding to complementary sequences 
in the 3’UTR of mRNA and inhibiting their translation (Bartel, 2009).  It is for these 
reasons that we carried out a repeat screen and a deconvolution screen.  It is clear 
that at multiple stages of the process, siRNAs did not validate as 128 genes from 
the genome-wide screens were whittled down to 26 genes in the final hit list when 
we applied criteria as defined by Swanton et al. (Swanton et al., 2007). Due to the 
fact that at least 2 of 4 siRNAs produced the same phenotypic effect in the 
deconvolution screen we are fairly confident that the genes in our hit list are not 
subject to off-target effects.   
 
Other potential issues are that some gene perturbations may indirectly effect drug 
sensitivity, rather than directly making an individual cell more resistant to erlotinib 
treatment.  For example, from experimental observations, it seems that more 
confluent cells are more resistant to erlotinib treatment, probably as increased cell-
cell contacts leads to increased pro-survival signalling.  Therefore genes that 
increase proliferation will most probably increase resistance to erlotinib. Such 
effects were identified in a study by Snijder et al. where they found the position of a 
cell in the centre or at the edge of a colony significantly affected the susceptibility of 
cells to viral infection (Snijder et al., 2009). Hopefully, employing the use of a 
residual Z score would remove most of the siRNA pools which contribute to drug 
response by affecting proliferation.  Any effects on cell growth should be identified 
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in the control screen, thereby reducing the residual Z score and preventing their 
evaluation as a hit. 
 
Another consideration was the length of the assay.  We used siRNA in order to 
target gene transcripts, which as described earlier imposed limits on the timescale 
of the experiment.  One concern is that silencing of genes that cause increased cell 
survival in erlotinib-treated conditions in short term assays do not necessarily have 
the same effect in the long term.  This may indicate they are less likely to be 
mechanisms of resistance in vivo, as they are not well tolerated by cells for more 
than a few days.  We did obtain hits from the screen that validate in longer term (10 
day) experiments and are described in chapters 4 and 5, however this is not the 
case for all genes.  One example of a gene that did not validate in long term 
experients is PHF8 (PHD finger protein 8), a histone demethylase with activity 
towards H3K9me1/2 (Qi et al., 2010).  In the screen PHF8 siRNA appears to cause 
increased resistance to erlotinib, however long term experiments using shRNA 
targeting PHF8 failed to confirm this result.  Lui et al. suggest that PHF8 is 
essential in cell cycle progression, and it is possible that silencing of PHF8 
prevents cancer cell proliferation. Erlotinib is thought to exert a growth inhibitory 
effect mostly in the G1/S transition of the cell cycle (Ling et al., 2007) therefore, it is 
possible short term silencing of PHF8 reduces erlotinib-mediated cell death as it 
renders cells quiescent. A quiescent phenotype has been associated with 
increased drug tolerance and is a mechanism of transient drug resistance (Sharma 
et al., 2010). However, in this example longterm silencing of PHF8 by shRNA 
induced p16 expression and substantially reduced proliferation of PC9 cells which 
still have intact p16 and Rb expression (Arifin et al., 2010).     
 
Additionally of note, it has recently been published that loss of PDXK encoding 
Pyridoxal Kinase can increase resistance of NSCLC to cisplatin (Galluzzi et al., 
2012).  PDXK generates the bioactive form of vitamin B6 which exacerbates 
cisplatin-induced cell death.  Galluzzi and colleagues found that addition of the 
vitamin B6 precursor Pyridoxine sensitised NSCLC to a variety of stress conditions 
including hypoxia, nutrient depletion, ionizing irradiation and respiratory chain 
inhibition in a PDXK-dependent manner which suggests it is involved in general 
stress responses.  Although this study links PDXK to resistance to a different class 
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of therapeutics, it indicates PDXK plays a role in cell death in response to multiple 
stress conditions which could potentially extend to treatment with EGFR TKIs.  
Galluzzi et al. found low PDXK expression was associated with decreased disease-
free and overall survival of NSCLC patients regardless of whether they received 
adjuvant chemotherapy (Galluzzi et al., 2012).  Although this is a general 
association with survival, not specific to EGFR TKI response, it is encouraging that 
our screen uncovered a gene that has been associated with a prognostic value in 
patients. 
 
Of the other 22 genes identified, there are a few genes, which immediately caught 
our attention, notably NF1 (Neurofibromin 1) and DEPDC6/DEPTOR (DEP domain 
containing 6), as they both encode for negative regulators of pathways activated 
downstream of EGFR.  NF1 is a RAS GTPase activating protein, negatively 
regulating the function of RAS (Basu et al., 1992), and DEPDC6 is a negative 
regulator of mTOR (Peterson et al., 2009).  Both of these genes were followed up 
in more detail and will be discussed in chapters 4 and 5
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Chapter 4. NF1 loss increases resistance of NSCLC 
to EGFR TKI treatment. 
4.1 Introduction  
One of the genes identified in the screen as causing increased resistance to 
erlotinib upon gene silencing is NF1 (Neurofibromin 1).  As previously mentioned in 
the introduction NF1 is a RAS GTPase activating protein that negatively regulates 
RAS function by stimulating the hydrolysis of RAS-GTP to RAS-GDP (Basu et al., 
1992). Recently NF1 has gained attention as a tumour suppressor, whose loss can 
lead to resistance to drug treatment in a number of different settings. An shRNA 
screen in a neuroblastoma cell line identified that NF1 loss causes increased 
resistance to retinoic acid (Holzel et al., 2010). In this tumour type loss of NF1 
activates RAS-MEK signalling which in turn represses ZNF423, a transcriptional 
co-activator of retinoic acid receptors, reducing responsiveness to retinoic acid 
therapy.  Also, loss of NF1 expression has been identified as a determinant of 
resistance to tamoxifen treatment in estrogen receptor positive breast cancer, most 
likely via activation of classical RAS family proteins (HRAS, KRAS and NRAS) as 
well as the related RRAS2, leading to downstream activation of ERK (Mendes-
Pereira et al., 2011).  In an shRNA screen against tumour suppressor genes in 
A549 lung cancer cells, loss of NF1 increased paclitaxel resistance (Ji et al., 2007).  
These data indicate NF1 downregulation can cause resistance to multiple classes 
of drugs including microtubule stabilising agents as well as targeted therapies. 
 
Additional support for the role of NF1 in erlotinib resistance came from murine 
models of EGFR-driven NSCLC.  Politi and colleagues generated mouse models 
where expression of an active mutant EGFR can be induced in type II 
pneumocytes by doxycycline treatment. Expression of an L858R mutant or exon 19 
deletion mutant (L747-S752), leads to formation of lung tumours that are 
dependent on the expression of the mutant EGFR allele and respond to EGFR 
TKIs (Politi et al., 2006). Further, Politi generated mice with erlotinib resistant 
tumours, by treating mice with multiple on-off cycles of erlotinib until they were no 
longer responsive to drug treatment (Politi et al., 2010). In resistant tumours they 
Chapter 4. Results  
  92 
detected the EGFRT790M mutation, and Met amplifiation, however in half of all 
resistant tumours, non-overlapping with these common mechanisms they detected 
a reduction in Nf1 mRNA expression as quantified by qRT-PCR (Figure 4.1).  This 
indicates NF1 loss may be involved in erlotinib resistance in clinically relevant 
models of NSCLC. 
 
 
Figure 4.1. Nf1 expression is reduced in a murine model of erlotinib-resistant 
NSCLC (unpublished data provided by Katerina Politi).. 
A. Nf1 mRNA was quantified by RT-QPCR and normalised to lung epithelial 
marker Surfactant Protein C.  Nf1 mRNA levels for each tumour are shown 
relative to expression in normal adjacent lung tissue in each mouse. On the X-
axis L=normal lung, T=tumour and the numbers correspond to the mouse from 
which the samples were taken.  Where known mechanisms of resistance 
(EGFRT790M, Kras mutation, or Met amplification) were found they are indicated 
on the graph. 
B. Nf1 expression levels of untreated (-erl; erlotinib sensitive) and erlotinib-
treated (+erl; erlotinib resistant) tumours and adjacent normal lung from EGFR 
mutant mice are plotted. Erlotinib-resistant tumours are subdivided according to 
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known secondary lesions present in the tumours as indicated. P-values were 
determined by Mann-Whitney U-test.    
 
4.2 Reduction of NF1 expression renders lung cancer cells 
less sensitive to EGFR-TKI treatment 
In order to validate the role of NF1 in erlotinib resistance further we generated PC9 
cells stably expressing two individual shRNAs targeting different, non-overlapping 
regions of the NF1 coding sequence.  Both shRNAs efficiently decreased NF1 
expression at the protein and mRNA level, with shRNA #2 giving the most efficient 
silencing compared to scrambled control cells expressing a non-targeting shRNA 
(shSC) (Fig.4.2).  
 
Figure 4.2. NF1 protein and mRNA levels are efficiently reduced by shRNA 
constructs targeting NF1. 
PC9 cells were left uninfected or infected with a non-targeting shRNA (shSC) or 
shRNAs targeting NF1 (shNF1#1 and shNF1#2).  NF1 protein and mRNA levels 
were measured by western blotting and qRT-PCR respectively. 
 
In 72 hour survival assays both NF1 shRNA constructs increased resistance of 
PC9 cells to erlotinib treatment compared to shSC controls, with a 14-fold increase 
in IC50 for shNF1#1 and 21-fold for shNF1#2 (Fig 4.3).   
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Figure 4.3. NF1 silencing increases resistance to erlotinib.  
PC9 cells were left uninfected or infected with a non-targeting shRNA (shSC) or 
shRNAs targeting NF1 (shNF1#1 and shNF1#2). Cells were treated with the 
indicated concentrations of erlotinib for 72 hours, and cell survival was 
measured using the CellTiter-Blue assay. 
 
 
To look at the effects of NF1 silencing in the longer term, we carried out colony 
formation assays, where cells were plated at low density and treated with erlotinib 
for 10 days.  NF1 silencing substantially increased cell survival in these assays 
compared to shSC expressing cells (fig 4.4). 
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Figure 4.4. NF1 loss increases resistance to erlotinib in longer term assays. 
PC9 cells were infected with non-targeting control shRNA (shSC), or shRNAs 
targeting NF1 (shNF1#1 and #2).  Cells were grown in untreated or erlotinib-
treated conditions for 10 days and then fixed and stained with Sulphorhodamine 
B. 
 
In order to determine whether the effect of NF1 silencing is specific to EGFR-TKIs 
or whether it has a more general effect, increasing resistance to a broader range of 
drugs, we carried out 72 hour survival assays with other therapeutic drugs.  NF1 
silencing increased resistance to another EGFR-TKI (gefitinib) (Fig 4.5), however it 
had no effect on chemotherapeutic agents cisplatin or docetaxel, which function 
through DNA-crosslinking and microtubule stabilisation respectively (Fig 4.6). 
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Figure 4.5. NF1 loss increases resistance of PC9 cells to gefitinib treatment. 
PC9 cells were left uninfected or infected with a non-targeting shRNA (shSC) or 
shRNAs targeting NF1 (shNF1#1 and shNF1#2). Cells were treated with the 
indicated concentrations of gefitinib for 72 hours and cell survival was measured 
using the CellTiter-Blue assay. 
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Figure 4.6. NF1 silencing does not increase resistance to other 
chemotherapeutic drugs. 
PC9 cells were infected with a non-targeting shRNA (shSC) or shRNAs targeting 
NF1 (shNF1#1 and shNF1#2). Cells were treated with the indicated concentrations 
of (A) cisplatin or (B) docetaxel for 72 hours, and cell survival was measured using 
the CellTiter-Blue assay. 
 
4.3 NF1 silencing leads to MAPK pathway activation in the 
presence of erlotinib 
In order to determine whether NF1 silencing increases resistance to erlotinib via 
activation of RAS signalling, we assessed the levels of active RAS-GTP in shSC 
and shNF1 cells in the presence and absence of erlotinib.  In experiments where 
only one shRNA targeting NF1 was used shNF1 refers to shNF1#2, as this short 
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hairpin RNA provided the most efficient silencing. Both shNF1 and shSC cells 
showed a dramatic decrease in RAS-GTP levels upon erlotinib treatment, however 
shNF1 cells retain more RAS-GTP in the presence of erlotinib (Fig 4.7).   
 
 
Figure 4.7. RNAi-mediated NF1 silencing increases RAS activation. 
PC9 cells were infected with a non-targeting shRNA (shSC) or shRNA targeting 
NF1. Cells were treated with or without erlotinib for 1 hr before lysis, and RAS-
GTP was immunoprecipated from lysates with GST-Raf1-Ras Binding Domain, 
as described in the materials and methods. Total RAS protein from total lysates 
is shown as loading control.  
 
Downstream of RAS the two main signalling pathways are the MAPK pathway and 
PI3K pathway.  To determine the effect of NF1 silencing on these signalling 
pathways we examined the phosphorylation status of downstream signalling 
proteins.  Erlotinib treatment results in significantly decreased phosphorylation of 
EGFR, ERK1/2, and caused a less pronounced decrease in phosphorylation of 
AKT.  shNF1-expressing cells however retain some phosphorylated ERK1/2 in the 
presence of erlotinib, whereas phosphorylated ERK1/2 is completely abolished in 
shSC-expressing and parental PC9 cells (Fig.4.8).  
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Figure 4.8. NF1 loss leads to sustained activation of ERK1/2 in the presence of 
erlotinib. 
PC9 cells were uninfected (parental), or infected with non-targeting shRNA 
construct (shSC), or shRNAs targeting NF1 (shNF1#1 and shNF1#2). Cells 
were treated with or without 30 nM erlotinib for one hour prior to lysis for 
immunoblotting against indicated proteins. 
 
To confirm that NF1 silencing leads to sustained phosphorylation of ERK1/2 upon 
erlotinib treatment in other EGFR-mutant NSCLC cell lines, and that it is not a PC9 
cell line specific effect, H3255 and HCC4006 cells were infected with control 
shRNA (shSC) and shRNA targeting shNF1.  NF1 silencing caused both cell lines 
to retain more phosphorylated ERK1/2 in erlotinib-treated conditions compared to 
control (shSC) cells (Fig 4.9).  Silencing of NF1 also increased resistance of both 
cell lines to long term (10 day) erlotinib treatment (Fig 4.10), indicating NF1 loss 
can mediate resistance to erlotinib in multiple NSCLC cell lines.  
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Figure 4.9. NF1 loss leads to sustained phosphorylation of ERK in erlotinib-
treated conditions in other NSCLC cell lines. 
H3255 and HCC4006 cells were infected with non-targeting shRNA construct 
(shSC), or shRNA targeting NF1 (shNF1). A. Cells were treated with or without 
30 nM erlotinib for one hour prior to lysis for immunoblotting against indicated 
proteins. B. Cells were lysed for immunoblotting to confirm RNAi-mediated 
silencing of NF1. 
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Figure 4.10. NF1 loss increases resistance of other NSCLC cell lines to erlotinib 
in long term survival assays. 
H3255 and HCC4006 cells were infected with non-targeting shRNA construct 
(shSC), or shRNA targeting NF1 (shNF1).  Cells were grown in untreated or 
erlotinib-treated conditions for 10 days and then fixed and stained with 
Sulphorhodamine B. 
 
To confirm that NF1 silencing increases resistance to erlotinib by enhancing RAS 
signalling, we overexpressed the NF1-GRD (Gap Related Domain) in PC9 cells 
before silencing endogenous NF1 with shRNAs, which do not target the GRD 
(Fig.4.11).   
Chapter 4. Results  
  102 
 
Figure 4.11. Expression of an shRNA resistant NF1-GRD and silencing of 
endogenous NF1 by shRNA. 
PC9 cells were transfected with either the NF1-GRD (GRD) or empty vector 
(ev) and then infected with control shRNA (shSC) or shRNA targeting NF1. a) 
NF1-GRD mRNA levels detected by qRT-PCR with primers that recognise the 
NF1-GRD (endogenous and transfected). b) NF1 mRNA levels detected by 
qRT-PCR using primers that detect endogenous NF1, but not the transfected 
GRD.  
 
We postulated that if the cells still had RAS GAP activity of NF1 conferred by the 
GRD, they would not become more resistant to erlotinib upon endogenous NF1 
silencing.  Indeed it appears that it is the loss of NF1 RAS GAP activity that causes 
the increase in resistance, as shNF1 cells expressing a control vector became 
more resistant to erlotinib treatment, whereas shNF1 cells expressing the NF1-
GRD were substantially less resistant (Fig 4.12). 
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Figure 4.12. NF1-GRD expression prevents increased resistance to erlotinib in 
shNF1 cells. 
PC9 cells were transfected with either the NF1-GRD (GRD) or empty vector 
(ev) and then infected with control shRNA (shSC) or shRNA targeting NF1 
(A.shNF1#1 and B. shNF1#2). Cells were treated with the indicated 
concentrations of erlotinib for 72 hours and cell survival was measured using 
the CellTiter-Blue assay. 
 
The effect on erlotinib resistance seen with expression of the NF1-GRD correlates 
to the effects on ERK1/2 phosphorylation.  shNF1 cells expressing the empty 
vector retain phosphorylated ERK1/2 upon erlotinib treatment, whereas it is absent 
in shNF1 cells expressing the NF1-GRD (Fig 4.13). 
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Figure 4.13. Expression of the NF1 GRD restores signalling of shNF1 cells. 
PC9 cells expressing either an empty vector (ev) or NF1-GRD were infected 
with control shRNA (shSC) or shRNAs targeting NF1 (shNF1#1 and shNF1#2).  
Cells were left untreated or treated with erlotinib for 1 hr prior to lysis for 
immunoblotting against indicated proteins. 
 
Our data thus far, pointed to the maintenance of ERK1/2 phosphorylation in shNF1 
cells in erlotinib-treated conditions as the cause of increased resistance.  This was 
supported by further work when we transfected PC9 cells with a myristoylated AKT, 
or MEK-DD construct.  Myristoylated AKT is constitutively active as it is tethered to 
the plasma membrane.  In the MEK-DD construct, serine has been substituted with 
negatively charged aspartate at residues 218 and 222 to mimic phosphorylation at 
these sites and constitutively activate the kinase.  MEK-DD cells retained some 
phosphorylation of ERK1/2 in the presence of erlotinib and myrAKT had similar 
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levels of AKT phosphorylation in the presence and absence of erlotinib, indicating 
both constructs were expressed and the proteins activated (Fig 4.14).  In 72 hour 
survival assays myr-AKT expressing cells were moderately more resistant to 
erlotinib treatment than control cells with a 2-fold increase in IC50, whereas MEK-
DD expressing cells were substantially more resistant with a 40-fold increase in 
IC50 (Fig 4.15).  10 day colony formation assays produced similar results.  Myr-AKT 
cells were again moderately more resistant than control cells, whilst cell survival 
was dramatically increased in MEK-DD cells (Fig 4.16).   
 
 
Figure 4.14. Expression of myristoylated AKT and MEK-DD constructs in PC9 
cells.  
PC9 cells expressing the murine ecotropic receptor (EcoR), were infected with 
retroviral myristoylated AKT and MEK-DD constructs. Cells were treated with 
erlotinib for 1 hr prior to lysis for immunoblotting.  A. Expression of myristoylated 
AKT construct and constitutive activation in untreated and erlotinib-treated 
conditions. B. Activation of MEK-DD construct is shown by the sustained 
phosphorylation of ERK1/2 seen in MEK-DD cells upon erlotinib treatment.  
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Figure 4.15. PC9 cells expressing activated forms of AKT or MEK have increased 
resistance to erlotinib treatment. 
PC9 cells were left uninfected, infected with murine ecotropic receptor alone 
(Eco-R), or subsequently infected with myr-AKT or MEK-DD constructs.  Cells 
were treated for 72 hours with indicated concentrations of erlotinib, and cell 
survival was measured using the CellTiter-Blue assay. 
 
 
Figure 4.16. Active AKT and MEK increase resistance of PC9 cells to erlotinib 
treatment. 
PC9 cells infected with the murine ecotropic receptor alone or expressing active 
forms of AKT (myr-AKT) and MEK (MEK-DD) were cultured in the presence of 
indicated concentrations of erlotinib for 10 days. 
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The increase in erlotinib resistance conferred by MEK-DD expression, could be 
prevented by combining erlotinib treatment with a MEK inhibitor AZD6244, 
indicating it is indeed the action of MEK which augments resistance to erlotinib in 
these cells (Fig 4.17). 
 
 
Figure 4.17. MEK-DD expressing cells are sensitive to a combination of erlotinib 
and a MEK inhibitor. 
PC9 cells expressing the murine ecotropic receptor alone (EcoR) or expressing 
active MEK (MEK-DD) were treated with the indicated concentration of erlotinib, 
with (dotted line) or without (solid line) 1 µM AZD6244 for 72 hours. 
 
4.4 Combination treatment of EGFR-TKIs and MEK inhibitors is 
effective against NF1-depleted cells 
As shNF1 cells demonstrate higher levels of ERK phosphorylation than shSC cells 
in the presence of erlotinib, and expression of a constitutively active MEK variant 
dramatically increases resistance to erlotinib we postulated that inhibition of MEK 
may ‘resensitise’ shNF1 cells to erlotinib treatment. shSC expressing control cells 
are not sensitive to MEK inhibition alone and the combination treatment does not 
dramatically effect the IC50 (Fig 4.18).  However as with the MEK-DD expressing 
cells, the combination of erlotinib treatment with MEK inhibitor AZD6244 restores 
the sensitivity of shNF1 cells to erlotinib treatment (Fig 4.18). In shNF1 cells EGFR 
inhibition or MEK inhibition alone is not sufficient to abolish phosphorylation of 
ERK1/2, however the combination of EGFR and MEK inhibition completely 
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eradicates phosphorylation of ERK1/2. Even when membranes are exposed for a 
long time no signal for phosphorylated ERK1/2 appears (Fig 4.19).  This again 
supports the idea that NF1 loss increases resistance to erlotinib by maintaining a 
higher level of ERK1/2 phosphorylation in erlotinib-treated conditions.   
 
 
Figure 4.18. Combination treatment of erlotinib and a MEK inhibitor is effective 
against NF1-depleted cells. 
PC9 cells stably infected with a non-targeting shRNA (shSC) or shRNA 
targeting NF1 (shNF1) were treated for 72 hours with the indicated 
concentrations of erlotinib, either alone or in combination with 1 µM AZD6244 
(MEK inhibitor).   
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Figure 4.19. Combined erlotinib and MEK inhibitor treatment abolishes 
phosphorylation of ERK1/2 in shNF1 cells. 
shSC and shNF1 expressing cells were treated with the indicated drugs for 1 
hour prior to lysis for immunoblotting. 
 
The same effect could not be produced by combination with an AKT inhibitor. Using 
a dose that inhibits AKT phosphorylation, without causing a substantial decrease in 
survival alone in the shSC cells, shNF1 cells could not be resensitised to erlotinib 
treatment (Fig 4.20).  
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Figure 4.20. Combination treatment of erlotinib and an AKT inhibitor is not 
effective in NF1-depleted cells. 
PC9 cells stably infected with a non-targeting shRNA (shSC) or shRNA 
targeting NF1 (shNF1) were treated for 72 hours with the indicated 
concentrations of erlotinib, either alone or in combination with 100 nM MK2206 
(AKT inhibitor).   
 
Interestingly PC9-ER cells (erlotinib resistant clones), generated by long term 
culturing in the presence of erlotinib are not sensitive to a combination of erlotinib 
and MEK inhibitor (Fig. 4.21).   
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Figure 4.21. PC9-ER cells are not sensitive to a combination of erlotinib and a 
MEK inhibitor. 
PC9 parental cells (Parental) or PC9 erlotinib resistant cells (PC9-ER) were 
treated with the indicated concentrations of erlotinib, either alone or in 
combination with a MEK inhibitor (AZD6244) for 72 hours.  Cell survival was 
quantified using the CellTiter-Blue assay. 
  
PC9-ER cells are extremely resistant to erlotinib.  Previously, DNA sequencing 
revealed these cells contain the EGFR-T790M mutation, which is not detectable in 
the parental PC9 population.  Analysis of signalling by immunoblotting reveals that 
PC9-ER cells retain a low level of phosphorylated ERK1/2 in the presence of the 
erlotinib and MEK inhibitor combination (Fig 4.22). 
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Figure 4.22. PC9-ER cells retain phosphorylated ERK1/2 in the presence of 
combined erlotinib and MEK inhibitor treatment. 
PC9 parental and erlotinib resistant (PC9-ER) cells were treated with the 
indicated drug combinations for 1 hour prior to lysis for immunoblotting. 
 
Additionally PC9-ER cells, like the shNF1 cells are not sensitive to the combination 
of erlotinib and an AKT inhibitor (Fig.4.23).   
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Figure 4.23. PC9-ER cells are not sensitive to a combination of erlotinib and an 
AKT inhibitor. 
PC9 parental cells (Parental) or PC9 erlotinib resistant cells (PC9-ER) were 
treated with the indicated concentrations of erlotinib, either alone or in 
combination with an AKT inhibitor (MK2206) for 72 hours.  Cell survival was 
quantified using the CellTiter-Blue assay 
 
 
4.5 Discussion 
In our genome-wide screen we identified NF1 as a gene that increases resistance 
to erlotinib treatment upon RNAi- mediated silencing. We decided to follow up NF1 
as a hit, as it is a logical candidate due to its role as a negative regulator of RAS. 
Additional reasons for working further on NF1 were that it is mutated in 
approximately 7% of lung adenocarcinomas, including a patient sample containing 
an EGFR activating mutation (Ding et al., 2008), and it was also identified as 
downregulated in erlotinib resistant tumours in a EGFR-mutant murine model of 
NSCLC (Figure 4.1).  These data suggest NF1 loss of function may occur in vivo in 
NSCLC.  
 
Since this project began NF1 loss has been identified in resistance to multiple 
targeted therapeutics, indicating it could be a common-node by which different 
cancer types re-activate signalling in response to targeted inhibition.  Examples of 
this include increased resistance to retinoic acid in neuroblastoma (Holzel et al., 
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2010), and resistance to tamoxifen in estrogen positive breast cancer (Mendes-
Pereira et al., 2011).  Aside from loss of NF1, other mutations that activate the 
MAPK pathway have been described to have comparable effects on resistance to 
EGFR inhibitory drugs.  RAS activation by mutation had been described in primary 
resistance and more recently acquired resistance to EGFR inhibitors. KRAS 
mutation and amplification has been uncovered in colorectal cancer as a 
mechanism of acquired resistance to anti-EGFR antibodies cetuximab or 
panitumumab (Diaz et al., 2012; Misale et al., 2012).  In lung cancer, an activating 
NRAS Q61K mutation was discovered in an erlotinib-resistant subline of erlotinib-
sensitive 11-18 cells, which were generated by culturing cells in the presence of 
erlotinib for three to six months (Ohashi et al., 2012). In the same study, 1% of 
tumours sequenced from NSCLC with acquired resistance to erlotinib harboured a 
BRAF mutation.  Together, these data suggest that mutations functioning to 
activate the MAPK pathway are common in acquired resistance to EGFR inhibitory 
drugs, and support our finding that NF1 loss contributes to resistance to erlotinib.   
 
In keeping with the previous observations, we found activation of the MAPK 
pathway as the key determinant of resistance in NF1-depleted cells.  The most 
striking difference we observed between shNF1 cells and shSC cells was a higher 
level of sustained ERK1/2 phosphorylation in shNF1 cells in the presence of 
erlotinib.(Figure 4.8).  Phosphorylation of AKT did not dramatically differ between 
shSC and shNF1 cells, however erlotinib treatment does not inhibit AKT to the 
same extent as ERK, therefore any differences seen may be more difficult to detect 
(Figure 4.8).  In colorectal cancer PI3K-AKT signalling seems to be activated 
predominantly by signalling from IGFR1 rather than EGFR (Corcoran et al., 2012b).  
Activation of PI3K-AKT downstream of other receptor tyrosine kinases could 
explain the rather minor inhibition of AKT by erlotinib in the NSCLC cells we used.  
The lack of increased phosphorylation of AKT in response to NF1 silencing also 
corresponds to data from KRAS-mutant colorectal cancer cell lines.  Silencing of 
KRAS strongly reduces phosphorylation of ERK1/2 in these cells, but has little 
effect on activation of AKT, indicating RAS predominantly signals through the 
MAPK pathway in some contexts (Ebi et al., 2011).  
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Overexpression of constitutively active MEK and AKT confirmed the dominance of 
MAPK signalling in resistance to erlotinib treatment, as active MEK dramatically 
increased erlotinib resistance, whilst active AKT resulted in a much more modest 
increase in resistance (Figures 4.15 and 4.16). Due to the sustained ERK1/2 
phosphorylation seen in shNF1 cells upon erlotinib treatment, as well as the effect 
of active MEK on resistance, we postulated combined erlotinib and MEK inhibitor 
treatment could be effective in resistant NF1-depleted cells.  Indeed, the addition of 
a MEK inhibitor ‘resensitised’ shNF1 cells to erlotinib treatment, restoring their 
sensitivity to a similar level as shSC cells (Figure 4.18).  An AKT inhibitor could not 
resensitise shNF1 cells to erlotinib, again indicating the increased resistance of 
shNF1 cells is not due to activation of AKT signalling (Figure 4.20).  This is 
comparable to the situation observed in acquired resistance to EGFR inhibitors by 
KRAS mutation and amplification in colorectal cancer.  Misale and colleagues 
found the combination of cetuximab and a MEK inhibitor effective against KRAS 
amplified or mutated resistant clones derived from sensitive parental cell lines.  On 
the other hand cetuximab and a PI3K inhibitor was not effective (Misale et al., 
2012).   
 
Subsequently, by predominantly acting through MAPK signalling, loss of NF1 
differs from the amplification of MET and the acquisition of a secondary mutation in 
EGFR in driving erlotinib resistance.  Amplification of MET, observed in 
approximately 5% of patients is thought to predominantly drive activation of the 
PI3K-AKT pathway downstream of ERBB3, although additional activation of the 
MAPK pathway is observed (Engelman et al., 2007) The EGFRT790M mutation, as it 
sustains activation of EGFR possibly activates additional pathways on top of the 
MAPK pathway, for example AKT or STAT signalling.  Interestingly, we saw the 
combination of erlotinib and a MEK inhibitor was not effective in PC9 cells 
harbouring the EGFRT790M mutation, suggesting additional signalling may contribute 
to resistance (Figure 4.21).  Another explanation could be that T790M is simply a 
more potent inducer of MEK activity than NF1 loss, and we did not reach a 
combined dose of erlotinib and MEK inhibitor high enough to inhibit MEK signalling 
in these cells. There is clearly some residual ERK1/2 phosphorylation in PC9 
erlotinib resistant cells after combined erlotinib and MEK inhibitor treatment (Figure 
4.22) whereas it is completely abolished in shNF1 cells (Figure 4.19). However the 
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dose of MEK inhibitor used was already quite high (1 µM), therefore it is improbable 
that a combined dose that would inhibit ERK signalling in T790M-mutant tumours 
could be used in vivo without high toxicity and off-target effects.  These results 
have substantial ramifications for the development of combination therapeutic 
regimes in EGFR-TKI resistant non-small cell lung cancer.  Our data suggests an 
erlotinib and MEK inhibitor combination would be effective in some patients with 
erlotinib resistance, for example with NF1 loss of function or the activating 
mutations in the MAPK pathway described by others, but not in patients which have 
acquired the EGFRT790M mutation. 
 
 
Figure 4.24. NF1 loss activates RAS-MAPK signalling. 
NF1 loss increases levels of RAS-GTP in resistant cells, leading to higher 
activation of the MAPK pathway in the presence of erlotinib, and increased cell 
survival. 
 
Additionally, it is possible NF1 loss contributes to erlotinib resistance via RAS-
independent mechanisms. Shapira and colleagues noted that NF1-deficient mouse 
embryonic fibroblasts and malignant peripheral nerve sheath tumour cells were 
more resistant to apoptosis induced by treatment with staurosporine and UV 
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irradiation. This could not be reversed by inhibition of RAS, indicating a RAS-
independent mechanism was involved (Shapira et al., 2007). However, our data 
strongly suggests NF1 loss contributes to erlotinib resistance via a RAS dependent 
mechanism as increased resistance to erlotinib upon endogenous NF1 silencing 
could be prevented by overexpression of the NF1-GRD (Figure 4.12). Other 
potential NF1-dependent RAS-independent mechanisms of increased resistance 
could be via Epithelial-Mesechymal Transition (EMT). As stated in the introduction 
EMT is a clinically validated mechanism of acquired resistance to EGFR-TKIs in 
NSCLC. NF1 loss contributes to EMT in neurofibromatosis type 1 (Arima et al., 
2010), and in epicardial cells in development (Baek and Tallquist, 2012). However, 
when the expression of E-cadherin (epithelial marker) and vimentin (mesenchymal 
marker) was examined, there was no difference between shSC- and shNF1-
expressing PC9 cells indicating EMT had not occurred in response to NF1 silencing.   
 
Currently, we have validated our data in vitro, and it is supported by findings in a 
murine model of erlotinib resistant EGFR-mutant NSCLC (Katerina Politi, 
unpublished data).  NF1 mutations are common in a wide range of neoplasms and 
have been found in approximately 7% of NSCLC suggesting mutations in NF1 
could potentially yield non-functional protein products leading to acquired 
resistance to EGFR-TKIs in vivo (Ding et al., 2008).  Unfortunately we have not 
been able to validate our findings in patients, due to a lack of access to clinical 
samples.  In order to confirm the presence acquired NF1 mutations, pre-treatment 
and post-treatment samples are required, and such patient data sets are difficult to 
obtain.  Nf1 mRNA levels were decreased in erlotinib resistant tumours in the 
EGFRL858R murine model of NSCLC (Figure 4.1), however the mechanism by which 
this occurs is currently unknown.  NF1 expression is regulated at multiple levels, 
therefore there are several potential routes by which NF1 function could be lost in 
resistant tumours. Aside from mutation possible mechanisms of downregulation 
include promoter methylation, proteasomal degradation, regulation by microRNA, 
alternative splicing and RNA editing (Andersen et al., 1993; Chai et al., 2010; 
Mancini et al., 1999; McGillicuddy et al., 2009; Skuse et al., 1996). 
 
The NF1 promoter contains CpG dinucleotide rich regions, which are subject to 
methylation. In the promoter region is a methylation free CpG island, which if 
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methylated would affect binding of SP1 and CREB transcription factors, and could 
lead to NF1 silencing (Mancini et al., 1999).   In order to see whether this is the 
case we asked our collaborator Dr. Marc Laydanyi to look at the methylation 
patterns of the NF1 promoter in EGFR mutant lung cancer patients who had 
developed resistance to EGFR TKIs. In the 4 matched pre-treatment and resistant 
samples of which there was enough DNA, bisulfite sequencing was performed.  No 
hypermethylation of the NF1 promoter was found, and although the number of 
patient samples is limited and it is not possible to rule out methylation, this is in 
agreement with current literature, which suggests methylation of NF1 is not a 
common mechanism of NF1 inactivation (Harder et al., 2004; Luijten et al., 2000). 
 
NF1 is ubiquitinated and degraded by the proteasome in response to growth factor 
stimulation in a number of cell lines, including schwann cells and fibroblasts.  In 
these cell types Neurofibromin is rapidly degraded in response to stimulation, but 
then quickly restored to normal levels to attenuate RAS signalling (Cichowski et al., 
2003).  In a subset of glioblastoma cell lines proteasomal degradation of NF1 is 
aberrantly activated by hyperactivation of PKC alpha and this is essential for 
transformation and tumourigenesis (McGillicuddy et al., 2009). One potential way of 
NF1 degradation may be enhanced, would be the overexpression, or increased 
activation of components in the ubiquitination and proteasomal degradation 
pathway. Recently the E3 ubiquitin ligase RING component responsible for the 
transfer of ubiquitin from E2 to NF1, which targets NF1 for degradation has been 
identified as RNF7 (ring finger protein 7), also known as SAG/ROC2/RBX2 (Tan et 
al., 2011).  Tan and colleagues discovered degradation of NF1 mediated by RNF7 
was essential for vascular and neural development in mice.  RNF7 resides on 
chromosome 3q which is frequently amplified in NSCLC (Balsara et al., 1997; Lu et 
al., 1999), and high RNF7/GAPDH expression is predictive of poorer patient 
survival in NSCLC (Sasaki et al., 2001).  Therefore it is possible that 
overexpression of RNF7 as a result of gene amplification could increase NF1 
degradation and subsequently increase resistance to erlotinib treatment.  
 
NF1 protein expression can also be decreased by targeting by microRNAs 
(miRNAs).  miRNAs are small RNA molecules which regulate gene expression at a 
post-transcriptional level.  In recent years it has been shown that expression of 
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miRNAs is frequently altered in cancer, resulting in changes in protein expression.  
In the genetic disorder Neurofibromatosis type I microRNA 10b has been 
implicated in reducing the expression of NF1.  Chai and colleagues found that NF1 
malignant peripheral nerve sheath tumours (MPNST) had 20-30 fold higher levels 
of microRNA 10b than non-NF1 MPNSTs (Chai et al., 2010).  In SK-ES1 cells, of 
neuroectodermal origin, high microRNA 10b expression correlated with low 
expression of NF1, and inhibition of microRNA 10b increased NF1 protein levels 
(Chai et al., 2010).  However, transfection of an miR10b mimic into PC9 cells did 
not have a significant impact on NF1 expression or erlotinib resistance.  There are 
multiple miRNA binding sites in the NF1 3’UTR, such as sites for miR103a/107, 
therefore it is possible that other miRNAs are involved in the regulation of NF1 
expression (TargetScan: www.targetscan.org/vert_61/). 
 
Also, NF1 activity can be affected by splicing.  In humans there are two main 
isoforms of NF1, which differ in their RAS GTPase activity.  Isoform I of NF1 
contains an additional in-frame coding exon, exon 23a, which correlates to a 21 aa 
segment within the NF1 GRD.  Isoform II does not contain this coding exon, and 
concordantly exhibits approximately 10-fold higher RAS GTPase activity (Andersen 
et al., 1993).  It is possible that alterations in splicing regulation could cause 
changes in respective levels of the NF1 isoforms, resulting in more isoform I than 
isoform II.  This would lead to an overall decrease in NF1 activity, and could be a 
potential mechanism for NF1 downregulation in erlotinib resistant tumours. In PC9 
cells the vast majority of NF1 present was the less active isoform I, therefore a 
further increase in the proportion of isoform I is unlikely to have a significant impact 
on erlotinib resistance, however such a mechanism may occur in vivo. 
 
A third isoform of NF1 lacking GTPase activity is generated by C-U editing of the 
NF1 RNA transcript.  The NF1 transcript undergoes editing at nucleotide position 
2914, which converts a cytidine to a uridine and generates a premature stop codon.  
This results in a truncated version of neurofibromin finishing in the amino terminus 
of the GAP related domain, therefore lacking GTPase activity (Skuse et al., 1996). 
Examples of such editing have been found in tumours from Neurofibromatosis type 
1 patients (Cappione et al., 1997; Mukhopadhyay et al., 2002).  C-U editing is 
carried out by the APOBEC family of cytidine deaminases. Recent publications 
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suggest the ABOPEC family may be involved in formation of mutational clusters in 
breast tumours (Nik-Zainal et al., 2012), therefore it is possible these ABOPECs 
have an active role in human cancer and could contribute additionally to 
tumourigenesis by editing of NF1 mRNA.  
 
Currently, conclusive evidence for NF1 downregulation in erlotinib resistant NSCLC 
is lacking, and the mechanism of NF1 loss of function is unknown.  Clearly, as 
previously stated here, this is a complicated problem to unravel, as there are 
multiple levels of regulation.  Ultimately, we would like to analyse patient samples 
for differences in NF1 protein expression and for the presence of NF1 mutations to 
confirm how this occurs in the real-life setting.  
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Chapter 5. DEPTOR loss increases resistance of 
non-small cell lung cancer (NSCLC) to EGFR 
tyrosine kinase inhibitors (TKIs) by feedback 
upregulation of EGFR. 
5.1 DEPTOR structure and function 
DEPTOR is a 48 KDa protein comprised of 2 N-terminal DEP domains and a C-
terminal PDZ domain.  It has been identified as a negative regulator of mTOR 
signalling. However, little is known about the exact mechanism by which DEPTOR 
inhibits mTOR function. It is known that endogenous DEPTOR interacts directly 
with mTOR via the PDZ domain of DEPTOR and the FAT domain of mTOR 
(Peterson et al., 2009).  Loss of DEPTOR in HeLa cells leads to increased 
phosphorylation of downstream targets of mTOR signalling, predominantly S6K, 
AKT and SGK1 (Peterson et al., 2009). This mTOR signalling activation occurs via 
increased kinase activity of mTOR, as both mTORC1 and mTORC2 
immunoprecipitated from DEPTOR-depleted cells displayed higher in vitro kinase 
activity (Peterson et al., 2009).  
 
5.2 DEPTOR expression and mTOR signalling in cancer     
DEPTOR expression is greatly varied in different cancer types.  In some cancer 
types it is downregulated compared to normal tissue, while in other cancer types it 
is over-expressed (Peterson et al., 2009). Studies in different cell types suggest 
DEPTOR can act as an oncogene or a tumour suppressor by differentially affecting 
mTORC1 and mTORC2 through the action of various feedback loops.  In multiple 
myeloma cells, DEPTOR overexpression is driven by overexpression of cMAF and 
MAFB transcription factors as a result of chromosomal translocations.  In a subset 
of multiple myelomas, DEPTOR overexpression is essential for survival, as it 
asymmetrically inhibits mTOR signalling in this cell type (Peterson et al., 2009).  
Specifically, DEPTOR overexpression relieves the negative feedback of mTORC1 
to IRS1.  In this feedback loop inhibition of mTORC1 leads to inactivation of S6K 
and subsequently relieves repression of IRS1. This activation of IRS1 activates 
PI3K/AKT signalling (O’Reilly 2006). This is striking, since in vitro results suggest 
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DEPTOR should also inhibit mTORC2, but AKT remains phosphorylated at Ser473 
with DEPTOR over-expression, indicating mTORC2 is still active (Peterson et al., 
2009). Suppression of DEPTOR in multiple myeloma cell lines in which it is over-
expressed induces apoptosis. By contrast, depletion of DEPTOR protects HeLa 
cells from serum deprivation induced apoptosis which indicates DEPTOR loss can 
have opposing effects on cell survival depending on the cell context (Peterson et al., 
2009).  
 
DEPTOR protein stability is tightly regulated by mTOR signalling.  A set of papers 
recently described the mechanism by which DEPTOR is degraded by the 
proteasome in response to mTOR activation upon serum stimulation (Duan et al., 
2011; Gao et al., 2011; Zhao et al., 2011).  Gao and Duan both found that 
phosphorylation of DEPTOR by Casein Kinase I and mTOR creates a 
phosphodegron (phosphorylated amino acid sequence to which F box components 
of E3 ubiquitin ligases bind), targeting DEPTOR to the E3 ubiquitin ligase SCFβTrCP 
for ubiquitination and proteasomal degradation.  Zhao and colleagues also found 
that DEPTOR was degraded via a SCFβTrCP-dependent mechanism in response to 
growth factor stimulation. However they suggest that RSK1 and S6K1 are the 
kinases responsible for DEPTOR phosphorylation rather than mTOR and Casein 
Kinase I.  mTOR signalling is activated in a variety of tumour types and often 
correlated with poor prognosis.  In NSCLC patients showing phosphorylation of 
components of the mTOR signalling pathway (phosphorylation of mTOR, AKT and 
S6K) demonstrated a worse prognosis than those who scored negative for mTOR 
pathway activation (Liu et al., 2011).  Also, activation of mTOR signalling via PTEN 
loss has been reported in H1650 cells, an EGFR-mutant NSCLC cell line. This loss 
of PTEN is believed to cause resistance to EGFR TKIs (Sos et al., 2009).  
Consequently, it is possible that DEPTOR protein levels are decreased in a subset 
of NSCLC with activated mTOR signalling, and that this reduction contributes to 
erlotinib resistance. 
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5.3 Reduction in DEPTOR expression increases resistance of 
NSCLC cells to erlotinib treatment. 
DEPTOR was one of the candidates in our siRNA screen for erlotinib resistance, 
since DEPTOR silencing reduced sensitivity of PC9 cells to erlotinib treatment.  As 
a negative regulator of mTOR, a downstream component of the EGFR signalling 
pathway, we first examined if DEPTOR loss would lead to increased mTOR 
signalling and whether this altered mTOR signalling could increase resistance to 
EGFR TKIs.  Direct siRNA knockdown experiments demonstrated the Dharmacon 
SMARTpool, which efficiently reduces levels of DEPTOR mRNA (Figure 5.1) and 
protein (Figure 5.2), causes a reduction in erlotinib sensitivity over 72 hours (Figure 
5.3).  In deconvolution experiments, in which the siRNAs that comprise the 
SMARTpool were used individually, oligos 2 and 4 gave the most efficient silencing 
of DEPTOR at an mRNA level (Figure 5.1) and caused the largest increase in 
erlotinib resistance compared to non-targeting siRNA controls (Figure 5.3).  
Interestingly, these two siRNAs were the ones that initially validated in the larger 
screen.  This suggests the effects seen on resistance are a consequence of 
DEPTOR silencing and are not off-target effects, as two independent siRNA 
produce the same biological effect. 
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Figure 5.1. The deconvoluted SMARTpool targeting DEPTOR efficiently reduces 
DEPTOR mRNA levels. 
DEPTOR mRNA levels were quantified by RT-QPCR 48 hours after transfection 
with either a non-targeting control (siSC), the individual siRNAs of the 
SMARTpool targeting DEPTOR, or the combined pool.   
 
 
 
Figure 5.2. The deconvoluted SMARTpool targeting DEPTOR efficiently reduced 
DEPTOR protein levels. 
PC9 cells were transfected with either a non-targeting control (siSC) or the 
individual or combined siRNAs of the SMARTpool targeting DEPTOR.  Cells 
were lysed 48 hours after transfection and protein levels were quantified by 
immunoblotting. ERK1/2 is shown as a loading control. 
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Figure 5.3. DEPTOR silencing increases resistance of PC9 cells to erlotinib 
treatment. 
PC9 cells were transfected with the indicated siRNAs.  48 hours after 
transfection cells were treated with the indicated concentrations of erlotinib for 
72 hours.  Cell viability was measured using the Cell Titer Blue assay. A. Cell 
survival at each erlotinib dose plotted as a curve, results shown are triplicate 
samples from one representative experiment.  B. Cell survival (the same data 
as in A) is shown as a Survival Fraction 50 (SF50), which is the concentration of 
erlotinib necessary to result in 50% cell survival compared to untreated controls.  
 
To further validate these effects, and see if DEPTOR depletion could increase 
resistance to erlotinib in longer-term assays, we infected PC9 cells with two short 
hairpin RNA (shRNA) constructs targeting DEPTOR.  Both constructs efficiently 
reduced DEPTOR mRNA and protein levels, compared to a control non-targeting 
shRNA (shSC) (Figure 5.4).  To test whether DEPTOR-depletion could cause 
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increased resistance to erlotinib in the longer term we grew shSC and shDEPTOR 
cells in the presence of increasing doses of erlotinib for 10 days (Figure 5.5).  Cells 
infected with either hairpin targeting DEPTOR were approximately twice as 
resistant as shSC cells to erlotinib treatment. 
 
 
Figure 5.4. shRNAs targeting DEPTOR efficiently reduce DEPTOR expression at 
the mRNA and protein level. 
PC9 cells were infected with either a control non-targeting shRNA (shSC), or  
shRNA constructs targeting DEPTOR (shDEPTOR #1 and shDEPTOR #2).   A.  
mRNA levels were quantified by qRT-PCR.  B. Protein levels were measured by 
immunoblotting, AKT is shown as a loading control. 
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Figure 5.5. Silencing of DEPTOR increases resistance of PC9 cells to erlotinib 
treatment in long term cell survival assays. 
PC9 cells were stably infected with either a non-targeting control shRNA 
construct or shRNA constructs targeting DEPTOR (shDEPTOR #1 and #2). 
Cells were grown in the presence of indicated concentrations of erlotinib for 10 
days and then fixed and stained with Sulphorhodamine B. 
 
To examine if this DEPTOR-mediated resistance was general to EGFR-mutant 
lung cancer cells, we also infected another EGFR-mutant NSCLC (HCC4006) with 
shSC and shDEPTOR constructs.  shRNA targeting DEPTOR efficiently reduces 
DEPTOR mRNA and protein levels in HCC4006 cells (Figure 5.6).  Longer-term 
cell survival assays showed similar results to those seen in PC9 cells. DEPTOR-
depleted cells were again less sensitive to 25 nM erlotinib treatment, with an 
increase in overall cell survival from 26% to 43% (Figure 5.7).  Although the 
differences in cell survival in long-term assays are relatively minimal, such modest 
reductions in drug response could over time result in a substantial increase in cell 
survival of shDEPTOR cells compared to control cells. 
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Figure 5.6. Efficiency of DEPTOR silencing in HCC4006 cells. 
HCC4006 cells were infected with a non-targeting control shRNA construct 
(shSC) or shRNA construct targeting DEPTOR (shDEPTOR #1).  A.  mRNA 
levels were quantified by qRT-PCR.  B. Protein levels were measured by 
immunoblotting, AKT is shown as a loading control. 
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Figure 5.7.  shRNA targeting DEPTOR increases resistance of HCC4006 cells to 
erlotinib treatment. 
HCC4006 cells were infected with control shRNA (shSC) or shRNA targeting 
DEPTOR (shDEPTOR #1). Cells were grown in the presence of 25 nM erlotinib, 
or without drug for 10 days.  Cells were fixed and stained with sulforhodamine 
B.  
 
5.4 DEPTOR silencing does not increase resistance of PC9 
cells to other chemotherapeutic drugs 
To ascertain whether DEPTOR silencing causes a general increase in resistance to 
multiple classes of drugs, we tested whether DEPTOR silencing affected resistance 
to gefitinib (another EGFR-TKI) and two chemotherapeutic agents, cisplatin and 
docetaxel, which serve as standard of care in non-EGFR-mutant NSCLC.  As seen 
in Figure 5.8, DEPTOR-depleted cells were substantially more resistant to gefitinib 
than control cells, similar to the effect seen with erlotinib. On the other hand, 
depletion of DEPTOR by siRNA had no effect on the resistance of PC9 cells to 
docetaxel or cisplatin (Figure 5.9).  This suggests that DEPTOR loss specifically 
affects EGFR-TKI sensitivity without generally affecting the response to 
chemotherapeutics. 
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Figure 5.8. DEPTOR depletion increases resistance of PC9 cells to gefitinib. 
PC9 cells were transfected with non-targeting siRNA (siSC) or siRNA targeting 
DEPTOR(siDEPTOR).  48 hours after transfection cells were treated with the 
indicated concentrations of gefitinib for 72 hours.  Cell viability was measured 
using the CellTiter-Blue assay. 
 
 
 
Chapter 5. Results  
  131 
 
 
Figure 5.9. DEPTOR silencing does not effect responses to other 
chemotherapeutic drugs. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of A. cisplatin or B. docetaxel for 72 hours. Cell viability was 
measured using the CellTiter-Blue assay. 
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5.5 DEPTOR silencing increases EGFR protein levels and AKT, 
ERK1/2 and mTORC2 activation. 
To elucidate the mechanism of decreased erlotinib sensitivity in DEPTOR-depleted 
cells, we assessed the total levels and phosphorylation states of several key 
components of the EGFR signalling pathway in siDEPTOR cells and siSC cells.  
We compared signalling in untreated and erlotinib-treated conditions.   As expected, 
siDEPTOR cells had more active mTOR signalling, demonstrated by increased 
levels of AKT phosphorylation at Ser473 and increased phosphorylation (and 
protein levels) of SGK1 substrate NDRG1 (Figure 5.10).  Unexpectedly, siDEPTOR 
cells showed a strong upregulation of EGFR protein levels, and maintain higher 
levels of phosphorylated EGFR than siSC cells after 1 hour of erlotinib treatment 
(Figure 5.10).  This effect was also visible in PC9 cells stably expressing shRNA 
targeting DEPTOR (Figure 5.11A).  As seen with DEPTOR siRNA, shDEPTOR 
cells had more phosphorylated ERK1/2 and NDRG1 than shSC control cells in the 
presence of erlotinib.  Quantification of phosphorylated ERK1/2 indicated 
shDEPTOR cells have 3.7 times more phosphorylated ERK1/2 than shSC cells in 
untreated conditions and retain 60% more phosphorylated ERK1/2 than shSC cells 
upon erlotinib treatment (Figure 5.11B). These values are similar to those seen in 
siSC and siDEPTOR transfected cells (Figure 5.10B). Additionally similar effects on 
signalling (albeit at a lower magnitude) were observed in HCC4006 cells 
expressing shRNA targeting DEPTOR (Figure 5.12), indicating they were not cell 
line specific. 
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A. 
Chapter 5. Results  
  134 
Figure 5.10. DEPTOR silencing activates AKT, ERK1/2 and mTORC2 signalling. 
A. PC9 cells transfected with siSC (control siRNA), or siRNA targeting DEPTOR 
were treated with 30 nM erlotinib for 1 hr before lysis.  Phosphorylation states of 
the proteins shown indicate AKT, ERK1/2 and mTORC2 (indicated by 
pNDRG1) are more active in siDEPTOR cells in the presence or absence of 
erlotinib. B. Levels of pERK1/2/ total ERK1/2 as shown in A were quantified 
using ImageJ. pERK1/2/ total ERK1/2 in the siDEPTOR transfected cells are 
presented relative to siSC transfected cells in untreated and erlotinib treated 
conditions. 
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Figure 5.11. shRNA targeting DEPTOR increases EGFR, AKT, ERK1/2 and 
mTORC2 signalling. 
A. PC9 cells expressing with shSC (control shRNA), or shRNA targeting 
DEPTOR were left untreated or treated with 30 nM erlotinib for 1 hr before lysis.  
Phosphorylation states of the proteins shown indicate AKT, ERK1/2 and 
mTORC2 (indicated by pNDRG1) are more active in shDEPTOR cells in the 
presence or absence of erlotinib. B. Levels of pERK1/2/ total ERK1/2 as shown 
in A were quantified using ImageJ. pERK1/2/ total ERK1/2 in the shDEPTOR 
A. 
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expressing cells are presented relative to shSC expressing cells in untreated 
and erlotinib treated conditions. 
 
 
 
 
 
Figure 5.12. Depletion of DEPTOR increases activation of ERK1/2 and mTORC2 
in HCC4006 cells. 
A. PC9 cells expressing with shSC (control shRNA), or shRNA targeting 
DEPTOR were left untreated or treated with 30 nM erlotinib for 1 hr before lysis 
A. 
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for immunoblotting against the indicated proteins.  B. Levels of pERK1/2/ total 
ERK1/2 as shown in A were quantified using ImageJ and levels of pERK1/2/ 
total ERK in shDEPTOR cells are presented relative to shSC cells in erlotinib 
treated conditions. Over-exposure of the blot meant that pERK1/2 /total ERK1/2 
could not be accurately determined in untreated conditions. 
 
5.6 DEPTOR silencing increases the abundance of EGFR 
protein. 
Most surprisingly, DEPTOR-depleted cells have much higher EGFR protein levels 
than control cells (Figure 5.13).   DEPTOR-depleted cells have augmented levels of 
MAPK and AKT signalling, as demonstrated by increased phosphorylation of 
ERK1/2 and AKT in untreated and erlotinib-treated conditions (Figure 5.11).  We 
hypothesised that this increased downstream signalling, and consequently the 
decreased sensitivity of DEPTOR-depleted cells to erlotinib is a result of feedback 
upregulation of EGFR signalling. 
 
 
Figure 5.13. DEPTOR silencing increases the abundance of EGFR protein 
compared to Sc control cells 
PC9 cells were infected with a non-targeting control shRNA (shSC) or one of 
two shRNAs targeting DEPTOR (shDEPTOR #1 and shDEPTOR #2).  
 
To ascertain if the increase in EGFR protein levels was a result of increased levels 
of EGFR transcript, we analysed the mRNA levels of EGFR in DEPTOR-depleted 
cells relative to controls.  siDEPTOR cells have approximately 1.7 fold more EGFR 
mRNA than control cells, whilst cells expressing shRNA against DEPTOR have 
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approximately 1.5 fold more EGFR mRNA than control cells (Figure 5.14). This 
indicates that loss of DEPTOR results in either increased transcription of EGFR 
mRNA or elevated stability of the EGFR transcript. 
 
 
 
Figure 5.14. DEPTOR silencing by siRNA and shRNA increases EGFR mRNA 
levels. 
A. DEPTOR expression is efficiently silenced by DEPTOR siRNA. B. DEPTOR 
silencing by siRNA leads to increased EGFR mRNA levels.  C. DEPTOR 
silencing by shRNA (shDEPTOR #1) leads to increased EGFR mRNA levels 
(D). 
 
 Many reports have implicated the upregulation of alternative receptors in 
resistance to RTK-targeted therapies (Dua et al., 2010; Engelman et al., 2007).  
Therefore we checked the expression and activation of HER2, ERBB3, MET and 
IGFR1, as key receptors found to be involved in resistance to EGFR-targeted 
therapeutics.  We found that there was no difference in expression or activation of 
these receptors indicating that it is not a general effect on RTKs, and that 
DEPTOR-loss specifically upregulates EGFR (Figure 5.15).   
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Figure 5.15.  DEPTOR depletion does not affect abundance of other key receptor 
tyrosine kinases. 
PC9 cells expressing shRNA targeting DEPTOR or a control non-targeting 
shRNA (shSC), were lysed, and cell lysates were immunoblotted for the 
indicated proteins. 
 
To confirm that the increase in EGFR protein with DEPTOR loss correlates to 
increased downstream activity, we immunoprecipitated EGFR from shSC and 
shDEPTOR cells and assessed the binding of adaptor proteins that mediate 
signalling downstream of EGFR.  In keeping with the increased EGFR protein 
levels in total lysates, more EGFR was immunoprecipitated from shDEPTOR cells 
than shSC cells.  With this increase in EGFR, there was also an increase in GRB2 
co-immunoprecipated with EGFR from shDEPTOR cells in the presence of erlotinib 
(Figure 5.16).  This indicates the additional EGFR in DEPTOR-depleted cells is 
capable of downstream signalling, and results in higher total EGFR:GRB2 binding 
in shDEPTOR cells in the presence of erlotinib.   
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Figure 5.16. DEPTOR-depleted cells have increased levels of EGFR and EGFR-
mediated signalling. 
PC9 cells expressing shRNA targeting DEPTOR or a control non-targeting 
shRNA (shSC) were left untreated or treated for 1 hr with 30 nM erlotinib prior 
to lysis.  EGFR was immunoprecipated from the cell lysates, and 
immunoprecipates were subjected to immunoblotting for EGFR and GRB2 (IP: 
α-EGFR).  Total lysates are shown as loading controls. 
 
SOS is one of the major binding partners of GRB2 downstream of EGFR, with 
which it normally binds to EGFR in a pre-complexed form.  GRB2/SOS directly 
binds to RAS, where SOS acts as a Ras GEF, to enhance release of GDP from 
RAS and promote formation of active RAS-GTP.  To confirm that shDEPTOR cells 
have more active RAS, RAS activity assays were performed.  shDEPTOR cells had 
slightly higher levels of active RAS in erlotinib-treated conditions (Figure 5.17).  
While the difference between shSC and shDEPTOR cells is small, signalling 
pathways are capable of amplifying such modest effects downsteam enough to 
drive the decrease in sensitivity to erlotinib seen in shDEPTOR cells. 
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Figure 5.17. DEPTOR-depleted cells have slightly higher levels of active RAS 
than control cells. 
PC9 cells expressing shRNA targeting DEPTOR or a control non-targeting 
shRNA (shSC) were left untreated or treated for 1 hr with 30 nM erlotinib prior 
to lysis. RAS-GTP was immunoprecipated from lysates with GST-Raf1-Ras 
Binding Domain, as described in the materials and methods. Total RAS protein 
from total lysates is shown as loading control. B. Levels of Ras-GTP/Total Ras 
were quantified using ImageJ and are presented relative to untreated shSC 
cells. 
 
Taken together, the above results suggest that increased EGFR levels lead to 
augmented MAPK and AKT signalling.  To test whether the upregulation of EGFR 
was simply a consequence of increased signalling through AKT and MEK we 
examined the levels of EGFR protein in PC9 cells overexpressing active forms of 
AKT and MEK, as described in chapter 4.  There was no difference in EGFR 
expression between control cells (PC9 cells expressing the murine ecotropic 
receptor) and PC9 cells expressing active MEK or AKT (Figure 5.18).  This 
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indicates that increased levels of EGFR protein are not simply an effect of 
increased downstream signalling flux. 
 
 
 
Figure 5.18.  EGFR abundance is not affected by active MEK or AKT 
PC9-EcoR cells were infected with retroviral MEK-DD and myr-AKT constructs.  
Cells were treated with erlotinib for 1 hr prior to lysis, to demonstrate activation 
of the MEK-DD construct.   
 
5.7 Inhibition of mTOR or MEK restores sensitivity of 
siDEPTOR cells to erlotinib 
To determine which effector pathways contribute to erlotinib resistance in 
DEPTOR-depleted cells, we treated siSC and siDEPTOR cells with various 
pathway inhibitors in combination with erlotinib. To examine downstream signalling, 
we employed a MEK inhibitor (AZD6244), an AKT inhibitor (MK2206), an allosteric 
mTOR inhibitor (temsirolimus) to inhibit mTORC1, and an mTOR kinase inhibitor 
(AZD8055) to inhibit both mTOR complexes.  Each combination was examined 
over a 72-hour dose response (Figures 5.19-5.26).  Only the mTOR kinase inhibitor 
and the MEK inhibitor effectively restore erlotinib sensitivity of siDEPTOR cells to 
that of the control cells (Figure 5.19 and Figure 5.23). Analysis of the signalling in 
siSC and siDEPTOR cells upon combined erlotinib and MEK inhibitor treatment 
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suggest this is due to a clear reduction in ERK phosphorylation (Figure 5.21).  
Additionally the combination leads to a further decrease in S6 phosphorylation than 
erlotinib treatment alone, however this is also seen with the mTOR allosteric 
inhibitor temsirolimus that does not restore erlotinib sensitivity of DEPTOR-
depleted cells (Figure 5.25 and 5.26).  The combination of erlotinib and an AKT 
inhibitor partially restores the sensitivity of siDEPTOR cells to erlotinib treatment, 
however this is not as effective as the erlotinib and MEK inhibitor combination 
(Figure 5.21).  The combination of erlotinib and an AKT inhibitor decreases 
phosphorylation of AKT more than either drug alone, and also decreases activation 
of S6 (Figure 5.22).  This is possibly as there is no additional inhibition of ERK, in 
fact phosphorylation of ERK is slightly higher with the combination treatment, rather 
than erlotinib alone (Figure 5.22).  
 
The mTOR allosteric inhibitor did not resensitise DEPTOR-depleted cells to 
erlotinib. The difference in survival between DEPTOR-depleted cells and control 
cells was greater in the combination treatment of erlotinib and temsirolimus than 
with erlotinib alone.  Immunoblotting suggests this is because only S6 
phosphorylation is affected by temsirolimus treatment.  There is no effect on 
phosphorylation of 4EBP1 indicating not all mTORC1 substrates are effectively 
targeted (Figure 5.26).  There is a slight increase in phosphorylation of AKT upon 
temsirolimus treatment, which is likely to be a result of the feedback activation of 
AKT via IRS1 downstream of S6K inhibition (O'Reilly et al., 2006) and may account 
for the lack of effect on cell survival.  On the other hand the combination of erlotinib 
and the mTOR kinase inhibitor restored the cell survival of the siDEPTOR cells to 
that of the control cells (Figure 5.23).  Analysis of the activation of key signalling 
proteins suggests that the combination augments inhibition of AKT, S6 and 
decreases phosphorylation of 4EBP1 (Figure 5.24).   
 
Taken together these results suggest that inhibition of ERK, or both mTOR 
complexes (or at least effective inhibition of mTORC1) in combination with erlotinib, 
can restore sensitivity of the siDEPTOR cells to erlotinib treatment.   
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Figure 5.19.  Combination treatment of erlotinib and a MEK inhibitor restores 
sensitivity of siDEPTOR cells to erlotinib to that of Sc control cells. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of erlotinib either with or without 1 µM AZD6244 for 72 hours. A. 
Cell survival at each erlotinib dose is plotted as a curve. Results shown are 
from triplicate samples from one representative experiment.  B. Cell survival 
(the same data as in A) is shown as a Survival Fraction 50 (SF50). 
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Figure 5.20.  Combination treatment of erlotinib and MEK inhibitor restores 
sensitivity of siDEPTOR cells to erlotinib by abolishing activation of ERK1/2. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of erlotinib either with or without 1 µM AZD6244 for 4 hours prior 
to lysis for immunoblotting against the indicated proteins. 
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Figure 5.21. Combination treatment of erlotinib and an AKT inhibitor partially 
resensitises DEPTOR-depleted cells to erlotinib treatment. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of erlotinib either with or without 100 nM MK2206 for 72 hours. 
A. Cell survival at each erlotinib dose is plotted as a curve. Results shown are 
from triplicate samples from one representative experiment.  B. Cell survival 
(the same data as in A) is shown as a Survival Fraction 50 (SF50. 
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Figure 5.22. Combined erlotinib and AKT inhibition partially resensitises 
DEPTOR-depleted cells to erlotinib treatment. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of erlotinib and MK2206 (AKT inhibitor) for 4 hours prior to lysis 
for immunoblotting. 
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Figure 5.23. Combined treatment of erlotinib and an mTOR kinase inhibitor 
restores sensitivity of siDEPTOR cells to erlotinib to that of Sc control cells. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of erlotinib either with or without 25 nM AZD8055 for 72 hours. 
A. Cell survival at each erlotinib dose is plotted as a curve. Results shown are 
from triplicate samples from one representative experiment.  B. Cell survival 
(the same data as in A) is shown as a Survival Fraction 50 (SF50). 
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Figure 5.24. Combined erlotinib and mTOR kinase inhibitor treatment restores 
sensitivity to erlotinib. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of erlotinib either with or without 25 nM AZD8055 for 4 hours. 
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Figure 5.25. Combination treatment of erlotinib and temsirolimus does not 
restore sensitivity of siDEPTOR cells to Sc control levels. 
PC9 cells were transfected with siRNA targeting DEPTOR or a non-targeting 
control (SC).  48 hours after transfection, cells were treated with the indicated 
concentrations of erlotinib either with or without 1 µM temsirolimus for 72 hours. 
A. Cell survival at each erlotinib dose is plotted as a curve. Results shown are 
from triplicate samples from one representative experiment.  B. Cell survival 
(the same data as in A) is shown as a Survival Fraction 50 (SF50). 
 
Cell survival after 72 hrs erlotinib treatment
-4 -2 0 2
0
50
100
Sc    
DEPTOR      
Sc + temsirolimus
DEPTOR + temsirolimus
log[erlotinib] (!M)
C
e
ll 
s
u
rv
iv
a
l (
%
 o
f u
n
tr
e
a
te
d
 c
o
n
tr
o
l)
!"
#!"
$!"
%!"
&!"
'!"
(!"
)!"
*!"
+," -./012"""" +,"3"456789:;86<7" -./012"3"
456789:;86<7"
+
=
'
!
">
?
@
A"
A
B
Chapter 5. Results  
  151 
 
Figure 5.26. Temsirolimus treatment effectively inhibits rpS6 phosphorylation, 
but does not resensitise cells to erlotinib treament. 
PC9 cells transfected with siSC or siDEPTOR were treated for 4 hours with the 
indicated drugs.  
  
We were intrigued by the difference between the reversal of resistance with the 
mTOR kinase inhibitor compared with the minor effect of the rapamycin analogue. 
To further investigate the relative contributions of mTORC1 and mTORC2 to the 
decreased erlotinib sensitivity of DEPTOR-depleted cells, siRNAs targeting 
RAPTOR or RICTOR were used to specifically inhibit the function of mTORC1 
(RAPTOR) and mTORC2 (RICTOR).  Silencing of either RAPTOR or RICTOR 
substantially reduced the survival of DEPTOR-depleted cells, indicating that both 
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mTOR complexes are required for cell survival in DEPTOR-depleted cells (Figure 
5.28).  
 
Figure 5.27. RICTOR and RAPTOR are both essential for survival of DEPTOR-
depleted cells in the presence of erlotinib. 
PC9 cells were transfected with either non-targeting siRNA or siRNA targeting 
DEPTOR alone or in combination with siRNA targeting RAPTOR or RICTOR.  
A. Cells were treated with a 0-10 µM dose range of erlotinib for 72 hours and 
SF50 was determined by CellTiter-Blue. Results shown are from triplicate 
samples from one representative experiment.  Efficiency of silencing was 
measured at the protein level by immunoblotting. 
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5.8 Discussion 
Here we show that loss of DEPTOR decreases sensitivity of EGFR-mutant NSCLC 
cells to erlotinib treatment.  Silencing of DEPTOR resulted in multiple changes in 
cell signalling.  The most prominent changes were modest increases in 
phosphorylation of EGFR, ERK, AKT and NDRG1 and increased expression of 
EGFR.  As multiple pathways are affected it is a challenge to clearly delineate 
which of this changes cause the decreased sensitivity of DEPTOR-depleted cells to 
erlotinib, or how these changes occur.  mTOR signalling involves several feedback 
loops, so perturbation of the pathway can have effects that are not necessarily 
easy to predict (Efeyan and Sabatini, 2010). The classical example of an mTOR 
feedback loop is the inhibition of IRS1 and subsequently AKT which occurs 
downstream of mTORC1 activation via S6K (O'Reilly et al., 2006).  This feedback 
loop has severely limited the effects of mTORC1 allosteric inhibitors, as they block 
the negative feedback downstream of mTORC1 which leads to increased AKT 
activation. The same negative regulatory mechanism also leads to upregulation of 
MAPK signalling, via S6K1/PI3K/RAS, as discovered in the analysis of tumours 
from patients treated with rapamycin (Carracedo et al., 2008). 
 
Our hypothesis is that DEPTOR-loss upregulates EGFR expression and activation 
to increase resistance to erlotinib. The mechanism by which DEPTOR loss leads to 
erlotnib resistance is analogous to the intrinsic resistance to RAF inhibitors seen in 
BRAF-mutant colon cancer.  Recently two studies implicated upregulation of EGFR 
in resistance to vemurafenib (BRAF inhibitor) (Corcoran et al., 2012a; Prahallad et 
al., 2012).  Both studies showed that feedback to EGFR increased resistance to 
RAF inhibition by reactivating MAPK signalling.  The groups however came up with 
slightly different mechanisms of action.  Prahallad and colleagues postulate that 
inhibition of ERK signalling by a BRAF inhibitor reduces activity of CDC25C, which 
in turn leads to de-repression of EGFR phosphorylation (Prahallad et al., 2012).  
On the other hand, Corcoran et al. did not observe increased phosphorylation of 
EGFR upon vemurafenib treatment.  Instead, they suggest that decreased ERK 
signalling upon BRAF inhibition decreases expression of Sprouty4, which 
subsequently increases activation of RAS downstream of RTK activation (Corcoran 
et al., 2012a).  
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DEPTOR loss augments levels of EGFR expression and increases erlotinib 
resistance compared to control cells, similar to the intrinsic resistance to BRAF 
inhibition of colorectal cancer cells compared to melanoma cells. As will be 
discussed in greater detail, upregulation of EGFR by DEPTOR seems to be at both 
the protein and mRNA levels and results in an increase in EGFR and MAPK 
activation.  In contrast, EGFR upregulation in response to BRAF inhibition occurs 
by inactivation of negative regulators of EGFR signalling as a consequence of drug 
treatment (Corcoran et al., 2012a)(Prahallad et al., 2012). 
 
In order to ascertain the directionality of signalling we expressed active MEK and 
AKT proteins in PC9 cells.  Expression of an active MEK or AKT construct did not 
increase EGFR levels, which indicates upregulation of EGFR is not a consequence 
of the increased AKT and MAPK pathway signalling seen in DEPTOR-depleted 
cells.  The schematic in Figure 5.29 outlines the increases in signalling observed in 
DEPTOR-depleted cells, and the proposed directionality of signalling.  In brief, the 
hypothesis is that DEPTOR loss activates mTORC1 and mTORC2 to increase 
EGFR protein synthesis, leading to augmented MAPK signalling.  Additionally 
activation of mTORC2 may contribute to resistance by activating pro-survival 
signalling downstream of AGC kinases.  This is a working hypothesis and more 
data is needed in order to conclusively state the mechanism by which DEPTOR 
loss increases resistance to EGFR TKIs.  Methods that would allow us to test this 
proposed mechanism of action will be discussed in the following sections. 
 
Further work is needed to conclusively state that the increase in EGFR protein 
levels and increased signalling is the cause of resistance in DEPTOR-depleted 
cells. Possible approaches to address EGFR-dependency include overexpression 
of EGFR in PC9 cells to confirm increased EGFR expression can mediate erlotinib 
resistance. Additionally we could test whether combining erlotinib treatment with 
another EGFR inhibitor such as AG1478 reverses the increased resistance of 
DEPTOR-depleted cells.  DEPTOR loss leads to an upregulation of EGFR mRNA 
levels, as indicated by Q-RTPCR analysis. However it is not clear whether the 
upregulation of EGFR occurs solely at the level of transcription or mRNA stability, 
or whether there is additionally an increase in translation of EGFR transcript.  The 
impact on translation could be assessed by measuring the incorporation of 
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radiolabelled amino acids such as 35S-Cys/Met into newly synthesised proteins to 
determine differences in the rate of protein synthesis between control and 
DEPTOR-depleted cells.  Aside from effects on protein synthesis, EGFR protein 
stability may be increased in DEPTOR-depleted cells.  Cycloheximide timecourse 
experiments could be conducted in order to compare the half-life of EGFR in 
control and DEPTOR-depleted cells in the absence of new protein synthesis.  
 
Currently it is not possible to decisively conclude that elevated mTOR signalling is 
responsible for the increase in EGFR protein levels. We think that elevated mTOR 
signalling is responsible for the upregulation of EGFR as it is well-established that 
mTOR plays a vital role in the control of transcription and translation (Ma and 
Blenis, 2009). mTORC1 is thought to regulate gene expression via regulation of 
transcription factors such as HIF1α (hypoxia-inducible factor 1 alpha), SREBP1 and 
SREBP2 (sterol regulatory element binding protein 1 and 2) (Magnuson et al., 
2012).  mTORC1 activates translational initiation and elongation via 
phosphorylation of S6K which leads to activation of several targets including rpS6 
and eukaryotic elongation factor 2 kinase (eEF2K) (Zoncu et al., 2011).  
Additionally mTORC1 phosphorylates 4EBP1 which causes it to release eIF4E, 
allowing formation of the translation initiation complex eIF4F and promoting cap-
dependent translation (Ma and Blenis, 2009).  This year two groups published 
important studies which elucidate further the role of mTOR signalling in translation 
(Hsieh et al., 2012) (Thoreen et al., 2012).  Both studies identified novel regulatory 
elements in the 5’ UTR of mRNAs specifically regulated by mTOR aside from the 
previously described 5’ terminal oligopyrimidine (TOP) motif. Hsieh et al identified a 
pyrimidine-rich translational element within the 5’UTRs of 63% of mTOR target 
mRNAs (Hsieh et al., 2012), whereas Thoreen and colleagues identified previously 
unrecognised TOP motifs or related TOP-like motifs in mRNAs specifically 
regulated by mTORC1 (Thoreen et al., 2012).  Both studies demonstrate that the 
translational impact of mTORC1 on specific mRNAs is predominantly mediated by 
the regulation of 4EBP1 by mTORC1.  These new insights are very interesting and 
prompt us to further examine whether DEPTOR loss may impact EGFR levels by 
effecting translation via activation of mTORC1. 
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Aside from the published role of DEPTOR as a negative regulator of mTOR 
(Peterson et al., 2009), we hypothesise that DEPTOR loss mediates increased 
erlotinib resistance through augmented mTOR signalling, as immunoblotting of 
lysates from control and DEPTOR-depleted cells indicates DEPTOR loss increases 
phosphorylation of downstream targets of mTOR signalling, namely AKT and 
NDRG1 downstream of mTORC2 (Figure 5.10). Phosphorylation of S6 (Figure 
5.20) and 4EBP1 (Figure 5.22) which function downstream of mTORC1 also 
appear to increased however the effects are more variable between experiments. 
Experiments using a combination of erlotinib with different targeted drugs revealed 
an mTOR kinase inhibitor restored the sensitivity of DEPTOR-depleted cells to 
erlotinib treatment (Figure 5.23) which additionally suggests that the decreased 
sensitivity of DEPTOR-depleted cells is dependent on augmented mTOR signalling.  
 
mTOR kinase inhibition but not use of a rapamycin analogue (rapalog) could 
resensitise siDEPTOR cells to erlotinib treatment.  This indicates increased 
activation of both mTOR complexes contributes to a more resistant phenotype, 
rather than only mTORC1.  It is important to note that rapalogs do not inhibit the 
ability of mTORC1 to phosphorylate all downstream targets equally.  In Fig 5.27 
phosphorylation of 4EBP1 does not really change in response to treatment with 
temsirolimus, whereas phosphorylation of ribosomal S6 is completely abolished.  
This is in keeping with findings by Hsieh et al, who found that the enhanced 
cytotoxic ability mTOR kinase inhibitor PP242 over rapamycin comes from its 
inhibition of 4EBP1 phosphorylation, and subsequent cap-dependent translation, 
rather than inhibition of rpS6 (Hsieh et al., 2010). The mTOR kinase inhibitor 
AZD8055 used here was more effective at inhibiting phosphorylation of 4EBP1, 
along with phosphorylation of AKT at Ser473, indicating mTORC2 was also 
inhibited (Fig 5.24). To examine the function of each mTOR complex more 
specifically we silenced RAPTOR (mTORC1) or RICTOR (mTORC2), and found 
both severely affect viability of DEPTOR-depleted cells in the prescence of erlotinib 
indicating both mTOR complexes still have a role in cell survival (Figure 5.27).  
Future work could include in vitro kinase assays of endogenous mTOR 
immunoprecipitated by RAPTOR or RICTOR to confirm activity of mTORC1 and 
mTORC2 in DEPTOR-depleted cells. It is possible DEPTOR loss may increase 
MAPK and PI3K-AKT signalling independently of mTOR activation, therefore future 
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experiments will address whether mTOR signalling has a direct role in erlotinib 
resistance. For example silencing of mTOR in DEPTOR-depleted cells would 
demonstrate whether mTOR is necessary for the upegulation of EGFR observed 
upon DEPTOR loss.  Additionally we will assess the effect of longer term treatment 
with the mTOR kinase inhibitor on EGFR levels to determine whether the mTOR 
kinase inhibitor restores the sensitivity of siDEPTOR cells by reducing EGFR 
protein abundance.  Upon establishing the role of mTOR activation in decreased 
erlotinib sensitivity upon DEPTOR loss it would be interesting to examine whether 
activation of mTOR signalling by other means, such as PTEN loss, loss of TSC1/2, 
or activating mutations in mTOR could also cause increases in EGFR protein 
abundance.  It is possible that loss of PTEN and TSC1/2 that predominantly affect 
mTORC1 activity would not cause this phenotype.  Activating mutations in mTOR, 
such as those identified by Gerlinger and colleagues (Gerlinger et al., 2012) may 
result in similar effects as DEPTOR loss, as it affects both complexes. 
 
Apart from upregulation of EGFR through increased transcription and translation 
via activation of mTORC1, DEPTOR loss may also decrease erlotinib sensitivity via 
activation of mTORC2.  One of the most striking effects of DEPTOR depletion is an 
increase in phosphorylation of NDRG1 which demonstrates increased mTORC2 
activation(Garcia-Martinez and Alessi, 2008).  Peterson et al., describe that loss of 
DEPTOR expression leads to a reduction in apoptosis in response to serum 
starvation in HeLa cells and HT-29 cells, and suggest that in HeLa cells at least it is 
an SGK1-dependent mechanism (Peterson et al., 2009). SGK1 in conjunction with 
AKT can negatively regulate FOXO1/3a to prevent induction of pro-apoptotic 
factors such as Fas-L and BH3-only BIMEL (Fu and Tindall, 2008; Garcia-Martinez 
and Alessi, 2008).  Additionally AKT and SGK1 can also phosphorylate BAD, which 
leads to its sequestration by 14-3-3 proteins in the cytoplasm, and blocks its pro-
apoptotic function (Datta et al., 1997).  Future work could probe the contribution of 
SGK1 to the increased survival of DEPTOR-depleted cells in response to erlotinib 
treatment, for example by depletion of SGK1 with RNAi, or inhibition with a specific 
SGK1 inhibitor (GSK650394).  Additionally we would like to assess whether 
NDRG1 is an essential mediator of the effects of DEPTOR depletion, or whether in 
this context it purely serves as a read-out of increased mTORC2 activity (Garcia-
Martinez and Alessi, 2008).   
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Aside from the combination treatment of an mTOR kinase inhibitor and erlotinib, 
the combination of a MEK inhibitor and erlotinib was also effective at resensitising 
DEPTOR-depleted cells to erlotinib treatment.  We hypothesise that this is because 
DEPTOR loss leads to upregulation of EGFR and subsequent downstream 
signalling.  EGFR mRNA and protein levels are increased in DEPTOR-depleted 
cells (Figure 5.13 and 5.14), which subsequently leads to increased recruitment of 
GRB2 (Figure 5.16) and activation of RAS (Figure 5.17) in basal and erlotinib 
treated conditions. We hypothesise that increased RAS activity drives the higher 
levels of ERK phosphorylation observed in DEPTOR-depleted cells, and that this 
increase in ERK activation leads to decreased sensitivity to erlotinib, as we see in 
NF1-depleted cells.  Inhibition of AKT was not as effective as inhibition of MEK at 
restoring sensitivity of DEPTOR-depleted cells, as we also found be to true with 
NF1 loss.  There are several potential reasons for this.  Firstly, as discussed in the 
previous chapter it seems that oncogenic events that activate RAS, i.e. NF1 loss or 
RAS activating mutations make cells more reliant on MAPK pathway activation, 
and therefore more susceptible to MEK inhibition (Misale et al., 2012).  Additionally, 
it has been demonstrated that AKT inhibition can drive increases in RTK 
expression, for example ERBB3, by activating FOXO-mediated transcription 
(Chandarlapaty et al., 2011).  Therefore such feedback mechanisms may limit the 
efficacy of AKT inhibition.  Also treatment with the combination of erlotinib and an 
AKT inhibitor (MK2206) resulted in slightly higher levels of phosphorylated ERK 
compared to erlotinib alone, suggesting there may be some compensatory 
activation of the MAPK pathway (Figure 5.22). Finally, AKT appears upstream of 
mTORC1 and downstream of mTORC2, therefore perturbing AKT signalling may 
have other unforeseen effects on the mTOR signalling network already disturbed 
by DEPTOR loss.  
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Figure 5.28.  Proposed mechanism - DEPTOR loss leads to upregulation of EGFR 
levels and MAPK pathway signalling. 
DEPTOR loss leads to activation of mTOR signalling and increased EGFR 
abundance.  EGFR upregulation results in augmented MAPK signalling, and 
subsequently enhanced cell survival.  mTORC2 activation increases AGC 
kinase activity to enhance survival.  Green arrows represent observed 
increases in signalling (as assessed by Western blotting). 
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DEPTOR loss did not appear to increase the abundance of other receptors, namely 
ERBB2, ERBB3, MET and IGF-R1, however one cannot rule out the possibility that 
other receptors were also involved. For example Wilson et al recently described 
activation of FGFR2 in response to exogenous FGF can rescue EGFR-mutant 
NSCLC cell lines from erlotinib treatment, therefore upregulation of FGF2 
expression could potentially increase erlotinib resistance (Wilson et al., 2012). 
Additionally, increased expression of tyrosine kinase receptor AXL has been 
reported in erlotinib resistant NSCLC xenografts and in patients (Zhang et al., 
2012). Further work could more extensively characterise protein levels and 
activation of these receptors.  The decrease in erlotinib sensitivity seen in 
DEPTOR-depleted cells is an effect one may expect from upregulation of the 
targeted protein, in that it can still be saturated by higher concentrations of erlotinib. 
A larger increase in resistance would probably be expected if DEPTOR additionally 
upregulated alternative receptors not targeted by erlotinib (Engelman et al., 2007; 
Zhang et al., 2012). It would be interesting to see if DEPTOR-depletion could cause 
upregulation of EGFR in other cancer cell lines, for example in HER2-amplified 
breast cancer cells, BRAF-mutant melanoma and EML4-ALK-positive NSCLC 
since upregulation of signalling through EGFR as an alternative receptor tyrosine 
kinase is known to be a mechanism of resistance to targeted therapies in these 
cancer types (Dua et al., 2010) (Corcoran et al., 2012a; Prahallad et al., 2012; 
Tanizaki et al., 2012).  Additionally, it would be intriguing to know whether DEPTOR 
loss could drive the upregulation of the driving oncogenic receptor in cancer cell 
lines dependent on other RTKs, rather than EGFR (eg. EML4-ALK fusion protein, 
or ERBB2).  DEPTOR loss therefore could have a wider role in drug resistance in 
multiple cancer types. 
 
As mTOR signalling is involved in multiple cellular processes (Laplante and 
Sabatini, 2012), only a small fraction of mTOR signalling has been examined here, 
and it is likely DEPTOR loss has other effects than considered in this chapter.  For 
example further work could examine the role of PKCα activation downstream of 
mTORC2, or the effect of DEPTOR loss on autophagy.  Inhibitors of growth factor 
signalling, such as erlotinib, can induce autophagy and autophagic cell death has 
been proposed to contribute to the anti-cancer activity of some drugs (Cheong et 
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al., 2012).  However it has also been suggested that stress-induced autophagy can 
drive drug resistance, and that inhibition of autophagy can enhance the growth 
inhibitory effect of EGFR TKIs in NSCLC (Han et al., 2011).  Therefore it would be 
interesting to examine whether there is a change in the level of autophagy upon 
depletion of DEPTOR and if this contributes to resistance to erlotinib. Also PKC 
alpha has been demonstrated to inhibit apoptosis, and may contribute to decreased 
sensitivity of DEPTOR-depleted cells to erlotinib.  For example, increased 
expression of PKC alpha has been detected in a tamoxifen resistant breast cancer 
cell line, where PKC alpha downregulates apoptosis by decreasing JNK activity 
(Wang et al., 2012). Little is known about the effects DEPTOR expression has on 
these pathways and it would be intriguing to investigate their involvement in drug 
response in DEPTOR-depleted cells.  
 
Additionally DEPTOR loss may contribute to erlotinib resistance via epithelial-
mesenchymal transition (EMT).  Earlier this year, Chen and colleagues showed 
loss of DEPTOR expression occurred as a result of RNAi-mediated silencing of 
BMK1 (Mitogen Activated Protein Kinase 7) (Chen et al., 2012).  They suggest loss 
of DEPTOR results in activation of PI3K and mTORC2, and subsequent 
downregulation of GSK3β.  GSK3β deactivation increases stability of the 
transcription factor Snail which in turn downregulates E-cadherin and ZO-1 (Zona 
Occludens 1), both of which have key functions in maintenance of epithelial 
morphology (Chen et al., 2012).  As EMT is a mechanism of resistance to EGFR 
TKIs it would be interesting to look for evidence of EMT in NSCLC depleted of 
DEPTOR (Sequist et al., 2011). 
 
Although NF1 and DEPTOR depletion have some similar effects on signalling, 
there are subtle but important differences.  For example, NF1 loss increases 
phosphorylation of ERK compared to control cells only in erlotinib-treated 
conditions while DEPTOR-depleted cells have higher levels of phosphorylated ERK 
in basal conditions. Sustained activation of MAPK signalling may not be an 
advantageous situation for cells, due to activation of negative feedback loops, for 
example upregulation of Sprouty and SPRED (sprout related EVH1 domain) 
proteins which inhibit RAS/ERK signalling downstream of RTKs (Mason et al., 
2006; Meng et al., 2012). Indeed cell growth assays confirmed shDEPTOR cells 
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grew more slowly than shSC cells which has also been observed in NSCLC cells 
carrying the EGFRT790M mutation (Chmielecki et al., 2011).  This means that 
DEPTOR loss may only be beneficial to cancer cell survival in the event of 
selection by erlotinib treatment, while NF1 loss potentially could be stably 
maintained without the negative effects of MAPK hyperactivation. 
 
In conclusion, DEPTOR loss upregulates EGFR expression, MAPK signalling, and 
mTOR signalling and increases cell survival in the presence of erlotinib.  As mTOR 
signalling is involved in a myriad of cellular processes it is likely DEPTOR loss has 
other effects than those considered here.  Additionally, the mechanism by which 
DEPTOR functions to inhibit mTOR signalling or what other functions it may have 
are ill-defined.  As described earlier further work is needed to conclusively link the 
increase in EGFR levels to decreased erlotinib sensitivity, and to determine the 
mechanism by which EGFR is upregulated. Ongoing work also includes the use of 
shRNA resistant DEPTOR cDNA to restore sensitivity of DEPTOR-depleted cells 
erlotinib.  As increased resistance to erlotinib and augmented EGFR expression 
were observed upon the expression of two non-overlapping shRNAs, we are 
confident it is a real biological effect and not an off-target effect.  The upregulation 
of EGFR in response to DEPTOR loss is an intriguing observation, which may be of 
relevance in other tumour types where EGFR upregulation can contribute to drug 
resistance (Corcoran et al., 2012a; Dua et al., 2010; Prahallad et al., 2012). Finally, 
loss of DEPTOR expression is a novel potential mechanism of resistance to EGFR 
TKIs.  DEPTOR protein expression is negatively regulated by mTOR signalling 
(Duan et al., 2011; Gao et al., 2011; Zhao et al., 2011), which is upregulated in 
some NSCLC patients (Liu et al., 2011), therefore it would interesting to see if there 
was a correlation between low levels of DEPTOR expression and poor response to 
EGFR TKIs in vivo.  
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Chapter 6. Discussion 
6.1 Targeted therapeutics 
The aim of developing targeted therapeutic agents in place of treatments that 
exploit other more general properties of cancer cells, such as sensitivity to DNA 
damage and hyperproliferation, was to limit the toxic side-effects on healthy cells in 
the body.  The rationale of targeted therapeutics is that cancers have a specific 
genetic lesion on which they have become dependent, a state commonly referred 
to as ‘oncogene addiction’ (Weinstein, 2002).  Thus, inhibition of the protein 
product of this genetic lesion (or signalling pathway in which the protein functions) 
should cause cancer regression.  In contrast, non-cancerous tissues would not be 
affected by the targeted agent as they do not contain the particular genetic 
aberration and therefore have not developed dependence on the targeted 
signalling pathway. Under this premise, an array of targeted therapeutics has been 
developed, including trastuzumab targeting HER2, imatinib targeting BCR-Abl and 
erlotinib and gefitinib targeting EGFR (Carter et al., 1992; Druker et al., 1996; 
Fukuoka et al., 2003).   
 
Beyond directly targeting the mutant oncogene, it is possible for tumours to 
become dependent on genes that are not oncogenic themselves, but are 
necessary for the oncogenic state, termed ‘non-oncogene addiction’ (Solimini et al., 
2007). The expression or mutational status of such genes is not altered in cancer, 
however they have key roles in pathways necessary for tumour cell survival, 
making them additional potential drug targets.  Cancer cells have undergone 
extensive rewiring in the process of oncogenesis, which makes them more 
dependent on certain pathways than normal cells.  An example of this is the 
reliance of BRCA1 and BRCA2 mutant breast cancers on base-excision repair 
pathways that sensitises them to Poly (ADP-ribose) Polymerase (PARP) inhibition 
(Farmer et al., 2005).  PARP inhibition prevents the repair of single-strand breaks 
by base-excising repair, which subsequently progress to double strand breaks.  
Double-strand breaks are predominantly repaired by homology-directed repair that 
requires BRCA1/2, therefore in BRCA deficient tumours treated with PARP 
inhibitors cells are overwhelmed with DNA damage that triggers cell death.  Non-
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cancerous cells which express wild type BRCA1/2 are still capable of normal DNA 
repair and are therefore less affected by PARP inhibitors (Annunziata and Bates, 
2010).  However, whilst therapeutics targeted at oncogene and some non-
oncogene addicted cancers have met with initial success in the clinic, resistance is 
reported eventually for all targeted therapies. 
 
6.2 Resistance – primary or acquired? 
Along with effective therapeutic delivery and dose-limiting toxicity, drug resistance 
is the ultimate problem standing in the way of the success of targeted therapeutics. 
For example, even with drugs that show remarkable initial responses, such as 
BRAF inhibitors in BRAF-mutant melanoma, the extension of overall patient 
survival is generally modest as tumours recur as resistance develops.  Drug 
resistance can be divided into two categories: primary (de novo) and acquired 
resistance. De novo resistance refers to failed response from the start of treatment, 
while acquired resistance occurs when tumours respond initially to treatment, but 
later fail to respond and continue to grow.  Notably, the distinction between these 
two categories has increasingly blurred through the years (as discussed below). 
 
An example of primary resistance is the presence of KRAS mutations in EGFR-
driven colon cancer, which results in insensitivity to the EGFR monoclonal 
antibodies cetuximab and panitumumab (Amado et al., 2008; Karapetis et al., 
2008).  An example of acquired resistance is the emergence of the EGFR 
secondary mutation T790M in non-small cell lung cancer (NSCLC), which drives 
resistance to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib.  However, 
increasing sensitivity of DNA sequencing has revealed that acquired resistance in 
many cases is really the emergence of drug resistant clones that are present in the 
tumour population prior to treatment.  This has been shown in several situations of 
acquired resistance, for example the T790M mutation can be detected in EGFR-
mutant NSCLC tumours prior to treatment (Maheswaran et al., 2008) (Oh et al., 
2011).  Additionally, KRAS mutations can be detected prior to emergence of 
panitumumab resistance in colon cancer, which mathematical modelling predicts 
must be present in subclones before treatment (Diaz et al., 2012).  Nevertheless, 
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there is data suggesting acquired resistance can occur as a result of ongoing 
somatic mutation, and not only through the selection of pre-existing drug-resistant 
clones.  In another study describing KRAS mutations and amplifications in 
cetuximab resistant colorectal cancer, one KRAS mutation found in the Lim1215 
cell line after culturing long term in the presence of cetuximab was not found in the 
parental cell line prior to treatment, even upon high-coverage deep sequencing. 
This suggests this resistance mutation occurred during drug treatment (Misale et al., 
2012).  Additionally, a missense S492R mutation in EGFR that confers resistance 
to cetuximab in colorectal cancer could not be detected by deep sequencing of pre-
treatment samples although EGFR amplification was detected in both pre and post-
cetuximab treated samples (Montagut et al., 2012).  
 
6.3 Common themes of resistance mechanisms 
When reviewing mechanisms of resistance to different targeted therapies in 
different cancer types, there is a striking similarity among the common mechanisms 
and signalling pathways they employ.  Broadly, mechanisms can be sub-divided 
into three modes of action: re-activation of the targeted signalling pathway, 
activation of a compensatory signalling pathway, or cellular transformation and 
reprogramming which alters cell phenotype and therefore drug sensitivity. 
 
6.3.1 Reactivation of the targeted pathway 
Reactivation of the targeted pathway can occur at multiple stages, either at the 
point of the targeted protein itself  (by amplification or secondary mutations that 
block drug action), or by activating mutations functioning downstream in the 
pathway.  For example, copy number gain of ALK has been detected in NSCLC 
patients with ALK gene rearrangements post-crizotinib treatment; this amplification 
was associated with acquired resistance to crizotinib (Doebele et al., 2012).  
Additionally, resistance driven by amplification of the target also occurs in BRAF-
mutant driven melanoma (Shi et al., 2012).  As shown here, loss of DEPTOR 
functions in an analogous manner to increase resistance to erlotinib in NSCLC by 
upregulating EGFR expression.  In the instance of copy number gain or increased 
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expression of the targeted gene without additional mutation, the resistance is ‘drug-
saturable’, meaning that tumour cells are still sensitive to the drug at higher 
concentrations.  This is true for both BRAF amplification and DEPTOR loss, which 
shift the response to targeted drugs without making them totally insensitive.  
Secondary ‘gatekeeper’ mutations that prevent drug-binding or reduce the affinity 
of the kinase for the drug have been identified in BCR-ABL, EGFR, and EML4-ALK 
(Gorre et al., 2001)(Pao et al., 2005a)(Choi et al., 2010).  In such cases, tumour 
cells are rendered unresponsive and higher concentrations of drug are largely 
ineffective. 
 
One could argue that comparatively small effects on drug sensitivity (drug-
saturable) are not clinically relevant as the drug is still effective at a higher 
concentration. However, the study by Shi and colleagues suggests otherwise.  
Although BRAF amplification caused a level of resistance that was drug-saturable 
in-vitro, it was found in 20% of patients that experienced disease progression whilst 
being treated with BRAF inhibitors.  No other commonly occurring mechanism was 
identified in these tumours, suggesting that BRAF amplification was enough to 
drive resistance in patients (Shi et al., 2012).  Therefore although the effect of 
DEPTOR loss on drug sensitivity is relatively modest, it could potentially affect drug 
response in vivo.   
 
Downstream of receptor tyrosine kinases several activating mutations have been 
identified which reactivate downstream signalling.  Prime examples are the 
amplification and mutation of KRAS downstream of EGFR in colorectal cancer 
(Bonanno et al., 2010) and reactivation of MAPK signalling by COT in RAF inhibitor 
resistant melanoma (Johannessen et al., 2010).  NF1 loss fits with this group of 
resistance mechanisms to activate RAS downstream of targeted inhibition.  
Resistance mechanisms resulting from downstream reactivation of signalling are 
highly potent, as the signalling input of the targeted lesion is now redundant.  In 
patients with such resistance mechanisms, dose escalation of the targeted therapy 
is not as effective and alternative or additional drugs need to be used.  Loss of 
DEPTOR could potentially also effect erlotinib resistance by activating mTOR 
signalling separate from its upregulation of EGFR.  For example, by activating AKT 
and SGK1 downstream of mTORC2, DEPTOR loss could inhibit induction of 
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expression of pro-apoptotic proteins by forkhead transcription factors and 
downregulate proapoptotic BAD (Datta et al., 1997; Fu and Tindall, 2008; Garcia-
Martinez and Alessi, 2008).  However, a more substantial resistance to erlotinib 
might be expected if survival signalling was strongly activated independently of 
EGFR. NF1 loss results in a much more potent increase in resistance than loss of 
DEPTOR, indicating mechanisms of resistance activating signalling downstream of 
the targeted protein are a more effective strategy for cancer cells. 
 
6.3.2 Activation of alternative signalling pathways 
Another common finding in acquired resistance is the upregulation of alternative 
signalling pathways, leading to downstream survival signalling.  A key example of 
this is the amplification of MET in erlotinib resistant NSCLC.  Amplified MET 
heterodimerises with ERRB3 to activate PI3K-AKT signalling, thereby providing an 
alternative route to survival (Engelman et al., 2007).  One of the most recently 
identified examples is increased activation of the tyrosine receptor kinase AXL in 
erlotinib-resistant NSCLC (Zhang et al., 2012).  Zhang and colleagues found AXL 
expression and activation was increased in erlotinib resistant HCC827 cells, which 
seems to increase resistance at least in part by activating PI3K-AKT and MAPK 
pathways independently of EGFR.  Another example of signalling through 
alternative receptors can be found in HER2 positive breast cancer, where 
trastuzumab resistance is associated with overexpression of EGFR and IGFR1 
(Gallardo et al., 2012).  These findings highlight flexibility and redundancy in the 
way tumour cells signal through receptor tyrosine kinases, which will be discussed 
further in later sections.  In relation to the role of DEPTOR loss, it would be 
interesting to see if DEPTOR-depletion could cause upregulation of EGFR in other 
cancer cell lines, for example in HER2-amplified breast cancer cells, BRAF-mutant 
melanoma and EML4-ALK-positive NSCLC, where it is associated with drug 
resistance (Dua et al., 2010) (Corcoran et al., 2012a; Prahallad et al., 2012; 
Tanizaki et al., 2012).  . Potentially DEPTOR loss could increase resistance to 
targeted therapies in multiple cancer types by upregulating EGFR as an alternative 
receptor tyrosine kinase  
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6.3.3 Histological transformation 
Arguably, the least well understood class of resistance involves phenotypic 
transformation.  One well-described type of phenotypic change is the epithelial-
mesenchymal transition (EMT). EMT is a phenotypic transformation of epithelial 
cells to a more mesenchymal phenotype, demonstrated by loss of epithelial 
markers such as E-cadherin and cytokeratins, and gain of mesenchymal markers 
such as vimentin and N-cadherin.  EMT is reported to cause resistance in multiple 
cancer types to targeted therapeutics, including resistance to EGFR-TKIs in 
NSCLC (Chung et al., 2010; Sequist et al., 2011). Epithelial-mesenchymal 
transition is thought to render cells less sensitive to drug treatment, via 
engagement of cell survival pathways such as signalling through NF-kappaB. Also, 
as mentioned in the introduction, EMT has been associated with ‘kinase switching’, 
therefore therapies targeted at RTKs may fail as the cells have switched 
dependency to signalling through an alternative receptor (Thomson et al., 2008).  
Recently activation of an alternative receptor and occurrence of EMT was observed 
with AXL activation in EGFR-mutant NSCLC which mediates resistance to EGFR 
TKIs (Zhang et al., 2012). We have found no evidence that NF1 loss causes EMT 
in NSCLC, therefore it is unlikely that depletion of NF1 contributes to erlotinib 
resistance via this mechanism. DEPTOR loss has been associated with EMT 
(Chen et al., 2012), however whether this occurs in NSCLC, or can lead to drug 
resistance is yet to be elucidated.  
 
More recently histological transformation to small cell lung cancer was observed in 
patients with non-small cell lung cancer resistant to erlotinib treatment.  How this 
occurs is not known, however it appears to be a bona fide resistance mechanism 
detected in multiple cases (Arcila et al., 2011; Sequist et al., 2011).  Identification of 
such histological transformation has substantial ramifications for treatment, as 
transformed tumours behave as SCLC and respond to standard chemotherapy for 
this class of lung cancer.  These observations point out the importance of re-biopsy 
of patients upon discovery of resistance, in order to successfully adjust therapy to 
prevent disease progression.  Also, it demonstrates that histological analysis is 
necessary to complement genetic testing for resistance mechanisms.  Sequist et al. 
found tumours demonstrating transformation to small cell lung cancer retained the 
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EGFR activating mutation and 4 out of 5 tumours showed no evidence of new 
mutations associated with resistance (Sequist et al., 2011). Therefore from a 
genetic standpoint these tumours should still be sensitive to erlotinib treatment, 
however this is clearly not the case. 
 
6.4 Tumour heterogeneity as a challenge to targeted 
therapeutics. 
Aside from the aforementioned issues that generally effect drug resistance on a 
cell-autonomous level there are many other mechanisms when drug resistance is 
considered at a tumour or patient level.  With increasingly powerful DNA and RNA 
sequencing techniques it is now possible to probe the heterogeneity that exists 
within single tumours and between different tumours (primary tumours and 
metastases) in the same patient.  Recently, Gerlinger and colleagues performed 
exon sequencing on patients with metastatic renal cell carcinoma and identified 
substantial intratumour heterogeneity, as well as heterogeneity between the 
primary tumour and different metastatic sites (Gerlinger et al., 2012). They found 
that only 34% of mutations found by multi-region sequencing of the primary tumour 
were detected in all regions biopsied.  Such findings clearly have significant 
implications in the administration of targeted therapies, as potentially only a subset 
of tumour cells would contain the genetic lesion conferring sensitivity to treatment. 
In such instances only a portion of the tumour would be targeted, and could lead to 
the outgrowth of the non-targeted population.  This work highlights the importance 
of identifying mutations that occur early in tumour development, and are therefore 
ubiquitous.  Targeting of genetic alterations in the trunk of the phylogenetic tree is 
more likely to be an effective therapeutic approach, than targeting branch 
mutations, which only occur in some areas of a tumour or tumours (Gerlinger et al., 
2012). 
 
6.4.1 Evolutionary dynamics and implications for therapy 
As discussed previously, the emergence of drug resistance is widely accepted to 
be a Darwinian process, by which tumour cells are a mixed population and the 
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‘fittest’ survive and outgrow.  Drug treatment acts as a selection pressure, and 
enriches for tumour cells that have acquired mutations causing resistance to 
subsequently outgrow the remaining sensitive population.  Such a model appears 
to be supported by studies of patients given ‘drug holidays’, where resistant 
tumours can again respond to therapy after a drug-free period, suggesting that 
without selection pressure the tumour is re-populated by sensitive cells (Becker et 
al., 2011; Oxnard et al., 2011b).  This could be explained by the observation that in 
the absence of an EGFR TKI NSCLC cells carrying the EGFR T790M mutation 
proliferate more slowly than their sensitive counterparts, suggesting drug resistant 
clones may be less ‘fit’ than the bulk tumour population in untreated conditions 
(Chmielecki et al., 2011).  However, that sensitive cells survive the initial treatment, 
suggests the possibility of insufficient targeting of the tumour or that these 
‘sensitive’ cells may have some level of resistance, perhaps similar to the drug-
tolerant cells seen by Sharma et al (Sharma et al., 2010). One strategy could be to 
adjust dosing schedules to prevent the selection of drug resistant phenotypes.  
Chmielecki and colleagues suggest that intermittent high-dose pulses of BIBW-
2992 (an irreversible EGFR inhibitor) in conjunction with a continuous low dose of 
erlotinib treatment would slow the outgrowth of resistant clones (Chmielecki et al., 
2011). The idea is that the low dose of erlotinib would kill sensitive cells without 
creating a high selective pressure which favours the expansion of resistant clones, 
whilst the intermittent the high dose of BIBW-2992 would kill any emerging T790M-
containing cells. They found this regime did not select for T790M mutation, and 
PC9 cells took twice as long to develop resistance, however eventually an 
alternative mechanism of resistance did emerge (Chmielecki et al., 2011). 
 
Aside from drug treatment, cancer cells must adapt to other stresses, such as 
hypoxia or lack of nutrients, which can vary significantly over the area of a tumour.  
Gillies et al. point out that different areas of a tumour are under different selection 
pressures, for example some areas will be more hypoxic, due to distance from 
blood vessels (Gillies et al., 2012). This situation can lead to substantial 
heterogeneity within a tumour, and can have a significant impact on cell behaviour. 
Therefore, one suggestion is that instead of targeting specific signalling pathways, 
general ‘hallmarks of cancer’ should be targeted instead.  An example of this is the 
targeting of low extracellular pH, a physical characteristic of tumours associated 
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with drug resistance.  Hypoxia and increased glycolysis in tumours creates an 
acidic extracellular environment, which in turn negatively effects the uptake of weak 
base chemotherapeutic drugs (Wojtkowiak et al., 2011). However, there are very 
few hallmarks of cancer that can be targeted and are truly specific to cancer cells.  
Essentially the same principle of targeting general characteristics underlies 
chemotherapy, which is aimed at the highly proliferative phenotype of cancer cells, 
but therefore affects all proliferating cells.  This can lead to high levels of toxicity as 
proliferative cell populations such as lymphocytes and the intestinal epithelium are 
also affected. Coming full circle, toxicity is one of the reasons why more specifically 
targeted drugs were developed and could be a problem of more general 
therapeutic approaches. 
 
6.4.2 Tumour heterogeneity – not so heterogenous after all? 
There is one aspect of Gerlinger and colleagues work that does provide hope for 
the use of targeted agents, which is the suggestion of convergent phenotypic 
evolution.  Distinct mutations of SETD2, PTEN and KDM5C were detected in 
different regions of the same tumours (Gerlinger et al., 2012).  This suggests that 
mutations in the same genes can arise independently in the same tumour. 
Therefore, although they are genetically distinct, they rely on the same signalling 
pathways and potentially could be treated in the same way. This example 
demonstrates how in natural selection ‘nature selects for phenotype, not genotype’ 
(Gillies et al., 2012) and creates some hope that tumour cells in a genetically 
heterogeneous tumour may not behave so differently after all. 
 
Other suggestions that targeted therapies can be successful in heterogeneous 
cancers come from ER (estrogen receptor) positive breast cancer.  In this subtype 
of breast cancer only 10% of cells in a tumour need to be assessed as ER positive 
by immunohistochemistry for the tumour to be classed as ER positive.  Most of 
these tumours respond well to endocrine therapy, which implies the tumour as a 
whole still depends on estrogens, even if ER expression cannot be found in all cells 
(Bhatia et al., 2012). This could be due to technical limitations of staining, or 
because ER expression fluctuates and immunohistochemistry can only provide a 
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snapshot.  Alternatively it could be that signalling is required between different 
subpopulations and there is a co-dependence between ER positive and ER 
negative cells.  
 
6.5 Tumour microenvironment in drug resistance 
Drug resistance can arise from interactions between tumour cells and the tumour 
milieu, adding another layer of complexity.  It has become clear that the 
microenvironment has a profound influence on phenotype, and in some instances 
can override genotype. Recently, Wilson and colleagues performed a matrix 
analysis where they tested the ability of six different receptor tyrosine kinase 
ligands to ‘rescue’ 41 cancer cell lines from RTK-targeted therapies (Wilson et al., 
2012).  They found in nearly all cell lines that a ligand for an alternative RTK can 
rescue cells from sensitivity to an RTK-targeted therapy.  This suggests a high level 
of redundancy in RTK signalling, and that growth factors in the extracellular matrix 
potentially have very broad and potent roles in drug resistance. Some of their key 
findings were that exogenous HGF rescues EGFR-mutant NSCLC cell lines from 
erlotnib treatment, and also BRAF-mutant melanoma cells from RAF inhibition.  
This work was supported by another study in which expression of HGF by stromal 
cells is assocated wth innate resistance to RAF inhibitors in BRAF-mutant 
melanoma (Straussman et al., 2012). Mechanisms of resistance arising from the 
tumour microenvironment would not be identified by sequencing of the tumour cells, 
but could potentially by identified by immunohistochemistry. This work also relates 
to the upregulation of alternative receptors in resistant disease.  For example, as 
discussed in the introduction chapter exogenous HGF can lead to resistance by 
promoting the amplification of MET, however there are differences in signalling 
between the transient resistance mediated by continuous presence of HGF, and 
permanent resistance mediated via amplified MET (Turke et al., 2010).   
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6.6 The future of targeted therapeutics 
6.6.1 Combination therapies 
What has become apparent is that resistance arises to all targeted therapeutics 
and that new approaches are needed to deal with resistance.  Recently, it has been 
suggested that lessons could be learned from the approaches used in treating HIV, 
where progression is rare with current therapies (Bock and Lengauer, 2012). In 
contrast to single-agent targeted therapies in cancer, first-line treatment for HIV 
always uses a combination of drugs with different targets and mechanisms of 
action.  The introduction of combination therapeutics in HIV has had a dramatic 
impact on patient survival, and one could assume a similar benefit may be seen in 
cancer patients.  Combination therapies could provide a greater barrier to 
resistance, as they prevent some known feedback loops identified in cancer, and 
according to evolutionary principles, one would assume more genetic changes 
would need to be acquired before resistance emerges.   
 
Although combination treatments are not new in cancer treatment, as different 
chemotherapeutic drugs have been used in combination since the 1960s (Chabner 
and Roberts, 2005), and targeted therapies are commonly combined with standard-
of-care chemotherapy, the combination of targeted therapeutics has only recently 
emerged.  New clinical trials demonstrate an overwhelming shift towards 
combination treatments has now occurred.  It is clear that many drugs are not 
effective as single agents, most probably due to feedback mechanisms, leading to 
compensatory cell survival signalling.  For example, in the case of rapamycin, and 
subsequent allosteric mTOR inhibitors, inhibition of mTORC1 results in feedback 
activation of AKT and MAPK signalling via IRS1/2, rendering them ineffective as 
single agents in many tumour types ((Carracedo et al., 2008; O'Reilly et al., 2006)).  
Consequently, IGFR-1 antibodies are now in clinical trials with mTOR inhibitors to 
prevent this feedback loop (NCT01234857).  In our genome-wide screen we 
identified NF1 and DEPTOR as genes whose loss increased resistance to erlotinib 
treatment in EGFR-mutant NSCLC.  In follow-up experiments we used 
combinations of erlotinib with different drugs to determine combinations that may 
be effective in resistant patients with reduced expression of these genes.  The 
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combination of erlotinib and a MEK inhibitor was highly effective in both cases, 
which suggests it may be a therapeutic option for some patients with acquired 
resistance to erlotinib treatment. 
6.6.2 Combinations of targeted therapies – targeting the same pathway or 
different pathways? 
Combinations of targeted therapeutics are most commonly investigated upon 
development of resistance to a targeted monotherapy, and the strategy of 
combination varies depending on the mechanisms of resistance they are employed 
against.  Combinations may target the same protein, the same pathway or parallel 
pathways.  For example, resistance to trastuzumab, a Her2 inhibitor is mediated by 
dimerization of Her2 and Her3 and continued signalling from these dimers.  To 
overcome resistance another Her2 inhibitor, pertuzumab is effective, as it blocks 
Her2/Her3 dimerization (Nahta et al., 2004). An example of targeting downstream 
in the same pathway is combined BRAF and MEK inhibition to counteract 
resistance to BRAF inhibitors in melanoma that can arise through activation of MEK 
(by COT or CRAF activation) (Al-Lazikani et al., 2012). In this thesis a similar 
method of combination has been used to counter increased resistance to EGFR-
TKIs.  Here the EGFR inhibitor erlotinib was combined with a MEK inhibitor, to 
effectively block downstream activation of RAS by NF1 or DEPTOR loss.  
Interestingly, combined EGFR and AKT inhibition was not as effective in the 
mechanisms of resistance found, demonstrating not all downstream signalling 
pathways contribute equally to resistance. 
 
Additionally, there is evidence to support simultaneous targeting of parallel 
pathways.  Engelman and colleagues have suggested dual inhibition of MAPK and 
PI3K-mTOR signalling is required for effective treatment of EGFR-mutant NSCLC 
(Faber et al., 2009) as well as KRAS mutant lung cancer (Engelman et al., 2008). 
Those and similar reports combining MEK and AKT inhibition in NSCLC cell lines 
(Meng et al., 2010), have led to the phase I clinical trials testing the MEK and AKT 
inhibitor combination (NCT01021748).  The observations described here are 
supportive of such a combination, as treatment of PC9 cells with a MEK inhibitor 
leads to increased phosphorylation of AKT, indicating compensatory crosstalk 
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between MAPK and PI3K-AKT pathways. However, there are several serious 
issues to consider in the development and administration of combinations of 
therapeutics.  As described above simultaneous targeting of MEK and PI3K 
pathways is a highly attractive strategy to prevent signalling crosstalk, unfortunately 
early data from clinical trials suggest toxicity may impose limits on the effectiveness 
of such a combination.  Shimizu and colleagues found 53.9% of patients had grade 
III or greater adverse effects to the combination of an AKT and MEK inhibitor, or an 
mTORC1 inhibitor and a MEK inhibitor, 18.4 % of whom exhibited dose-limiting 
toxicity (Shimizu et al., 2012).   
6.6.3 Multi-target therapeutic agents 
Aside from combination of (presumably) single-target drugs, drugs that 
simultaneously target more than one pathway have shown some promise in the 
clinic.  Examples of multi-kinase inhibitors with clinical efficacy are sorafenib 
(targets PDGFR, VEGFR and Raf kinases) (Escudier et al., 2007) and vandetanib 
(inhibits EGFR, VEGFR and RET kinases) (Wells et al., 2012).  Indeed the ‘off-
target’ effects of drugs often contribute to their overall effectiveness, as was the 
case with sorafenib which was originally developed as a Raf kinase inhibitor.  The 
use of multi-kinase inhibitors would hopefully combat some of the redundancy seen 
in Wilson et al. where compensatory signalling via alternative RTKs drive 
resistance (Wilson et al., 2012)  
 
Other pleiotropic drugs including HSP90 (Heat shock protein 90) inhibitors, 
neddylation inhibitors and deactylase inhibitors are also coming to the fore.  As 
their actions affect the function or expression of multiple oncogenic proteins 
simultaneously, it is likely they will provide a greater barrier to resistance than 
single target therapies, and may be more effective on the heterogenous tumour cell 
population.  For example, HSP90 is a chaperone protein that regulates the folding 
and stability of multiple ‘client’ proteins including EGFR, HER2, ALK and BRAF 
(Neckers and Workman, 2012).  Inhibition of HSP90 decreases levels of all of 
these proteins simultaneously, therefore they can be used in multiple cancers 
driven by different oncogenes, and also eliminates many potential feedback and 
crosstalk loops. 
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The neddylation inhibitor MLN4924 is another drug in phase I clinical trials 
(NCT00677170, NCT01011530, NCT00911066), which may have relevance to two 
hits from the genome-wide screen described in this thesis, DEPTOR and NF1.  
Neddylation is required for the function of the cullin-RING ligases subset of E3 
ubiquitin ligases, and controls the targeted degradation of many proteins involved 
in oncogenesis.  For example cullin-RING ligases are involved in the degradation of 
p53, p27 and IκBα (Nawrocki et al., 2012).  It additionally has activity in causing 
DNA re-replication resulting in cancer cell death.  NF1 and DEPTOR are both 
proteins whose degradation is regulated by cullin-RING E3 ubiquitin ligases (Duan 
et al., 2011; Gao et al., 2011; Tan et al., 2011; Zhao et al., 2011). Therefore it is 
possible that in cases where protein degradation is enhanced, such as the loss of 
NF1 in glioblastoma, use of a neddylation inhibitor could restore NF1 protein levels, 
and reduce oncogenic signalling through RAS.   
 
However, something to consider when utilising drugs with multiple targets, is that 
there are also some proteins that you specifically do not want to target as they 
enhance toxicity and reduce efficacy.  Recently Dar and colleagues used a Ret-
kinase driven Drosophila model of multiple endocrine neoplasia type 2 to identify 
the compounds with the highest therapeutic index and the molecular mechanism 
that accounts for this (Dar et al., 2012).  They discovered inhibition of Ret in 
conjunction with Src, Raf and S6K provided the least toxicity and optimal efficacy, 
whereas drugs that inhibited Ret and Tor where substantially less effective and 
more toxic.  They identify Tor as an ‘anti-target’, whose inhibition increases 
activation of Erk signalling via feedback activation of Raf (Dar et al., 2012).   This 
study highlights the importance assessing the toxicity of multi-target therapeutic 
agents, and demonstrate that multiple rounds of drug development are necessary 
to produce the most favourable therapeutic index.  
 
6.6.4 Novel approaches to modelling resistance 
When resistance to first-line HIV therapies arises computer-assisted resistance 
prediction is implemented using viral genotyping data to devise patient-specific 
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combination therapies.  Such predictive methods are still some way off for 
resistance to cancer therapy, however they are certainly an attractive possibility 
(Bock and Lengauer, 2012).  In order to create a modelling system that can predict 
treatment response in-depth genetic information and drug response data needs to 
be collected.  Recently this has begun with a huge collaborative project called the 
‘Cancer Cell Line Encyclopedia’, which was undertaken to profile the sensitivity of 
479 cancer cell lines to 24 anticancer drugs.  In parallel with the pharmacological 
data, detailed gene expression and chromosomal copy number information was 
obtained, as well as mutational status of more than 1600 genes (Barretina et al., 
2012).  The aim of the project was to identifiy genetic, gene-expression and 
lineage-specific determinants of sensitivity to different classes of drugs.  Using this 
approach they confirmed known determinants, such as presence of EGFR 
mutations conferring erlotinib sensitivity.  They also identified unknown 
determinants of sensitivity, for example high SLFN11 expression confers sensitivity 
to topoisomerase inhibitors such as Irinotecan (Barretina et al., 2012).  
 
Additionally, screening methodologies, such as the genome-wide siRNA screen 
used here are useful in providing insight into mechanisms of resistance and have 
successfully identified clinically relevant causes of resistance.  For example RNAi 
screening identified upregulation of EGFR as a mechanism of resistance to BRAF 
inhibitors in colorectal cancer (Prahallad et al., 2012). Recently, advances in 
technology have allowed for the considerable upscaling of RNAi, and cDNA 
overexpression screening.  At the Broad Institute of Harvard and Massachusetts 
Institute of Technology, they have developed MicroSCALE technology (Microarrays 
of Spatially Confined Adhesive Lentiviral Features), which is essentially a 
miniaturised screening platform (Wood et al., 2012).  This allows for massive 
parallel screening of the effect of the expression of lentiviral ORF or shRNA 
libraries on multiple cell lines, in various drug treated conditions.  So far, they have 
used the technology to identify kinases whose overexpression increases resistance 
to MAPK inhibition in melanoma, and a potential role for NFκB pathway in MAPK 
inhibitor resistance (Wood et al., 2012).  
 
Another of the key methodologies coming to the fore is that of ‘xenopatient ‘models.  
In such models, pieces of tumour surgical specimems from a patient are 
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transplanted into nude mice where they can then be treated with various 
therapeutic regimes in order to identify effective treatments.  Bertotti and 
colleagues used this approach to identify markers of resistance to anti-EGFR 
therapy in metastatic colorectal cancer (Bertotti et al., 2011). In this study they 
identified amplification of Her2 as predictive of non-responsiveness to cetuximab. 
Xenograft experiments are carried out in immunocomprimised mice, therefore 
ignore any impact of the immune system, so it is necessary to combine these data 
with studies in good genetically engineered mouse models of resistant disease 
(such as the EGFR-L858R NSCLC model (Politi et al., 2010)).  Such approaches 
will provide further insight into how tumours respond to drug treatment in the 
context of the whole organism, more closely mimicking human disease. 
 
One could imagine that by integrating the results from genetically engineered 
mouse models, xenopatient, and patient cell line assays with detailed genomic 
characterisation it would be eventually possible to generate predictions of drug 
response based on genotype, in an approach more similar to that employed in HIV 
treatment (Bock and Lengauer, 2012).  As long as strong biomarkers and fast 
diagnostic tests, such as analysis of blood biopsies (Diaz et al., 2012) (Misale et al., 
2012), could be implemented, this would allow for fast application of highly 
personalised treatments on the occurrence of drug resistance.  However it is 
important to note that resistance in HIV occurs as a result of mutations in relatively 
few genes, compared to a much more complex situation in cancer.  Several 
hundred genes have been implicated in tumourigenesis, many of which can 
contribute to drug resistance, which makes modelling of resistance potentially 
orders of magnitude more complex. 
 
6.7 Concluding remarks 
When the studies described in this dissertation commenced, little was known about 
mechanisms of resistance to erlotinib in EGFR-mutant NSCLC, aside from the 
EGFRT790M mutation and MET amplification.  The screening approach taken here 
has yielded two interesting hits that validated in longer term experiments.  However, 
as both NF1 and DEPTOR are negative regulators of downstream EGFR pathway 
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signalling components, it is likely that these factors could have been identified in a 
smaller-scale, more-candidate driven approach.  Also, although Nf1 mRNA was 
reduced in resistant tumours in mice, currently we have not identified a mechanism 
of downregulation, and due to lack of clinical samples we do not have patient data 
to support the role of either gene in erlotinib resistance in vivo.  RNAi screening 
approaches have successfully been employed to identify clinically relevant 
mechanism of resistance, however they are not sufficient on their own to show the 
relevance of specific genes in vivo (Holzel et al., 2010; Prahallad et al., 2012).  
Multiple approaches yield the most convincing evidence for mechanisms of 
acquired resistance, and standard practice now seems to be the combination of in 
vitro cell-based assays, mouse models, and validation in patient samples. 
Therefore, to confirm the role of NF1 and DEPTOR in vivo analysis of patient 
samples with acquired resistance to erlotinib would be necessary.   
 
Having said that, reduced expression of NF1 and DEPTOR are interesting as they 
share properties with clinically detectable mechanisms of resistance, in that they 
reactivate MAPK signalling, either directly, or potentially by feedback to receptor 
tyrosine kinases.  Studying these mechanisms we also came to the same 
conclusions as others, that the combination of EGFR and MEK inhibition would be 
effective in some tumours which have acquired resistance to EGFR targeted 
therapies (Misale et al., 2012).  Activation of ERK seems to be a key aspect of 
many mechanisms of acquired resistance and a large number of clinical trials are 
exploring the use of MEK inhibitors, either alone or with other drugs.  A recent 
search on the World Health Organisation International Clinical Trials Registry 
platform (http://apps.who.int/trialsearch) found 67 trials testing MEK inhibitors, 38 of 
which were testing MEK inhibitors in combination with another drug.  These include 
the combination of erlotinib and a MEK inhibitor (NCT01192165, NCT01229150, 
NCT01239290), vandetanib (a VEGFR and EGFR inhibitor) and a MEK inhibitor 
(NCT01586624), and cetuximab and a MEK inhibitor (NCT01217450).   The 
findings of these trials will be interesting, as our data suggests the combination of 
EGFR and MEK inhibition would be effective in erlotinib resistant, EGFR-mutant 
NSCLC patients who do not have the gatekeeper EGFRT790M mutation, where the 
combination would be ineffective.   
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It is unlikely that combination therapeutics such as EGFR-TKI and MEK inhibitor 
combinations will be totally free from acquired resistance, however they might 
improve the response rate and duration in patients.  Additionally combining 
oncogene-targeted therapies (such as erlotinib), with more pleiotropic drugs (e.g. 
HSP90 inhibitors), or those targeting ‘non-driver’ mutations may also be effective 
strategies.  The biological rationale behind combinations must be strong for each 
setting in which they are used, and toxicity must be carefully considered.  If drug 
response predictions can be developed, and testing for strong biomarkers of 
response carried out swiftly, it is possible patients’ treatment regimes could be 
quickly altered upon emergence of resistance.  Then, patients may benefit from 
successive combinatorial treatments to significantly improve their lifespan. 
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Chapter 7. Appendix 
Appendix 1. 
Residual Z scores for genome-wide screen 1 and 2. Column A, B and C, provide 
the plate number, position number and well position for each siRNA pool 
respectively.  Column D states whether the siRNA is a sample siRNA or a control 
siRNA.  Column E shows the ID of the transcript targeted by the siRNA pool 
according to NCBI RefSeq database.  Column F shows the Dharmacon catalog 
number of the siRNA pool.  Column G gives the official gene symbol according to 
the HUGO Gene Nomenclature Committee. Columns H-P show the residual Z 
scores calculated by plotting each replicate of the control screen against each 
replicate of the drug screen.  Column Q, highlighted in yellow shows the median 
residual Z score (median of columns H-P) and is the value we used to rank the 
siRNA pools. Sheet 1 shows the data for screen 1, sheet 2 shows the data for 
screen 2. 
 
Appendix 2. 
List of siRNA pools which appeared in the top 2.5 % of all pools in screen 1 and the 
top 5% of screen 2 when ranking by residual Z score. Column A shows the ID of 
the transcript targeted by the siRNA pool according to NCBI RefSeq database.  
Column B shows the Dharmacon catalog number of the siRNA pool.  Column C 
gives the official gene symbol according to the HUGO Gene Nomenclature 
Committee. Column D shows the residual Z score of the siRNA pool in screen 1.  
Column E shows the residual Z score of the siRNA pool in screen 2. Column F 
indicates whether the siRNA pool appeared in the top 2.5% of screen 1 only 
(screen 1), or the top 2.5% of screen 1 and screen 2 (both).   
 
Appendix 3.  
Results of the deconvolution screen.  Sheet 1. Results of all siRNA pools in the 
deconvolution screen. Column A shows the ID of the transcript targeted by the 
siRNA pool according to NCBI RefSeq database.  Column B shows the official 
gene symbol according to the HUGO Gene Nomenclature Committee.  Column C 
gives the Dharmacon ID number for each siRNA oligonucleotide. Columns D-G 
show the SI (sensitivity index) calculated for each siRNA oligonucleotide of the 
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SMARTpool.  siRNAs are colour-coded as indicated according to the strength of 
their effect. Sheet 2.  siRNA pools regarded as hits for which at least two siRNAs 
had an SI value of ≥ 0.10 for sensitising siRNAs or ≤ -0.15 for desensitising siRNAs.
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